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1Kadoorie Centre for Critical Care Research and Education, Nuffield Department of Clinical
Neurosciences, University of Oxford, Oxford, UK
2Intensive Care National Audit and Research Centre, London, UK
3Centre for Reviews and Dissemination, University of York, York, UK
4Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge,
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Background: New-onset atrial fibrillation occurs in around 10% of adults treated in an intensive care
unit. New-onset atrial fibrillation may lead to cardiovascular instability and thromboembolism, and has
been independently associated with increased length of hospital stay and mortality. The long-term
consequences are unclear. Current practice guidance is based on patients outside the intensive care unit;
however, new-onset atrial fibrillation that develops while in an intensive care unit differs in its causes
and the risks and clinical effectiveness of treatments. The lack of evidence on new-onset atrial fibrillation
treatment or long-term outcomes in intensive care units means that practice varies. Identifying optimal
treatment strategies and defining long-term outcomes are critical to improving care.
Objectives: In patients treated in an intensive care unit, the objectives were to (1) evaluate existing
evidence for the clinical effectiveness and safety of pharmacological and non-pharmacological new-
onset atrial fibrillation treatments, (2) compare the use and clinical effectiveness of pharmacological
and non-pharmacological new-onset atrial fibrillation treatments, and (3) determine outcomes
associated with new-onset atrial fibrillation.
Methods: We undertook a scoping review that included studies of interventions for treatment or
prevention of new-onset atrial fibrillation involving adults in general intensive care units. To investigate
the long-term outcomes associated with new-onset atrial fibrillation, we carried out a retrospective cohort
study using English national intensive care audit data linked to national hospital episode and outcome data.
To analyse the clinical effectiveness of different new-onset atrial fibrillation treatments, we undertook a
retrospective cohort study of two large intensive care unit databases in the USA and the UK.
Results: Existing evidence was generally of low quality, with limited data suggesting that beta-blockers
might be more effective than amiodarone for converting new-onset atrial fibrillation to sinus rhythm
and for reducing mortality. Using linked audit data, we showed that patients developing new-onset
atrial fibrillation have more comorbidities than those who do not. After controlling for these differences,
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patients with new-onset atrial fibrillation had substantially higher mortality in hospital and during the
first 90 days after discharge (adjusted odds ratio 2.32, 95% confidence interval 2.16 to 2.48; adjusted
hazard ratio 1.46, 95% confidence interval 1.26 to 1.70, respectively), and higher rates of subsequent
hospitalisation with atrial fibrillation, stroke and heart failure (adjusted cause-specific hazard ratio 5.86,
95% confidence interval 5.33 to 6.44; adjusted cause-specific hazard ratio 1.47, 95% confidence interval
1.12 to 1.93; and adjusted cause-specific hazard ratio 1.28, 95% confidence interval 1.14 to 1.44,
respectively), than patients who did not have new-onset atrial fibrillation. From intensive care unit data,
we found that new-onset atrial fibrillation occurred in 952 out of 8367 (11.4%) UK and 1065 out of
18,559 (5.7%) US intensive care unit patients in our study. The median time to onset of new-onset atrial
fibrillation in patients who received treatment was 40 hours, with a median duration of 14.4 hours.
The clinical characteristics of patients developing new-onset atrial fibrillation were similar in both
databases. New-onset atrial fibrillation was associated with significant average reductions in systolic
blood pressure of 5 mmHg, despite significant increases in vasoactive medication (vasoactive-inotropic
score increase of 2.3; p < 0.001). After adjustment, intravenous beta-blockers were not more effective
than amiodarone in achieving rate control (adjusted hazard ratio 1.14, 95% confidence interval 0.91 to
1.44) or rhythm control (adjusted hazard ratio 0.86, 95% confidence interval 0.67 to 1.11). Digoxin
therapy was associated with a lower probability of achieving rate control (adjusted hazard ratio 0.52,
95% confidence interval 0.32 to 0.86) and calcium channel blocker therapy was associated with a
lower probability of achieving rhythm control (adjusted hazard ratio 0.56, 95% confidence interval
0.39 to 0.79) than amiodarone. Findings were consistent across both the combined and the individual
database analyses.
Conclusions: Existing evidence for new-onset atrial fibrillation management in intensive care unit patients
is limited. New-onset atrial fibrillation in these patients is common and is associated with significant
short- and long-term complications. Beta-blockers and amiodarone appear to be similarly effective in
achieving cardiovascular control, but digoxin and calcium channel blockers appear to be inferior.
Future work: Our findings suggest that a randomised controlled trial of amiodarone and beta-blockers
for management of new-onset atrial fibrillation in critically ill patients should be undertaken. Studies
should also be undertaken to provide evidence for or against anticoagulation for patients who develop
new-onset atrial fibrillation in intensive care units. Finally, given that readmission with heart failure and
thromboembolism increases following an episode of new-onset atrial fibrillation while in an intensive
care unit, a prospective cohort study to demonstrate the incidence of atrial fibrillation and/or left
ventricular dysfunction at hospital discharge and at 3 months following the development of new-onset
atrial fibrillation should be undertaken.
Trial registration: Current Controlled Trials ISRCTN13252515.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 71. See the NIHR Journals Library website for further project information.
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Atrial fibrillation can cause heart failure and stroke. It can also affect heart rate in different ways. It is
common for patients admitted to intensive care units to develop atrial fibrillation. When patients have
never had atrial fibrillation before, this is called ‘new-onset atrial fibrillation’.
We do not know how new-onset atrial fibrillation in patients treated in an intensive care unit
affects heart rate and blood pressure, what the best treatments are or how treatments affect how
people recover.
Methods
We looked at studies of new-onset atrial fibrillation treatments in intensive care units to see if some
treatments have been shown to work better.
We used a national database to see what happens to intensive care unit patients in the UK who
develop new-onset atrial fibrillation. We also used two databases from intensive care units in the UK
and the USA to see how many patients in the intensive care units have new-onset atrial fibrillation,
how atrial fibrillation affects heart rate and blood pressure, and whether or not some treatments work
better than others.
Results
Between 6% and 11% of intensive care unit patients develop new-onset atrial fibrillation. These
patients are more likely to die in hospital and in the first 90 days after discharge than those who
do not. They are also more likely to be readmitted to hospital with atrial fibrillation, stroke and
heart failure. The evidence for new-onset atrial fibrillation treatments is limited, but suggests that
beta-blockers or amiodarone may work better than calcium channel blockers or digoxin.
Conclusions
New-onset atrial fibrillation in intensive care units is common, and outcomes are worse in patients
who develop new-onset atrial fibrillation than in those who do not. Our research shows that some
new-onset atrial fibrillation treatments work better than others. This information will help us to plan
a study to improve health after new-onset atrial fibrillation.
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Of the 170,000 adults treated on UK intensive care units (ICUs) annually, 10,000–20,000 develop
new-onset atrial fibrillation (NOAF) and are clustered in subgroups, such as patients with sepsis. NOAF in
patients on ICUs can cause cardiovascular instability and thromboembolism. It is independently associated
with increases in length of hospital stay, mortality and health-care costs. It may also be associated with
increased long-term morbidity and mortality in patients who survive until hospital discharge.
The current atrial fibrillation (AF) treatment guidelines are based on patients outside ICUs. NOAF in
patients in an ICU differs in the causes of rhythm disturbance, and the risks and clinical effectiveness
of treatments. There is little evidence to guide NOAF treatment on ICUs; consequently, practice varies.
It is unclear whether or not NOAF developed in an ICU results in future episodes of AF, heart failure
or stroke. Optimal management strategies in ICUs and post ICU discharge are unknown.
Objectives
Scoping review
l To evaluate the evidence for the clinical effectiveness and safety of pharmacological and
non-pharmacological NOAF treatments.
l To provide guidance for the database analysis on:
¢ NOAF definitions used for patients in an ICU
¢ patient subgroups who develop NOAF in an ICU
¢ inclusion/exclusion of specific treatments and potential confounders
¢ determining barriers to future research.
Database analysis: RISK-II
l To determine how common NOAF is in critical care.
l To determine the typical characteristics of patients with NOAF in critical care and how they
compare with those of other patients in critical care.
l To increase the understanding of the outcomes of patients with NOAF in critical care and how they
compare with those of other patients in critical care.
l To investigate how much of the difference in outcomes is explained by differences in patient
characteristics and comorbidities.
Database analysis: MIMIC-III and PICRAM
l To compare the use and clinical effectiveness of pharmacological and non-pharmacological
NOAF treatments.
l To determine the incidence of short- and long-term NOAF complications.
DOI: 10.3310/hta25710 Health Technology Assessment 2021 Vol. 25 No. 71
Copyright © 2021 Bedford et al. This work was produced by Bedford et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.




In March 2019, we searched 13 electronic databases and trial registries, including MEDLINE, EMBASE™
(Elsevier, Amsterdam, the Netherlands) and Cumulative Index to Nursing and Allied Health Literature
(CINAHL), without date and language restrictions to identify published and unpublished studies.
Adults aged ≥ 16 years in general medical, surgical or mixed ICUs were eligible. We excluded studies
of cohorts defined by a single disease or a narrow disease group that are not normally admitted to
a general ICU, and studies based on service-specific ICUs. Pharmacological, electrical and other
non-pharmacological treatment strategies for treatment or prevention of NOAF and the use of short-
or long-term anticoagulation were eligible. Any eligible intervention could be a comparator, as could
no treatment, standard care and placebo. Outcomes were rhythm and rate control, length of ICU and
hospital stay, mortality (ICU, hospital, 30 days and long term), arterial thromboembolism and adverse
treatment effects. Quantitative studies (randomised and non-randomised trials, cohort studies, case
series with five or more patients reported, and trial protocols) were eligible. We included reviews,
practitioner surveys and opinion pieces.
Two reviewers independently screened titles, abstracts and full-text articles. Discrepancies were
resolved through discussion or via a third reviewer. Study details and findings were presented in
structured tables and described and summarised narratively.
Included studies were quality assessed using version 2 of the Cochrane risk-of-bias tool for randomised
trials and the Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) tool for larger
non-randomised comparative studies.
Expert panel
We identified a list of variables from our scoping review that may affect the treatment choice for
NOAF. We then circulated this list among our expert panel, who added to and refined the list. We
collated a final list of these confounding variables, which was ratified by our expert panel. We repeated
this process with definitions of NOAF, interventions of interest and outcomes of interest.
Database analysis: RISK-II
To investigate the long-term outcomes associated with NOAF, we analysed patient records from the RISK-II
database. RISK-II combines anonymised, linked, routinely collected data from the Case Mix Programme
national clinical audit of adult intensive care, Hospital Episode Statistics (HES) for England and the Office
for National Statistics (ONS) mortality databases. It includes patients admitted to ICUs in England between
1 April 2009 and 31 March 2016.We categorised admissions as involving NOAF, possible NOAF,
pre-existing AF or no AF, in accordance with evidence available from the linked HES records.
To compare characteristics and outcomes, we selected a cohort of comparator patients who did not
develop NOAF and who were matched on hospital and month/year of admission to an ICU. We
identified comorbidities using the International Classification of Diseases and Related Health Problems,
Tenth Revision, codes from linked HES records. We identified the date and cause of death from linked
ONS records. We identified subsequent hospital admissions using linked HES records and classified
these as involving AF, stroke or heart failure. We estimated associations between NOAF and outcomes
before and after adjustment for patient characteristics and comorbidities using multivariable regression
models adjusting for age, sex and comorbidities.
Database analysis: PICRAM and MIMIC-III
We carried out a retrospective cohort study of two large within-ICU databases from the USA and
the UK. We excluded patients with known pre-existing AF or an arrhythmia within 3 hours of ICU
admission. We identified the occurrence of AF from observation chart data.
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We compared patients who developed NOAF with patients who did not. We analysed the mortality
associated with NOAF before and after adjusting for confounding variables. We then identified a
cohort of patients who received treatment for their NOAF. We analysed the characteristics of treated
NOAF, including time to onset and duration. We also analysed the changes in haemodynamic parameters
and vasoactive medication use associated with NOAF onset.
We balanced treatment groups using propensity score weighting. We then investigated the efficacy of
different NOAF treatments for rate control, rhythm control and mortality.
Results
Scoping review
We screened 3651 articles by title and abstract, identifying 198 articles of potential interest. After
full-text screening, we included 25 group studies, 12 reviews, one survey and four opinion pieces.
A limited evidence base was available. Of 25 primary studies included in the review, two were
randomised controlled trials (RCTs). Of 11 non-randomised comparative studies, three attempted
to control for confounding factors. Where studies attempted to control for confounding, quality
assessment still identified concerns that bias might affect results. Most studies were single-group
studies lacking a comparator group. Studies used different treatment doses, administration methods
and time points to assess the success of conversion to sinus rhythm. Six studies were available as
conference abstracts only. Limited evidence from four studies suggested that beta-blockers might
be more effective than amiodarone for conversion to sinus rhythm and in reducing mortality. It is
unclear whether or not anticoagulant therapy results in a reduction in stroke risk and whether or
not the potential benefits outweigh the increased risk of bleeding in ICU patients. No conclusive
findings have been reported owing to the low quality of the reviewed evidence and the methodological
differences between the included studies. Most studies and reviews concluded that further research
is needed urgently.
Expert panel
The expert panel ratified a list of treatments of interest and confounding variables. The scoping review
highlighted that definitions of NOAF in patients on ICUs and definitions of treatment success varied.
In the absence of any consensus definition of NOAF, we adopted the agreed definition of AF in patients
outside an ICU, namely any AF lasting ≥ 30 seconds. We defined time to cardioversion as the time to
first reversion of sinus rhythm, and time to rate control as the time to a heart rate of < 110 beats per
minute (b.p.m.).
Database analysis: RISK-II
The analysis included 841,005 ICU admissions for 733,038 patients. We identified 4615 (0.6%)
admissions as involving NOAF and a further 3548 (0.4%) as involving possible NOAF. Each admission
involving NOAF was matched to six comparator admissions with no AF from the same month/year and
ICU. Patients with NOAF were older (mean age 71.5 years vs. 59.1 years) and had higher levels of
comorbidity, especially hypertension (66.1% vs. 47.2%), heart failure (24.8% vs. 10.1%) and valvular
heart disease (12.5% vs. 6.2%), than the comparator patients. After controlling for these differences,
patients with NOAF had substantially higher mortality in hospital and during the first 90 days after
discharge than patients who did not [adjusted odds ratio (aOR) 2.32, 95% confidence interval (CI)
2.16 to 2.48; adjusted hazard ratio (aHR) 1.46, 95% CI 1.26 to 1.70, respectively], and higher rates of
subsequent hospitalisation with AF, stroke and heart failure [adjusted cause-specific hazard ratio (CHR)
5.86, 95% CI 5.33 to 6.44; adjusted CHR 1.47, 95% CI 1.12 to 1.93; and adjusted CHR 1.28, 95% CI
1.14 to 1.44, respectively) than patients who did not.
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Database analysis: MIMIC-III and PICRAM
New-onset atrial fibrillation was common in ICU patients, occurring in 1065 out of 18,559 (5.7%)
eligible patients in US data and 952 out of 8367 (11.4%) eligible patients in UK data. In the study
cohort (patients treated for NOAF), the median time to onset of NOAF was 40 hours, with a median
duration of 14.4 hours.
In the combined database analysis, NOAF was associated with a significant increase in heart rate of
18 b.p.m., a reduction in systolic blood pressure of 5 mmHg and an increase in vasoactive-inotropic score
of 2.3 (all p < 0.001). NOAF was associated with a significantly increased risk of hospital mortality after
adjusting for confounding factors (CHR 1.84, 95% CI 1.69 to 2.00; adjusted CHR 1.58, 95% CI 1.45 to 1.71).
In the combined database analysis, we found no differences between beta-blockers and amiodarone in
rates of achieving rate control (aHR 1.14, 95% CI 0.91 to 1.44) or rhythm control (aHR 0.86, 95% CI
0.67 to 1.11). We found that digoxin therapy was associated with a lower rate of achieving rate control
than amiodarone (aHR 0.52, 95% CI 0.32 to 0.86). We found that calcium channel blocker therapy
was associated with a lower rate of achieving rhythm control than amiodarone (aHR 0.56, 95% CI
0.39 to 0.79). These findings were consistent with analyses of individual databases.
Discussion
Our scoping review revealed marked differences in the definitions of NOAF and the definitions of
treatment success between studies. Limited evidence suggested that beta-blockers might be more
effective than amiodarone for conversion to sinus rhythm and mortality outcomes. However, residual
bias may explain these assertions. The available literature suggests that it is unclear whether or not
the benefits of administering anticoagulants in critically ill patients with NOAF for stroke prevention
outweigh the increased risk of bleeding. Reluctance to initiate anticoagulation demonstrated in surveys
may be owing to the uncertainty of this risk–benefit balance.
The scoping review was performed using systematic, transparent and robust methods. The bibliographic
database searches were comprehensive, maximising identification of relevant studies, while also minimising
the possibility of publication or language biases affecting the review. The main limitation of the scoping
review was the methodological shortcomings of the studies identified, preventing conclusive findings.
The scoping review allowed definitions of NOAF and treatment success for the database analyses
to be agreed following the expert panel meeting, along with a long list of interventions and
potential confounders.
Analysis of the RISK-II database identified a group of patients who develop NOAF in critical care who
have substantially worse short- and long-term outcomes, including readmission with heart failure and
thromboembolism, than similar patients without any record of AF during or prior to ICU admission.
However, the group identified by hospital coding is much smaller than that found by analysis of ICU
data. Whether or not the findings would be replicated in this larger group is unclear. The increased
incidence of stroke suggests that there may be a role for anticoagulation in some patients who
develop NOAF during an ICU stay; however, the appropriate patient group, timing and duration of
anticoagulation are unknown.
Our within-ICU database analysis found that the treatment of NOAF with digoxin or calcium channel
blockers as first-line therapy, compared with amiodarone, is associated with poorer rate control
and rhythm control, respectively. Previous studies have suggested that beta-blocker therapy may
be associated with better outcomes than amiodarone therapy. Our findings revealed that patients
who received beta-blockers were less unwell at admission and more stable around AF onset. After
comprehensive adjustment of these factors, there were no identifiable differences in outcomes
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between these two treatments. To the best of our knowledge, our ICU database analysis provides
the first comparative study of NOAF treatments, where differences between treatment groups around
AF onset are adjusted for. The use of routine data provided a sample size large enough to detect
differences between these treatment groups. However, it is limited by its retrospective nature and
residual unmeasured confounding may contribute to any identified effects.
Applicability
Our RISK II database analysis included national data and our results are, therefore, meaningful for most
general adult ICUs in the UK. Our within-ICU database analysis included data from tertiary centres and
district general hospitals in the UK, alongside data from the USA, suggesting that our findings are
applicable elsewhere.
Conclusions
Our scoping review highlighted the need for standardised definitions in future research into NOAF.
We found that NOAF during an ICU stay is common and is associated with substantially increased
mortality, after correction for associated risk factors. Identifying optimal treatment strategies is a
research priority, with the potential to improve patient outcomes. Both amiodarone and beta-blockers
are commonly used but have significant side effects. Whether or not one is superior to the other
is unknown. A RCT of amiodarone compared with beta-blockers for the management of NOAF in
critically ill patients should be undertaken. Current evidence does not support the use of calcium
channel blockers or digoxin as first-line therapy for undifferentiated patients who develop NOAF
during an ICU stay.
There is little evidence for or against anticoagulation for patients who develop NOAF in an ICU. The
risk of thromboembolism is increased compared with those who do not develop NOAF, even when
corrected for known risk factors. However, current risk stratification tools have not been validated
in the ‘new-onset atrial fibrillation during intensive care unit population’ and do not take account of
within-ICU factors that may affect future outcome. Whether or not subgroups of patients who develop
NOAF while in an ICU may benefit from long-term anticoagulation is unknown. Studies should be
undertaken to create risk stratification tools or investigate whether or not current tools are applicable
to the ‘new-onset atrial fibrillation during intensive care unit population’ to identify patients sufficiently
at risk of future thromboembolism to merit consideration of anticoagulation.
Readmission with heart failure and thromboembolism increases over the 5 years following an episode
of NOAF while in an ICU, particularly in the first year. Whether or not these events are driven by
persistent left ventricular dysfunction and/or AF is unknown. A prospective cohort study to demonstrate
the incidence of AF and/or left ventricular dysfunction at hospital discharge and at 3 months following
development of NOAF should be undertaken.
Trial registration
This trial is registered as ISRCTN13252515.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 71.
See the NIHR Journals Library website for further project information.
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Description of the health problem
New-onset atrial fibrillation (NOAF) is defined as atrial fibrillation (AF) that occurs in a patient with
no known history of chronic or paroxysmal AF.1 It is a common arrhythmia in critically ill patients.2
It occurs in 5–15% of all patients admitted to a general intensive care unit (ICU),3,4 rising to 23% of
patients with septic shock.5
Organised atrial activity is important for ventricular filling and cardiac output.6 NOAF is temporally
associated with a reduction in cardiac output in non-ICU patients.7 The haemodynamic impact of
NOAF in critically ill patients is poorly understood, but limited data suggest that NOAF may precede
haemodynamic instability8 and may be associated with increased rates of thromboembolism.9 NOAF
during critical illness is associated with an increased risk of death in an ICU and in hospital.10,11 There is
also a significant organisational impact of NOAF because it is associated with an increased length of
ICU and hospital stay, and higher health-care costs.12
New-onset atrial fibrillation during critical illness may carry a long-term burden. Patients who develop
NOAF during sepsis and survive to hospital discharge have an increased risk of heart failure and
stroke, and poorer 1-year and 5-year survival.13,14 The long-term outcomes for patients who develop
NOAF in an ICU remains unclear.
It is not known whether NOAF in patients in an ICU is causally related to worse outcomes or whether
NOAF may be solely a marker of disease severity. However, there is clear mechanistic plausibility
behind a causal association. This demonstrates the need for optimal prevention, management and
follow-up. Although a recent scoping review has broadly described studies of NOAF treatment in
patients in an emergency department or an ICU, or after major surgery,10 an in-depth review of NOAF
in patients in an ICU focusing on treatment efficacy is required to put current treatment practices into
context and to inform future comparative studies.
Clear guidelines exist for the management of AF in patients in the community.15 However, there is a paucity
of evidence for its management in the critical care setting, for which the balance of risks and benefits
associated with different treatment options is unclear. Understandably, there is significant variation within
and between units in the management of this common problem.16 Many previous studies informing NOAF
treatment in ICUs are small or inadequately adjusted for confounding factors. Well-conducted, multicentre,
observational studies are required to highlight candidate interventions for clinical trials.
Overall aims and objectives of the study
Scoping review
l To evaluate the evidence for the clinical effectiveness and safety of pharmacological and
non-pharmacological NOAF treatments.
l To provide guidance for the database analysis on:
¢ NOAF definitions used for patients in an ICU
¢ patient subgroups who develop NOAF in an ICU
¢ inclusion/exclusion of specific treatments and potential confounders
l determining barriers to future research.
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Database analysis: RISK-II
l To determine how common NOAF is in critical care.
l To determine the typical characteristics of patients with NOAF in critical care and how they
compare with other patients in critical care.
l To increase the understanding of the outcomes of patients with NOAF in critical care and how they
compare with other patients in critical care.
l To investigate how much of the difference in outcomes is explained by differences in patient
characteristics and comorbidities.
Database analysis: MIMIC-III and PICRAM
l To compare the use and clinical effectiveness of pharmacological and non-pharmacological
NOAF treatments.
l To determine the incidence of short- and long-term NOAF complications.
Patient and public involvement
Patient and public involvement was vital throughout the study. Valerie Keston-Hole and Rob Lawrence
helped to develop the application, which was also reviewed by the Oxford Critical Care Patient Forum.
The group strongly supported the use of existing databases for the purposes of undertaking the work.
Valerie Keston-Hole sits on the group, which assesses applications for the use of the Post Intensive
Care Risk-adjusted Alerting and Monitoring (PICRAM) data used in this work. Ian and Cathy Taylor
provided us with a clear patient perspective when working with the expert panel and also helped us to
choose research recommendations. Meetings went well and easy access to the chief investigator meant
that things that were unclear could be explained by e-mail afterward and further thoughts considered.
In discussion with Ian and Cathy Taylor, we identified that an area that we would improve in the future
was how to present large numbers of initial data in a more comprehensible manner to our patient and
public involvement (PPI) colleagues. A suggestion for the future would be to provide supplementary
information that avoided technical terminology to help the understanding of the data by our PPI
colleagues prior to the meetings. This would allow more spontaneous comments and discussion during
the meeting. Our PPI work is not complete. We discussed our findings at the ICU patient forum. This
helped us to understand how to clearly communicate our findings.
BACKGROUND
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Chapter 2 Scoping review of treatments
for new-onset atrial fibrillation
Parts of this chapter are adapted with permission from Drikite et al.
17 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Scoping review methods
The scoping review followed the methodological framework described by Arksey and O’Malley,18 Levac
et al.19 and Daudt et al.,20 and the reporting complies with the recently published Preferred Reporting
Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR)
reporting guidelines.21
Literature searches
The search strategy was developed by an information specialist in MEDLINE (via Ovid®; Wolters
Kluwer, Alphen aan den Rijn, the Netherlands) without any date or language restrictions. The search
strategy included terms used to describe NOAF combined with a set of terms used for critical care.
An adapted MEDLINE search strategy was used to search the following databases in March 2019:
MEDLINE, EMBASE™ (Elsevier, Amsterdam, the Netherlands), Cumulative Index to Nursing and Allied
Health Literature (CINAHL), Web of Science™ [Clarivate Analytics, Philadelphia, PA, USA; including
Conference Proceedings Citation Index – Science (Clarivate Analytics)], OpenGrey, the Cochrane
Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials (CENTRAL) and
the Database of Abstracts of Reviews of Effects (DARE; searched from 1994 to 2015). We were not
able to search the National Guideline Clearinghouse, as suggested in our protocol,22 because this
database was no longer available. The following clinical trial databases were searched for studies in
progress or completed but not reported: International Standard Randomised Controlled Trial Number
(ISRCTN), ClinicalTrials.gov, the EU Clinical Trials register, additional World Health Organization
International Clinical Trials Registry Platform (ICTRP) trial databases and the National Institute for
Health Research Clinical Trials Gateway.
The search results were imported into EPPI-Reviewer 4 software (Evidence for Policy and Practice
Information and Co-ordinating Centre, University of London, London, UK) and duplicates were
removed. The search strategies can be found in Appendix 1. The reference lists of included review
articles and studies were also reviewed to identify any relevant studies.
Eligibility criteria
The eligibility criteria used to screen titles, abstracts and full-text articles were as follows.
l Population:
¢ Studies of adults (age ≥ 16 years) with NOAF (or without any history of AF, for prevention/
prophylactic studies) admitted to general medical, surgical or mixed ICUs were included.
¢ Studies of cohorts defined by a single disease or narrow disease group not normally admitted
to a general ICU (e.g. myocardial infarction) and studies based on service-specific ICUs
(e.g. cardiothoracic or neurosurgical) were excluded.
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¢ Studies in which a majority (> 50%) of patients belonged to a single, specific disease or operative
cohort (e.g. liver resections or lung surgery) and cohorts with a known history of chronic or
paroxysmal AF were excluded.
¢ Studies of disease groups commonly admitted to an ICU, such as sepsis and septic shock,
were included.
¢ Studies of patients with supraventricular arrhythmias if AF constituted at least 70% of
arrhythmias were included. Where these data were unavailable, we included studies that
grouped AF and atrial flutter together if no other arrhythmia types were included.
¢ Studies reporting on populations that were a mixture of NOAF and known AF were included
only if data for the NOAF subgroup were reported separately.
¢ Studies that included both ICU and non-ICU patients, but which did not present results
separately, were included only if > 50% of the total cohort were ICU patients and if a valid
method for confounding adjustment was used with ICU status included as a covariate.
l Intervention:
¢ Studies investigating pharmacological, electrical and other non-pharmacological (including
electrolyte) treatment strategies for treatment or prevention of NOAF were included.
¢ Studies of short- or long-term anticoagulation were included.
¢ Studies of ablation or surgical interventions were excluded.
l Comparators:
¢ Any eligible intervention could be a comparator, including no treatment or ‘standard care’.
¢ Placebo was also eligible.
l Outcomes – any of the following outcomes were eligible:
¢ rhythm and rate control
¢ length of ICU and hospital stay
¢ mortality (ICU, hospital, 30 days and long term)
¢ arterial thromboembolism and adverse treatment effects
¢ in the case of studies of preventative/prophylactic treatments, the incidence of NOAF had to
be reported.
l Study design – we included quantitative studies with the following designs:
¢ randomised and non-randomised trials
¢ cohort studies and case series containing five or more patients
¢ practitioner surveys and opinion pieces (for research recommendations and interventions not
otherwise identified) were also included.
Two reviewers independently screened titles and abstracts and potentially relevant full-text articles.
Any discrepancies between the reviewers were resolved either through discussion or by a third
reviewer if necessary. Titles, abstracts and full-text articles were screened using EPPI-Reviewer 4
software. The screening of titles and abstracts was facilitated by use of the highlighting function in
EPPI-Reviewer 4 (which highlights keywords associated with inclusion or exclusion criteria). This
function allowed more prompt decisions to be made. After screening the titles and abstracts, all
potentially relevant full-text articles were uploaded on Mendeley Reference Manager Software
(1.19.5; Elsevier, Amsterdam, the Netherlands) for easy access and sharing purposes.
Full-text articles that were not published in English included papers in French, German, Czech, Chinese
and Spanish. These were screened by native speakers. None of the foreign language articles was
eligible for the review.
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Data charting
Data-charting forms were developed for the following study designs:
l randomised controlled trials (RCTs)
l prospective comparative studies (non-RCTs)
l retrospective comparative studies
l single-group studies.
The extracted data included the following:
l details of the study (authors, country, setting, sample size and proportion of NOAF patients included
in the study)
l population characteristics (primary diagnosis; mean age; proportion of males; severity of illness;
proportion of patients on vasopressors; proportion of patients with cardiovascular disease, acute
renal failure, acute respiratory failure and mechanical ventilation; mean serum potassium levels;
and authors’ definition of NOAF)
l description of intervention and comparator(s)
l methods to address confounding (for non-randomised studies)
l results
l any relevant recommendations for the future research.
The data-charting forms were piloted on a small number of studies and were adapted accordingly
where necessary. Decisions about which population characteristics to extract were informed by a
recent systematic review on risk factors for NOAF on the ICU23 and a retrospective observational
study on predictors for sustained NOAF in the critically ill.24 All data were extracted by one reviewer
and checked by another member of the team; any disagreements would be referred to a third member
of the team.
Critical appraisal
Randomised trials were evaluated using version 2 of the Cochrane risk-of-bias tool (see Appendix 2).25
Non-randomised comparative studies that fulfilled the following criteria were evaluated for risk of bias
using the Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) tool:26
l reported as full papers
l included at least 100 patients per treatment arm
l reported on methods to adjust for confounding.
The ROBINS-I tool was adapted for use in this scoping review by including a stopping rule: the risk-
of-bias assessment stopped if a serious or critical risk-of-bias judgement was made for the ‘bias due to
confounding’ domain. For the confounding domain, decisions regarding which covariates should be
reported as being controlled for in analyses were made by the clinical experts in the CAFE (Critical
care Atrial Fibrillation Evaluation) study team, with supporting references where possible, and are
reported in Table 1, along with the risk-of-bias judgements.
Collating and summarising the results
The details of the primary studies were presented in structured tables categorised by study design.
For each type of study design, the extent, range and nature of the identified research were described.
Study parameters and results were then described and summarised narratively.
Expert panel review
We convened a face-to-face meeting of expert panel members to review our scoping review results
and to inform our subsequent database analysis. We created a list of variables identified from our
scoping review that may affect NOAF treatment choice. We then circulated this list among our expert
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APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; NA, not applicable; RD, risk
difference; RR, relative risk; SOFA, Sequential Organ Failure Assessment.
a For further details, see Tables 5 and 7.
b For groups receiving the following treatments: beta-blockers vs. calcium channel blockers, beta-blockers vs. digoxin
and beta-blockers vs. amiodarone.
c Not applicable because a serious risk-of-bias judgement was made for the ‘bias due to confounding’ domain
(see Critical appraisal).
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panel where it was independently added to and refined. We collated a final list of these confounding
variables, which was then ratified by our expert panel. We repeated this process with definitions of
NOAF, interventions of interest and outcomes of interest.
Scoping review results
Quantity and quality of the research available
Following the removal of duplicates from the articles retrieved by database searches, 3651 articles
were screened on their title and abstract. From those screened, 198 articles were identified as of
potential interest and were screened on their full text. Two articles were unobtainable: a conference
abstract published in 2000 and an old study from 1974 looking at amiodarone as a treatment of
supraventricular tachyarrhythmias in critically ill patients. Therefore, copies of the 196 full-text articles
were assessed for inclusion in the scoping review and 42 articles were included in the review. One
eligible article was identified from checking the reference lists of included review articles. Figure 1
illustrates the flow of the articles throughout the review process and the number of included articles
classified by study design. Studies excluded after full-text review are listed in Appendix 4, Table 19.
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FIGURE 1 Flow chart showing the number of studies identified, excluded and eligible for inclusion in the scoping review.
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Two RCTs were included. It was judged that the Balser et al.30 trial gave rise to some concerns about
possible bias, primarily owing to the lack of reporting of randomisation methods and the lack of
blinding. The Delle Karth et al.31 trial was judged to have a high risk of bias based on the lack of
reporting of randomisation methods, coupled with baseline differences in sex and age. Moreover,
the trial was not blinded with respect to investigators and caregivers.
Non-randomised comparative studies
Three non-randomised studies27–29 fulfilled the criteria (see Critical appraisal) to be evaluated using the
ROBINS-I risk-of-bias tool.
All three of the large, non-randomised studies were judged to have a serious risk of bias owing to
confounding. This was a result of either missing covariates in the propensity score matching or the risk
of residual confounding as a result of the measurement of the covariates. The two studies by Walkey
et al.28,29 stated that some key data were recorded on admission, but that these studies used enhanced
administrative data that lacked the detailed sequence of events. Some data relating to the admission
time point may not be representative of the time point at which a treatment decision was made. The
authors noted other limitations of these two studies, adding that the findings should be ‘considered
hypothesis-generating and supportive of the need for future clinical trials to investigate optimal
treatment of AF during sepsis’.28
Primary studies of clinical effectiveness and safety
Table 2 presents an overview of the primary study evidence identified in the review. Further details are
reported in the following sections, according to study design.
Randomised controlled trials
Two small RCTs30,31 were identified as eligible and were included in the review. Both trials investigated
pharmacological treatment strategies for rate control in patients with NOAF. Details of the RCTs are
presented in Tables 3 and 4. Two further RCTs51,52 that studied supraventricular tachycardias were identified,
but these were not eligible because < 70% of their study population were diagnosed with NOAF.
A RCT (n = 55)30 set in the USA compared esmolol (a beta-blocker) with diltiazem (a calcium channel
blocker) in a non-cardiac surgical population. The proportion of patients diagnosed with NOAF was
79% in the esmolol group and 80% in the diltiazem group. Both esmolol and diltiazem were second-line
treatments for NOAF because adenosine had been administered before the study treatments. The
authors reported that loading and infusion rates were adjusted to achieve a degree of ventricular rate
control similar to that achieved with standard dosing regimens used in their surgical ICU. The primary
outcome that was reported was the rate of conversion to sinus rhythm. There was no statistically
significant difference in conversion rate between the study groups within 2 hours for patients with
NOAF: 59% in those who received esmolol and 27% in those who received diltiazem (p = 0.067).
By 12 hours, 85% of patients who received esmolol had converted back to sinus rhythm, compared
with 62% of patients who received diltiazem (p = 0.116). No adverse events were reported.
Delle Karth et al.31 conducted a small RCT in Austria comparing diltiazem, an amiodarone (an
anti-arrhythmic medication with multiple mechanisms of action) bolus and an amiodarone bolus in
combination with 24 hours of infusion in a mixed ICU population. Ninety-five per cent of patients
enrolled in the trial (n = 57) were diagnosed with NOAF. The first study group received a dose of
25 mg of diltiazem by an intravenous (i.v.) bolus infusion over 15 minutes, followed by a continuous
infusion at a rate of 20 mg/hour for a total of 24 hours. The second study group was given a bolus
dose of 300 mg of amiodarone, followed by an i.v. infusion over 15 minutes. The third study group was
given a dose of 300 mg of amiodarone followed by an i.v. bolus infusion over 15 minutes, which was
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Amiodarone Delle Karth 2001,31
n= 60
Gerlach 2008,32 n = 61 Walkey 2016,28 n = 3174
Cho 2017,33 n= 448
Matsumoto 2015,34 n= 276
Balik 2017,35 n= 234
Mieure 2011,36 n= 126
Jaffer 2016,37 n= 65
Brown 2018,38 n = 33
Sleeswijk 2008,39 n = 29
Slavik 2003,40 n= not
reported
Liu 2016,41 n = 240
Mitrić 2016,42 n = 177
Kanji 2012,8 n = 139
Mayr 2004,43 n = 131
Burris 2010,44 n = 30
Beta-blockers Balser 1998,30 n = 55 No studies Walkey 2016,28 n = 3174
Matsumoto 2015,34 n= 276
Balik 2017,35 n= 234
Mieure 2011,36 n= 126
Jaffer 2016,37 n= 65
Brown 2018,38 n = 33
Nakamura 2016,45 n = 16 Liu 2016,41 n = 240
Kanji 2012,8 n = 139
Burris 2010,44 n = 30
Calcium channel blockers Delle Karth 2001,31
n= 60
Balser 1998,30 n = 55
Gerlach 2008,32 n = 61 Walkey 2016,28 n = 3174
Mieure 2011,36 n= 126
Jaffer 2016,37 n= 65
Brown 2018,38 n = 33
No studies Liu 2016,41 n = 240
























































































































































































































































































































































































































Propafenone No studies No studies Balik 2017,35 n= 234 No studies No studies
Digoxin No studies No studies Walkey 2016,28 n = 3174 No studies Liu 2016,41 n = 240
Burris 2010,44 n = 30
Ibutilide No studies No studies No studies Hennersdorf 2002,46 n = 26




No studies No studies No studies Sleeswijk 2008,39 n = 29 No studies
Prophylactic treatments




No studies No studies No studies Mayr 2003,49 n = 37 No studies
Electrical cardioversion No studies No studies No studies No studies Liu 2016,41 n = 240
Kyo 2019,50 n= 85
Anticoagulants
















































































TABLE 3 Methods and characteristics of RCTs
Study details Population characteristics Intervention Comparator




Sample size: n= 55
(esmolol, n = 28;
diltiazem, n = 27)
NOAF patients: n = 44
(80%) (esmolol, n= 22,
79%; diltiazem, n = 22,
81%)
Primary diagnosis: non-cardiac surgical patients
Primary diagnosis Esmolol (n) Diltiazem (n)
GI/GU 7 13
Thoracic 9 6
Nonthoracic vascular 4 3
Neurosurgery 2 3
Other 4 2
No surgery 2 0
Mean age: esmolol, 66 ± 15 years; diltiazem, 69± 11 years
Male: esmolol, n= 14 (50%); diltiazem, n= 16 (59%)
Severity of illness: APACHE III reported – esmolol, 59± 31; diltiazem,
65± 24
Patients on vasopressors: esmolol, n= 1 (3.57%); diltiazem, n = 3 (11%)
Cardiovascular disease Esmolol, n (%) Diltiazem, n (%)
Coronary artery disease 10 (36) 13 (48)
Recent MI or ischaemia 1 (3.57) 2 (7)
Left ventricular hypertrophy 3 (11) 1 (3.7)
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium: NR
Definition of NOAF: ‘SVT present for as long as 24 hours’
Esmolol: 12.5-mg i.v. bolus, followed
by additional 25- to 50-mg boluses
every 3–5 minutes until the heart rate
was < 110 b.p.m. or a total loading
dose of 250 mg was attained. The
maintenance infusion was 50 µg/kg/
minute for patients receiving > 30mg.
After 15 minutes, patients whose heart
rate exceeded 110 b.p.m. received
1–4 boluses of 25mg, followed by a
50 µg/kg/minute increment in their
maintenance infusion.The authors
reported that this was repeated after
30 minutes for patients whose heart
rate was > 100 b.p.m. Beyond
30 minutes, infusion rates were adjusted
by the treating physician to maintain
heart rates between 80 and 100 b.p.m. If
at any time a patient had symptomatic
hypotension or their systolic blood
pressure was < 80mmHg, the infusion
rate was decreased by 50% or a
phenylephrine infusion was
administered, or both
Line of NOAF treatment: second
line – adenosine given before the
study treatment
Diltiazem: loading infusion of 20 mg
over 2 minutes, immediately followed
by a 10mg/hour maintenance infusion.
After 15 minutes, patients whose heart
rate was > 110 b.p.m. received an
additional loading infusion of
25 mg and a 5 mg/hour increment in
their maintenance infusion. After
30 minutes, patients receiving a
maintenance infusion of < 15mg/hour
with a heart rate of > 100 b.p.m.
received an additional 5 mg/hour
increment in their infusion rate.
Beyond 30 minutes, infusion rates
were adjusted by the treating
physician to maintain heart rates
between 80 and 100 b.p.m. If at any
time a patient had symptomatic
hypotension or their systolic blood
pressure was < 80mmHg, the infusion
rate was decreased by 50% or a
phenylephrine infusion was
administered, or both
Line of NOAF treatment: second














































































































































































































































































































































































































TABLE 3 Methods and characteristics of RCTs (continued )
Study details Population characteristics Intervention Comparator




Sample size: n= 60
(diltiazem, n = 20;
amiodarone bolus,
n = 20; amiodarone
bolus + 24 hours,
n = 20)





















Others 1 3 1
Mean age: diltiazem, 64.8 ± 10 years; amiodarone bolus,
67.8 ± 9 years; amiodarone bolus + 24 hours, 71.2 ± 9 years
Male: diltiazem, n= 15 (75%); amiodarone bolus, n= 17 (85%);
amiodarone bolus + 24 hours, n = 11 (55%)
Severity of illness: APACHE III score reported – diltiazem, 75.1± 35;
amiodarone bolus, 76.7 ± 38; amiodarone bolus+ 24 hours, 59.7 ± 8
Patients on vasopressors at the time of onset: diltiazem, n = 14 (70%);
amiodarone bolus, n = 15 (75%); amiodarone bolus + 24 hours,
n= 15 (75%)
Patients with CVD: diltiazem, n = 13 (65%); amiodarone bolus,
n= 15 (75%); amiodarone bolus + 24 hours, n= 18 (90%)
Patients with acute renal failure: NR
Diltiazem: 25 mg of diltiazem by i.v.
bolus infusion over 15 minutes
followed by a continuous infusion at a
rate of 20 mg/hour for 24 hours
Line of NOAF treatment: first line
Amiodarone bolus: a bolus dose of
300 mg of amiodarone followed by
i.v. infusion over 15 minutes
Line of NOAF treatment: first line
Amiodarone bolus + 24 hours: a dose
of 300 mg of amiodarone followed by
an i.v. bolus infusion over 15 minutes
followed by a continuous infusion at a
rate of 45 mg/hour over 24 hours














































































Study details Population characteristics Intervention Comparator
Patients with acute respiratory failure: diltiazem, n = 6 (30%);
amiodarone bolus, n = 2 (10%); amiodarone bolus + 24 hours,
n= 1 (5%)
Mechanical ventilation at NOAF onset: diltiazem, n = 15 (75%);
amiodarone bolus, n = 17 (85%); amiodarone bolus + 24 hours,
n= 14 (70%)
Serum potassium level: NR
Definition of NOAF: recent-onset tachycardic AF was defined as
‘atrial fibrillation with a rate consistently > 120 beats/minute over a
30-minute period’
APACHE, Acute Physiology and Chronic Health Evaluation; b.p.m., beats per minute; CVD, cardiovascular disease; GI, gastrointestinal; GU, genitourinary; MI, myocardial infarction;












































































































































































































































































































































































































TABLE 4 Results of RCTs
Study Results Adverse effects
Recommendations for/barriers to
future research
Balser 199830 l A total of 59% of patients
receiving esmolol
converted to sinus rhythm
within 2 hours vs. 33% of
patients who received
diltiazem (intention to
treat; p = 0.049)
l The authors reported
conversion rates within
2 hours for patients with
NOAF: 59% (esmolol
group) vs. 27% (diltiazem
group) (p = 0.067)
l By 12 hours, 85% of
patients who received
esmolol had converted to
sinus rhythm, compared
with 62% of patients
who received diltiazem
(p = 0.116). About 40% of
the patients in both groups
received magnesium
between 2 and 12 hours,
and the authors reported
that this could have
potentially contributed
to enhanced rate control
and an increased rate of
conversion at 12 hours
l The authors compared the
length of ICU stay (days)
between the groups and
did not find it to differ
significantly: esmolol group
8.4± 9.5 vs. diltiazem
group 10.6 ± 13.4 days
l In-hospital mortality was
also reported to be not
significantly different:
31% in the esmolol group
compared with 38% in
the diltiazem group
No adverse effects Although intuition suggests that
ICU patients may benefit from
accelerated conversion to sinus
rhythm after operation, a much
larger trial would be necessary




l The number of patients
achieving successful
rate reduction (≥ 30%)
within 4 hours was not
significantly different
between the groups:
diltiazem group (group 1),
n= 14 (70%); amiodarone
bolus group (group 2),
n= 11 (55%); amiodarone
bolus+ 24 hours group
(group 3), n= 15 (75%)
(χ2 = 1.95; p = 0.38)
l The conversion to sinus
rhythm within 4 hours was
not significantly different
between the groups: group
1, n= 6 (30%); group 2,
l Bradycardia developed






resulted in a premature
discontinuation of the
study medication,







n= 1/20, 5%) (p = 0.01)
NR
SCOPING REVIEW OF TREATMENTS FOR NEW-ONSET ATRIAL FIBRILLATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
then followed by a continuous infusion at a rate of 45 mg/hour over 24 hours. Reported conversion
rates within 4 hours were similar in both groups: 30% converted back to sinus rhythm in the diltiazem
group, 40% in the amiodarone bolus group and 45% in the amiodarone bolus in combination with
24-hour infusion group. The authors reported a small number of adverse events (see Table 4).
Prospective comparative studies
We identified two prospective comparative studies, of which one32 investigated the effects of
pharmacological treatments for NOAF and the other27 looked at prophylactic treatment to prevent
NOAF in patients with septic shock. Details are presented in Tables 5 and 6.
Pharmacological treatments
Gerlach et al.32 conducted a small study (n = 61) that compared the effects of diltiazem with those of
amiodarone in a surgical ICU population in the USA.32 Ninety per cent of the included study participants
were diagnosed with NOAF. Both study treatments were administered in accordance with the protocol
developed by the participating surgical ICU medical team. The primary outcomes were conversion to
normal sinus rhythm at 24 hours, time to conversion and adverse treatment effects. The lengths of ICU
TABLE 4 Results of RCTs (continued )
Study Results Adverse effects
Recommendations for/barriers to
future research
n = 8 (40%); group 3, n= 9
(45%) (p = 0.61). When the
amiodarone groups were
pooled, the occurrence of
sinus rhythm was still not
significantly different
when compared with the
diltiazem group: n = 17/40
(42.5%) vs. n= 6/20 (30%),
accordingly (χ2 = 0.88;
p = 0.34)
l A significant heart rate
reduction at 24 hours was
reported in all groups
when compared with the
initial heart rate at time 0
(study entry) (p = 0.0001
for all). The authors
reported a trend towards a
poorer rate control beyond
11 hours for the amiodarone
bolus group
l Diltiazem showed slight
but significantly better rate
reduction when compared
with the amiodarone
groups: Fgroup 1 vs. 3 = 32.6,
p = 0.0001; Fover time= 179,
p= 0.0001; Fgroup 1 vs. 2= 48.7,
p= 0.0001;
Fover time= 117, p= 0.001
l The authors reported no
significant difference
between the amiodarone
groups: Fgroup 2 vs. 3= 3.02,
p= 0.08; Fover time= 102.68,
p= 0.0001
NR, not reported.
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TABLE 5 Methods and characteristics of prospective comparative studies (non-RCTs) of NOAF treatments
Study details Population characteristics Intervention Comparator




Sample size: n= 61
NOAF patients: n = 55
(90%) (diltiazem, n= 28;
amiodarone, n = 27)
Primary diagnosis




Other surgery 7 5
Mean age: diltiazem, 68.5 ± 14.6 years; amiodarone, 66.1 ± 16 years
Male: diltiazem, n= 18 (58%); amiodarone, n= 21 (70%)
Severity of illness: NR
Patients on vasopressors at the time of onset: n = 11 (18%) (diltiazem,
n= 8, 26%; amiodarone, n= 3, 10%)
Patients with CVD: n = 11 (18%) (diltiazem, n = 5, 16%; amiodarone,
n= 6, 20%)
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium: NR
Definition of NOAF: NR
Intervention treatment given to
patients during the first year of the
study. Diltiazem: 0.25 mg/kg i.v. bolus,
followed by continuous infusion of
5–15 mg/hour titrated to a heart rate
of < 120 b.p.m. Decisions to continue,
discontinue or change to oral therapy
after 48 hours were at the discretion
of the managing physicians
Line of NOAF treatment: not
specifically reported; however, no
other treatments reported
Comparator treatment given to
patients during the second year of the
study. Amiodarone: 150 mg i.v., over
at least 10 minutes, followed by
continuous infusion of 1 mg per
minute for 6 hours then decreased
to 0.5 mg per minute. The decision to
continue, discontinue or change to
oral therapy after 48 hours was at the
discretion of the managing physicians
Line of NOAF treatment: not
specifically reported; however,














































































Study details Population characteristics Intervention Comparator

















Intra-abdominal 72 (59) 72 (52)
Thoracic 24 (20) 32 (23)
Urinary 17 (14) 14 (10)
Other 10 (8) 20 (14)
Mean age: hydrocortisone, 65 ± 13 years; no hydrocortisone,
63± 15 years
Male: hydrocortisone, 61%; no hydrocortisone, 58%
Severity of illness: mean SOFA score (baseline) – hydrocortisone,
10± 4; no hydrocortisone, 8± 3
Mean SAPS II (baseline): hydrocortisone, 56± 20; no hydrocortisone,
50± 20
Mean SOFA score reported (during the first 24 hours of septic shock):







Noradrenaline 122 (99) 135 (98)
Dobutamine 29 (24) 6 (4)
Adrenaline 15 (12) 10 (7)
A hydrocortisone bolus of 100 mg
followed by an infusion of 200 mg/day
for 7 days followed by a short wean if
the patient remained on vasopressors
Line of NOAF treatment: not
















































































































































































































































































































































































































TABLE 5 Methods and characteristics of prospective comparative studies (non-RCTs) of NOAF treatments (continued )







Coronary disease 11 (9) 12 (9)
Valvular disease 5 (4) 7 (5)
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium: NR
Definition of NOAF: AF was defined as 30 seconds or more of an
irregular ventricular rhythm with absent P waves














































































and hospital stays were also reported. The authors found no statistically significant differences between
the study groups in the conversion rate at 24 hours and in the time to conversion. Similar lengths of
ICU and hospital stays were also reported. One patient in the diltiazem group and two patients in the
amiodarone group developed transient hypotension. This study was small and, therefore, probably
underpowered to detect any treatment differences. No power calculations were reported and methods
to account for confounding factors were not reported as being used in the analysis.
Prophylactic treatments
A study27 set in five French academic ICUs assessed the effect of hydrocortisone to prevent NOAF in
261 patients diagnosed with septic shock. Hydrocortisone was administered at the discretion of the
attending physician, although a study treatment schedule was recommended. Patients who received
hydrocortisone were more severely ill than those who did not. The unadjusted ICU and 28-day
mortalities in the hydrocortisone group were higher than in the no-hydrocortisone group [37% vs. 24%
(p = 0.018) and 38% vs. 26% (p = 0.036), respectively]. No relative risks (RRs) for ICU and 28-day
mortality were reported in the study. However, in the propensity score-weighted analysis, patients who














l Mean time to
conversion: diltiazem,
6.9 hours; amiodarone,
5 hours (p= 0.35)
l Both groups had
similar lengths of ICU
stay (mean days ± SD)
(diltiazem, 13.5± 11.9
days; amiodarone
group, 11.6 ± 10.9
days; p = 0.54) and
hospital length of stay
(diltiazem, 22.5± 18.9
days; amiodarone,

















trials are needed to































was –11.9% (95% CI
–23.4% to –0.5%;
p = 0.040) and the RR
was 0.58 (95% CI
0.35 to 0.98;
p = 0.041)
NR It would be interesting
to study high-risk
patients who develop
AF and the short- and
long-term outcomes in
patients treated or not
with hydrocortisone
CI, confidence interval; NR, not reported; RR, relative risk; SD, standard deviation.
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received hydrocortisone were less likely to develop NOAF than those who did not. The risk difference
between the groups was 11.9% and the RR of developing NOAF was 0.58 [95% confidence interval (CI)
0.35 to 0.98], which indicates a benefit of hydrocortisone.
Retrospective comparative studies
Nine retrospective comparative studies28,29,33–38,48 were identified, with sample sizes ranging between 33
and 7522 patients. Seven studies28,29,33–36,48 had a sample size of > 100 patients. Six studies took place
in the USA,28,29,36–38,48 two in Asia33,34 and one in Europe.35 All studies were published after 2010. Five
studies33,34,36,37,48 were available only as conference abstracts; therefore, limited data were available.
None of the studies reported treatment adverse events. Details of these studies can be found in
Tables 7 and 8.
Pharmacological treatments
Seven studies28,33–38 investigated the effects of pharmacological treatments. Four studies included
patients with sepsis28,33 or septic shock35,37 as their primary diagnosis. One study38 was conducted in a
surgical population and two studies34,36 did not clearly specify the type of ICU and study population.
A study by Walkey et al.28 was not limited to an ICU population. A large proportion of studies did not
report on the dose28,33,36–38 or the mode of administration33,36–38 of any treatment given. One study33
investigated the treatment effects of rate and rhythm control strategies, but the conference abstract
did not report which specific interventions were studied. Outcomes reported included cardioversion to
sinus rhythm,33–36,38 mortality28,33,35,37 and lengths of ICU and hospital stays.37
Most of the larger studies28,34–36 (sample size > 100 patients) compared amiodarone with beta-blockers
(e.g. landiolol and metoprolol). A large study28 from the USA reported that patients treated with
amiodarone were more likely than patients treated with beta-blockers to be critically ill with septic
shock. The RR of hospital mortality for patients who received beta-blockers compared with patients
who received amiodarone was 0.67 (95% CI 0.59 to 0.77) after adjustment for confounding, which
indicates a better outcome for patients with beta-blockers. However, the patient characteristics
between these groups were different and the matching of groups in the NOAF cohort was not
reported. Balik et al.35 reported higher ICU mortality in patients receiving amiodarone (40%) than in
patients receiving metoprolol (21%); however, this was reported as being not statistically significant.
Three studies34–36 compared conversion rates between amiodarone and beta-blockers, and found that
rates of conversion to sinus rhythm were slightly, but not significantly, higher in patients receiving
beta-blockers. However, Balik et al.35 did not adjust for confounding factors such as sickness score.
Matsumoto et al.34 and Mieure et al.36 did not report the methods used for the analysis.
Walkey et al.28 compared outcomes in patients who received digoxin and those who received beta-
blockers. Following propensity score matching (n = 1932), the RR of hospital mortality for patients who
received beta-blockers compared with patients who received digoxin was 0.75 (95% CI 0.64 to 0.88),
which indicates a better outcome for patients treated with beta-blockers.28 However, only around 60%
of patients in the propensity score-matched cohorts were ICU patients, and the study was restricted to
patients with sepsis; therefore, this study’s results should not be considered applicable to a broad ICU
population. Moreover, the study was judged as being at a serious risk of bias owing to confounding
(see Risk-of-bias assessments).
Four studies28,36–38 investigated the effects of calcium channel blockers (e.g. diltiazem). Walkey et al.28
found no statistically significant difference in mortality between patients who received beta-blockers
and patients who received calcium channel blockers (RR 0.99, 95% CI 86 to 1.15). Similarly, a conference
abstract by Jaffer et al.37 reported no statistically significant difference in death at discharge between
patients administered beta-blockers and patients administered calcium channel blockers. Two studies36,38
compared conversion rates between patients who were administered calcium channel blockers and
patients who were administered either amiodarone36 or beta-blockers. No meaningful conclusions
from the results of these two studies could have been made owing to the small sample sizes.
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TABLE 7 Methods and characteristics of retrospective comparative studies of NOAF treatments
Study details Population characteristics Intervention Comparator





Sample size: n= 234
(amiodarone, n = 177;
propafenone, n= 42;
metoprolol, n = 15)
NOAF patients: n = 163
(69.7%)
Primary diagnosis: septic shock
Primary sources of septic shock: respiratory (57.3%), abdominal (25.2%), urosepsis (7.3%),
wound/surgical (5.2%), catheter related (4.2%), maxillofacial (0.4%), neuroinfection (0.4%)
Mean age: amiodarone, 67.8± 11.4 years; propafenone, 66.8 ± 11.3 years;
metoprolol, 60.9± 8.3 years
Male: n= 139 (59.4%)
Severity of illness at the start of the anti-arrhythmic therapy:
APACHE II – amiodarone, 25 ± 11.4; propafenonel, 23.2 ± 11.1; metoprolol, 19.4 ± 11.9









Dobutamine 24 (16.9) 6 (7.7) –
Vasopressin 10 (7) 2 (2.6) –
Patients with CVD: n = 117 (50%) (amiodarone, n= 79, 56%; propafenone, n= 34, 43.6%;
metoprolol, n= 4, 28.6%)
Patients with acute renal failure: n= 64 (27.4%)
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: n = 232 (99.1%) (although does not specify
whether or not this was at the onset)
Serum potassium level (mmol/l): amiodarone, 4.4± 0.6; propafenone, 4.4± 0.6;
metoprolol, 4.3± 0.5
Definition of NOAF: NR
Propafenone: the median
total dose of propafenone
was 2.5 g (IQR 1.0–4.0 g).
The length of therapy was
5.0 days (IQR 2.0–8.5 days)
Line of NOAF treatment:
first and second line
Amiodarone: median total
dose of amiodarone was
3.0 g (IQR 1.8–4.6 g),
given by infusion over
4 days (2–6 days)
Line of NOAF treatment:
first and second line
Metoprolol: the median
i.v. metoprolol dose was
84mg/day (48–120mg/day)
The median length of
therapy was 5 days
(2–9 days)














































































































































































































































































































































































































TABLE 7 Methods and characteristics of retrospective comparative studies of NOAF treatments (continued )
Study details Population characteristics Intervention Comparator






Sample size: n= 448
NOAF patients: 100%
Primary diagnosis: sepsis
Mean age: 68.2 years
Male: 68.9%
Severity of illness: median CHA2DS2-VASc score, 3; median APACHE II score, 24
Patients on vasopressors: 59.9% (at the time of NOAF onset)
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: 84.5%
Serum potassium level: NR
Definition of NOAF: NR
Rhythm control (43.5%
patients): amiodarone
used in 95.4% of rhythm
control cohort




Line of NOAF treatment:
not specified





Sample size: n= 65
NOAF patients: 100%
Primary diagnosis: septic shock
Mean age: NR
Male: 56%
Severity of illness: NR
Patients on vasopressors: NR
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Amiodarone (administered
to 49% of patients)




of patients) and beta-
blockers (administered to
12% of patients)















































































Study details Population characteristics Intervention Comparator
Serum potassium level: NR
Definition of NOAF: NR





Sample size: n= 109




Primary diagnosis: septic shock
Mean age: NR
Male: NR
Severity of illness: mean APACHE IV score reported, 97 ± 32.5
Patients on vasopressors: NR
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium level: NR
Definition of NOAF: NR
Hydrocortisone (median
duration 4.2 days, IQR
1.1–8.1 days)





Line of NOAF treatment:
not applicable





Sample size: n= 276






Severity of illness: NR
Patients on vasopressors: NR
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Amiodarone: a loading
infusion of 150 mg over
30 minutes followed by a
continuous infusion of
20 mg/hour
Line of NOAF treatment:
not specified
Landiolol: a bolus infusion
of 7.5 mg followed by
continuous infusion of
2.5–7.5 mg/hour














































































































































































































































































































































































































TABLE 7 Methods and characteristics of retrospective comparative studies of NOAF treatments (continued )
Study details Population characteristics Intervention Comparator
Mechanical ventilation at NOAF onset: NR
Serum potassium level: NR
Definition of NOAF: NR




Sample size: n= 33
Initial treatment:
beta-blockers, n= 22;
amiodarone, n = 6; calcium
channel blockers, n = 2;




Primary diagnosis: oesophagectomy, n = 8; intra-abdominal surgery, n= 9; other surgery,
n = 9, trauma n= 7
Sepsis at the time of onset: n= 16 (48.5%)
Mean age: median age (IQR) 71 (64–80) years
Male: n= 19 (58%)
Severity of illness: NR for baseline or onset characteristics
Patients on vasopressors (within 24 hours of NOAF onset): n = 12 (36%)
Patients with CVD: coronary artery disease, 20%; stroke, 12%; peripheral vascular
disease, 9%
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset (only reported for within 24 hours of onset):
n = 5 (15%)
Serum potassium level: patients with serum potassium of < 4 mmol/l on first laboratory
after AF onset, n = 15 (45%)
Definition of NOAF: AF occurring in any patient with no documented history of AF
Beta-blockers




Line of NOAF treatment:




failure to restore sinus
rhythm, with amiodarone
being the most common














































































Study details Population characteristics Intervention Comparator





Sample size: n= 126
(amiodarone, n = 61;
diltiazem, n = 41;





Severity of illness: NR
Patients on vasopressors: NR
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium level: NR
Definition of NOAF: ‘onset 120 beats per minute’
Amiodarone
Line of NOAF treatment:
not specified
Diltiazem
Line of NOAF treatment:
not specified
Metoprolol
Line of NOAF treatment:
Not specified
First author and year:
Walkey 201628
Setting: 20% of hospitals
in the USA
Country: USA
Sample size: n= 39,693
(calcium channel blockers,
n = 14,202; beta-blockers,
n = 11,290; digoxin,
n = 7937, amiodarone,
n = 6264)











Respiratory 3583 (31.7) 5882 (41.4) 3118 (39.3) 2369 (37.8)
Gastrointestinal 2107 (18.7) 1692 (11.9) 1030 (13.0) 896 (14.3)
Urinary tract 4173 (37.0) 5439 (38.3) 3008 (37.9) 1980 (31.6)




140 (1.2) 150 (1.1) 82 (1.0) 76 (1.2)
Mean age: beta-blockers, 75.7± 11.3 years; calcium channel blockers, 75.6 ± 11.4 years;




























































































































































































































































































































































































































TABLE 7 Methods and characteristics of retrospective comparative studies of NOAF treatments (continued )




Male: beta-blockers, 50.4%; calcium channel blockers, 47.4%; digoxin, 48.5%;
amiodarone, 55.1%
Severity of illness: NR
Patients on vasopressors on first hospital day: beta-blockers, 29.1%; calcium channel
blockers, 26.5%; digoxin, 44.1%; amiodarone, 64.0%
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium level: NR
Definition of NOAF: AF that was not documented on hospital admission









Mean age: anticoagulation, 73.2± 11.7 years; no anticoagulation, 75.8 ± 11.7 years
Male: anticoagulation, n= 6941 (51%); no anticoagulation, n = 12,035 (42.2%)
Severity of illness mean (SD) CHA2DS2-VASc score reported: anticoagulation, 3.4 (1.5);
no anticoagulation, 3.6 (1.5)
Patients on vasopressors: anticoagulation, n = 5084 (37.4%); no anticoagulation,














































































Study details Population characteristics Intervention Comparator
NOAF patients: n = 7522














Heart failure 5712 (42.0) 9792 (39.2)
Coronary heart disease
or myocardial infarction
4532 (33.3) 7970 (31.9)
Valvular heart disease 2010 (14.8) 3348 (13.4)
Patients with acute renal failure: anticoagulation, n= 7612 (55.9%); no anticoagulation,
n = 15,814 (63.3%)
Patients with acute respiratory failure: anticoagulation, n = 5308 (39.0%);
no anticoagulation, n= 9442 (37.8%)
Mechanical ventilation at NOAF onset: NR
Serum potassium level: NR






i.v. heparin, SC enoxaparin,
SC dalteparin,
SC fondaparinux)
Patients who received oral
anticoagulants as their
initial anticoagulant were
excluded in the primary
analysis
Line of NOAF treatment:
not applicable as NOAF
treatment not studied
No anticoagulation
Line of NOAF treatment:
not applicable
APACHE, Acute Physiology and Chronic Health Evaluation; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischaemic attack,

















































































































































































































































































































































































































for/barriers to the future
research
Balik 201735 Linear regression analysis
involving univariate and
multivariate testing
l Amiodarone: restoration to sinus
rhythm was observed in 74% of
patients in the amiodarone group.
Four patients were switched to
the amiodarone group from the
propafenone group owing to
failure to restore sinus rhythm,
and one patient from the
metoprolol group did so because
of haemodynamic instability.
Cardioversion was achieved in
114 patients. However, 23.7% of
those required additional electric
cardioversion. Forty patients
(26%) who failed to restore sinus
rhythm were switched to the
propafenone group during the
first 24 hours
l Propafenone: sinus rhythm was
achieved in 88.9% of patients.
Forty patients were moved from
the amiodarone group to the
propafenone group. Four patients
were switched from propafenone
to amiodarone. Overall
cardioversion success rate of
86.1% at 24 hours was reported.
Of those, 35.5% needed
additional electric cardioversion
to achieve sinus rhythm
l Metoprolol: sinus rhythm was
restored in 92.3% of patients
without any additional electric
cardioversion. One patient was
moved to amiodarone infusion
l The authors reported statistically
not significant but higher ICU
mortality of amiodarone (40.4%,
OR 1.79) than propafenone
(30.4%) and metoprolol (21.4%).
The 28-day mortality was
reported as higher in the
amiodarone group (49.6%) than in
the propafenone group (39.5%)
and metoprolol group (21.4%).
In the univariate 1-year survival
analysis, long-term survival of the
propafenone group was similar
to the long-term survival of the
metoprolol group. Long-term
survival in both the propafenone
and the metoprolol group was
significantly higher than in the
amiodarone group (HR 1.76,
95% CI 1.06 to 2.3; p = 0.02). The
authors confirmed the result by
multivariate survival analysis. This
was corrected for age, dosage of
noradrenaline, SOFA score and
rate of CRRT (HR 1.58, 95% CI
1.04 to 2.4; p = 0.03). In the
univariate analysis, which
NR
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for/barriers to the future
research
excluded chronic AF patients, a
1-year mortality benefit in favour
of restoration of sinus rhythm in
septic shock (HR 0.48; p = 0.002)
was shown. After adjustment for
age, dosage of noradrenaline,
SOFA score and presence
of CRRT, the result was
not statistically significant.
(HR 0.67; p = 0.113)
Cho 201733
(abstract)
Propensity matching l The authors reported that
patients managed by rhythm
control strategy showed higher
sinus conversion rate than those
with rate control strategy (39.8%
vs. 19.8%; p < 0.001). However,
mortality rate (54.9% vs. 49.3%;
p = 0.529) or thromboembolic
events (5.5% vs. 7.6%; p = 0.635)





None l The authors reported no
significant difference between
the groups in the analysis of the
primary outcome of mortality or
for the secondary outcomes of
lengths of ICU and hospital stay.
The MELD score (liver function)
at the end of the ICU stay for the
amiodarone group (20.85 ± 8.70)
was significantly higher (p = 0.03)
when adjusted for age and gender
than the control (15.40), beta-
blocker (12.88) and calcium
channel blocker (17.10) groups
Further investigation
into the management of
arrhythmias in septic
shock is needed to
further elucidate
the potential benefits




Multivariate regression l The authors reported the overall
incidence of AF as 34.9%. It was
concluded that NOAF was
significantly less common
in patients who received
hydrocortisone than those
who did not (20.5% vs. 42.9%;
p = 0.022). The authors reported
that multivariate regression
showed that the receipt of
hydrocortisone was significantly
associated with a reduction in
NOAF (p = 0.006). No differences
in mortality, AF requiring
intervention or length of stay
were reported
Given the incidence rate








should include AF as a
secondary endpoint
continued
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NR l The authors reported that
single-drug pharmacological
cardioversion was attempted with
amiodarone in 26 cases (50%
cardioversion rate). Single-drug
pharmacological cardioversion
with landiolol was attempted
in 42 cases (67% cardioversion
rate). The mean time to sinus
conversion was 124 minutes
(95% CI 66 to 182 minutes) in the
amiodarone group and 72 minutes
(95% CI 52 to 91 minutes) in the
landiolol group. No evidence of
difference was found for sinus
conversion rates between the
amiodarone and landiolol groups.
The authors reported that
patients receiving landiolol had
statistically significant faster sinus
rhythm recovery than those who
received amiodarone (p < 0.001)
NR
Brown 201838 Markov chain analysis to





outcome can be achieved
by different medication.
No other methods to
address confounding were
reported
l The authors reported that
amiodarone was the most
successful at achieving the rate
and rhythm control in both cases,
as an initial treatment and as a
second-line treatment: six
patients (27%) who received beta-
blockers as a first-line therapy
converted to sinus rhythm vs. five
patients (83%) who received
amiodarone as a first-line
treatment vs. one patient (50%)
who received calcium channel
blocker as a first-line treatment;
11 patients (85%) who received
amiodarone as a second
treatment converted to sinus
rhythm vs. one patient (33%) who
received calcium channel blockers
as a second-line treatment
converted to sinus rhythm.
Markov chains analysis showed
that administering amiodarone as
a first-, second- or third-line
medication was more likely to
result in rate and rhythm control
than if beta-blockers were
administered (p = 0.001)
l The greatest success rate (92%)
to convert to sinus rhythm was
when beta-blockers were used
first, followed by amiodarone. This
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NR l The ventricular rate control to
< 100 b.p.m. within 24 hours from
initiation of treatment was
achieved in 85.2% (52/61) of
amiodarone patients, 85.0%
(35/41) of diltiazem patients and
87.5% (21/24) of metoprolol
patients (p = 1.00). The authors
reported that the mean relative
heart rate reduction (± SD) was
40.5 ± 13%, 38 ± 16% and
41.9 ± 12% in the amiodarone,
diltiazem and metoprolol groups,
respectively (p = 0.52). Conversion
to and maintenance of sinus
rhythm throughout the study
period occurred in 21.3%
of amiodarone patients, 7.3% of
diltiazem patients and 37.5% of
metoprolol patients (p = 0.013)
A large randomized
controlled trial designed
to determine the optimal
therapeutic strategy for a
heterogeneous cohort of
patients with new onset
AF with RVR [rapid
ventricular rate] is needed







acute organ failure and
type of infection
l Beta-blockers vs. calcium channel
blockers: no differences in hospital
mortality between the groups,
RR 0.99 (95% CI 0.86 to 1.15)
l Beta-blockers vs. digoxin: RR of
hospital mortality for patients
who received beta-blockers
compared with patients who
received digoxin was 0.75
(95% CI 0.64 to 0.88), indicating
a better outcome for patients
treated with beta-blockers
l Beta-blockers vs. amiodarone: RR
of hospital mortality for patients
who received beta-blockers
compared with patients who
received amiodarone was 0.67
(95% CI 0.59 to 0.77), indicating a





and supportive of the
need for future clinical
trials to investigate
optimal treatment of AF
during sepsis
Walkey 201629 A propensity score









infection and year of
hospitalisation
The authors reported RR of in-
hospital ischaemic stroke associated
with anticoagulation as 0.85 (95% CI
0.57 to 1.27) for patients with newly
diagnosed AF. The RR of bleeding
associated with parenteral
anticoagulation was reported as 0.97
(95% CI 0.83 to 1.14) for patients











among patients with pre-




diagnosed AF during sepsis
b.p.m., beats per minute; CRRT, continuous renal replacement therapy; HR, hazard ratio; MELD, Model for End-stage
Liver Disease; NR, not reported; OR, odds ratio; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.
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In addition, the Mieure et al.36 study was available only as a conference abstract in which the study
methods and population characteristics were not reported.
Prophylactic treatments
A small (n = 109 patients) study48 assessed the association of hydrocortisone with NOAF in patients
who were diagnosed with septic shock. The authors concluded that administering hydrocortisone was
associated with a reduction in the incidence of NOAF (20.5% in patients who received hydrocortisone
vs. 42.9% in those who did not; p = 0.022).48 No evidence of a difference in mortality and length of stay
between the study groups was reported. This study was published as a conference abstract; therefore,
limited data were available on the study population and analysis.
Anticoagulants
One large study29 (n = 7522) included a subgroup of patients who developed NOAF during sepsis in
hospital, of whom just over 60% of whom were treated in an ICU. Rates of in-hospital stroke were
low (n = 104, 1.9%). Given that the length of hospital stay was not reported, the duration of exposure
was unclear. Following propensity score matching (n = 5585 analysed) there was no evidence of a
difference in rates of in-hospital ischaemic stroke events between patients who did and those who did
not receive parenteral anticoagulation (RR 0.85, 95% CI 0.57 to 1.27). Given the low event rate, the
study may have had inadequate power to determine whether or not a statistically significant difference
exists. There was no statistically significant difference in the risk of bleeding associated with parenteral
anticoagulation between the groups (RR 0.97, 95% CI 0.83 to 1.14).
Prospective single-group studies
Six prospective single-group studies39,40,45–47,49 were included in the review. The sample sizes of the
included studies39,45–47,49 ranged from 16 to 37 patients; one study40 did not report the sample size.
Four studies were undertaken in Europe,39,46,47,49 one in Asia45 and one in North America.40 Five
articles39,40,46,47,49 were published between 2002 and 2008, and one article45 was published in 2016.
One publication40 was available only as a conference abstract.
One study45 was conducted in a mixed ICU and one study40 was conducted in a general ICU.Two studies47,49
were conducted in specialty ICUs, such as surgical or medical ICUs. The type of ICU was not clearly
specified in two studies.39,46 Four studies39,45–47 investigated the treatment effects of pharmacological
treatments and one study49 looked at electrical treatments. One study40 reported both the treatment
effects of pharmacological treatments and the preventative effects of anticoagulation for stroke
prophylaxis. Details of the prospective single-group studies can be found in Appendix 3, Tables 15 and 16.
Pharmacological treatments
Pharmacological treatments such as amiodarone,40 ibutilide,46,47 beta-blockers45 and MgSO4–amiodarone
step-up scheme39 were investigated. Four studies39,40,46,47 reported conversion to sinus rhythm as the
primary outcome and one study45 looked at mortality as an outcome.
Slavik et al.40 investigated the treatment effects of amiodarone; however, results were not clearly
reported in this conference abstract.
A study45 (n = 16) set in Japan investigated the effects of switching therapy from landiolol to the
Bisoprolol patch (Bisono® tape, Toa Eiyo Corp, Tokyo, Japan) in a mixed ICU population. This study
reported that survival was achieved in 81% of the patients in whom switching therapy was introduced.
Another very small study39 (n = 29) investigated the effects of a new treatment protocol consisting of
the infusion of magnesium sulphate (MgSO4) as a first-line therapy and amiodarone as a second-line
therapy in the case of no conversion. The study population was mixed and comprised medical and
surgical ICU patients who were diagnosed with NOAF. Study treatments were administered as per
institutional protocol based on MgSO4–amiodarone step-up scheme, for which infusion of amiodarone
was started if conversion to sinus rhythm or reduction in the ventricular rate of < 110 beats per
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minute (b.p.m.) within 1 hour after the start of MgSO4 infusion was not achieved. The authors reported
that amiodarone was required in 13 MgSO4 non-responders, of whom 11 converted to normal sinus
rhythm within 24 hours. No adverse events were reported.
Two very small studies46,47 investigated the treatment effects of ibutilide. Both studies administered i.v.
ibutilide, with a maximum dose of 2 mg. Hennersdorf et al.46 (n = 26) reported slightly lower conversion
rate to sinus rhythm than Delle Karth et al.47 (n = 17) (71% vs. 82%, respectively).
Electrical treatments
A small study49 (n = 37) assessed the effect of direct current cardioversion (DCC) in a surgical ICU
population. The treatment for patients with regular supraventricular tachyarrhythmia consisted of a
maximum of four consecutive cardioversions with an energy delivery of 50 J, 100 J, 200 J and 300 J.
For patients with irregular supraventricular tachycardia, cardioversion was performed with an energy
delivery of 100 J, 200 J and 360 J. Thirty-five per cent of patients (n = 13) primarily responded to DCC
with restoration of sinus rhythm for ≥ 5 minutes, of whom 62% (n = 8) remained in sinus rhythm at
1 hour. At 24 and 48 hours, 16% and 13.5% of patients remained in sinus rhythm, respectively.
Anticoagulants
Slavik et al.40 studied i.v. heparin as a prophylactic treatment for stroke; this was used in 36% of NOAF
episodes. The authors did not report which anticoagulant was used in the other 64% of NOAF cases.
It was reported that stroke prophylaxis was achieved in 91% of NOAF episodes. The authors concluded
that the appropriateness of therapy for stroke prophylaxis was ‘optimal’. This was decided using
prespecified study definitions. Five per cent of the study population experienced major bleeding as a
side effect of i.v. heparin.40 It must be noted that only an abstract was available for this study; therefore,
limited data were obtained. Moreover, the definition of ‘appropriateness of therapy assessed as optimal,
appropriate and inappropriate’ was not provided.
Retrospective single-group studies
Six retrospective single-group8,41–44,50 studies were identified, with sample sizes ranging from 30 to 240
patients. Four studies8,41–43 had a sample size of > 100 patients. Two studies were set in each of North
America8,44 and Asia,41,50 one in Europe43 and one in Australia.42 One article43 was published in 2004 and
five articles8,41,42,44,50 were published between 2010 and 2019.
Four studies8,42,43,50 were conducted in mixed ICUs, one study in a surgical ICU44 and one study in a medical
ICU.41 Three studies investigated the treatment effects of pharmacological treatments,8,42,43 one study
investigated electrical treatments50 and two studies looked at both pharmacological and electrical
treatments.41,44 The details of the retrospective single-group studies can be found in Appendix 3, Tables 17
and 18.
Pharmacological treatments
The following pharmacological treatments were investigated in the included studies: amiodarone,8,41–44
beta-blockers (e.g. metoprolol, esmolol and sotalol),8,41,44 calcium channel blockers (e.g. diltiazem)41,44 and
digoxin.41,44 Two studies41,44 did not report on the dose and mode of administration of the treatments studied.
Four larger studies8,41–43 (n > 100 patients) investigated the treatment effects of amiodarone. Conversion
rates to normal sinus rhythm ranged from 65% to 87%.8,41,43 Studies reported different time points for
conversion rates; for example, at some point while receiving amiodarone8 and during the first 48 hours
of amiodarone therapy.43 Maintenance of normal sinus rhythm in patients who had converted back while
receiving amiodarone ranged from 49% to 59% at the time of ICU discharge.8,42 The studies reported
different time points at which maintenance of sinus rhythm was achieved, such as until discharge from
the ICU.42 It should be noted that, where reported, the dose and administration of amiodarone were
heterogenous between the studies.8,42,43 One study43 reported on treatment adverse effects associated
with amiodarone, finding increases in serum concentrations of creatinine and bilirubin.
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A study41 undertaken in a population with sepsis reported that 76% of patients who were given beta-
blockers (n = 88), 71% of those who were administered calcium channel blockers (n = 66) and 55% of
those who were given digoxin glycosides (n = 27) converted back to sinus rhythm within 7 days after
the onset of NOAF. Although some authors also studied the treatment effects of beta-blockers, calcium
channel blockers and digoxin, the sample sizes were too small to make any meaningful conclusions8,44
or the results were not clearly reported.44
Electrical treatments
Kyo et al.50 investigated the effect of electrical cardioversion in a mixed ICU population (n = 85).
A median of one shock per electrical cardioversion session was reported and the delivered electrical
cardioversion energies in the first and second shocks were ≤ 100 J in 91% and 83% of all electrical
cardioversion patients, respectively. The authors reported successful electrical cardioversion, defined
as conversion to sinus rhythm for at least 5 minutes after an electrical cardioversion session, in 48%
of patients, and 13% of these patients maintained sinus rhythm until ICU discharge.
Liu et al.41 administered electrical cardioversion to eight patients and reported that 50% of these
patients converted back to normal sinus rhythm. No more details on the intervention and outcome
were available.
Reviews and guidelines
Twelve review articles53–64 were included in the current review. Of these, two were systematic
reviews,53,56 six were narrative review articles54,57–59,62,64 and four were review articles55,60,61,63 that
proposed a treatment algorithm based on available evidence. Most of the included reviews53–55,57–61,63,64
(n = 10) were published after 2012. No guidelines were identified in this scoping review.
Systematic reviews
Yoshida et al.53 conducted a systematic review of the epidemiology, prevention and treatment of
NOAF in critically ill patients. One database was searched and eligibility criteria were specified for
study inclusion in the systematic review. The authors assessed the methodological quality of the
included studies using the Grading of Recommendations Assessment, Development and Evaluation
(GRADE) system.65 No studies on NOAF prevention were included in the systematic review and
five studies8,30,39,66,67 investigating treatments for NOAF were eligible. Of the five studies identified
by Yoshida et al.,53 three 8,30,39 were eligible for this scoping review and two66,67 were excluded on
outcome. The five included studies, of which one was a RCT,30 evaluated the clinical effectiveness of
NOAF treatments, such as amiodarone, beta-blockers, calcium channel blockers, digoxin, magnesium
sulphate and DCC. However, no conclusive findings on the treatment strategies were reported. The
authors concluded that the current evidence for the management of NOAF in a general ICU population
is very limited and further research is urgently required.
In 2008, Kanji et al.56 published a systematic review of RCTs to assess the treatments of NOAF in
non-cardiac ICU patients. Three databases were systematically searched, the study eligibility criteria
were clearly specified and a quality assessment of each included RCT was conducted using a basic
rating instrument (the Jadad scale68). Four RCTs30,51,52,69 that assessed the efficiency of procainamide
(a sodium-channel blocker), flecainide (a sodium-channel blocker), esmolol, amiodarone, verapamil,
diltiazem and magnesium were included in the Kanji et al.56 review. Only one RCT 30 identified by
Kanji et al.56 was included in this scoping review. Two RCTs51,52 had a study population consisting of
< 70% of NOAF patients (and so were not eligible for this scoping review). The other study69 included
in the Kanji et al.56 review investigated patients with AF; however, it was not clear whether or not
these patients had NOAF (therefore, this study was excluded on population in this scoping review).
The authors were not able to make evidence-based recommendations for pharmacological rhythm
conversion strategies for a general ICU NOAF population owing to considerable methodological
heterogeneity of the included RCTs. The authors emphasised the need for well-designed and adequately
powered RCTs to evaluate treatment strategies for critically ill patients with NOAF. Moreover, they
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recommended that future research should address treatments of choice and goals of care using a
standardised outcome measure of success.
Other types of review
The evidence on pharmacological54,55,57–63 and electrical55,59,62,63 treatment strategies for NOAF was
discussed in the other review articles. Four articles54,57,59,63 discussed the management of NOAF in
sepsis patients and six articles57,60–64 reviewed the literature on anticoagulation strategies for critically
ill patients with NOAF. Four articles55,60,61,63 proposed an algorithm for the management of NOAF in an
ICU setting based on the available evidence.
Pharmacological treatments
It is widely reported that the management of arrhythmias in critical care settings is a major problem59,62
and that research on optimal therapeutic strategies for critically ill patients with NOAF is urgently
needed.54,55,57–59,61–63 Some articles55,58,61 argued that beta-blockers may be a reasonable first-choice
treatment given the current evidence of decreased mortality55 and improved heart rate control.55,58
By contrast, some authors discussed amiodarone as being a potentially effective treatment54,57,59,60,62
based on current evidence and its widespread use; however, it was also recognised that amiodarone
has potentially significant side effects.54,60,62 Other pharmacological treatments, such as propafenone,54,62
calcium channel blockers,55,62,63 digoxin54,55,62 and ibutilide,62 were discussed, but no conclusive findings
were made. Four articles55,60,61,63 proposed a treatment algorithm, but the algorithms should be
interpreted cautiously because they were developed based on limited evidence that was not identified
and critiqued systematically.
Electrical treatments
Reviews suggested that DCC might often be unsuccessful55 and might also be associated with a high
relapse rate.55,62 More evidence in critically ill populations is required to support this62 and the current
findings should be used to guide research in therapy and mechanisms.
Anticoagulants
A review article62 concluded that there was no clear evidence of whether or not stroke risk reduction
outweighs the increased risk of bleeding when using therapeutic anticoagulation in critically ill patients
with NOAF. Labbe et al.64 reported a high frequency of major bleeding events and recommended
that anticoagulation therapy should be administered only in patients with the highest risk of arterial
thromboembolic events. This assertion of high bleeding rates referenced one study that did not compare
bleeding events between patients who received anticoagulation and patients who did not, and one study
that found no significant difference in bleeding events between these two patient groups. A patient-
centred single-case decision approach of whether or not to use anticoagulant therapy was also suggested
in another review.57 Sibley and Muscedere61 recommended that anticoagulation therapy should be
initiated if AF persists for > 48 hours and in patients with a high risk of arterial thromboembolic events.61
Only one review article61 discussed which drug would be appropriate to use for anticoagulation in ICU
patients. Unfractionated heparin was reported to be the drug of choice for critically ill patients owing
to its short half-life and reversibility with protamine; however, it must be noted that the authors of the
review61 did not provide any references for this statement.
Surveys and opinion pieces
Surveys
Only one survey16 was identified in the current review. The UK-wide survey on the practice of the
management of NOAF in critically ill patients was conducted in 2016 and was sent to all members of
the Intensive Care Society (London, UK). A total of 3152 questionnaires were sent and 397 responses
were received. The survey included questions on demographic variables of participants and their
critical care unit, and a set of questions that aimed to determine the management strategies for NOAF
and anticoagulation practice. In total, 72% of respondents were consultants, 46% worked in a district
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general hospital and 81% worked in a mixed ICU. The authors reported that 81% of respondents used
amiodarone for the treatment of NOAF. Only 12% of respondents reported using beta-blockers. It was
reported that 64% of respondents would not use anticoagulant therapy in critically ill patients with
NOAF, whereas 31% of respondents would start anticoagulation therapy within 72 hours. The survey
revealed that low-molecular-weight or high-molecular-weight heparin was considered appropriate for
anticoagulant therapy.
Opinion pieces
Four opinion pieces70–73 were identified in the current review. Two72,73 were published in 2008 and are
responses to a systematic review of RCTs investigating the treatments for NOAF in a critically ill, non-
cardiac ICU population.56 Both authors72,73 agree with the conclusion of Kanji et al.:56 that the evidence
is lacking and that the answers still need to be provided. Walton72 believes that the best agent for use
in NOAF is amiodarone because it combines rapid rate control effects and a low risk of precipitating
ventricular tachyarrhythmias.72 However, Trohman73 favours the use of beta-blockers as the initial
pharmacotherapy. Both authors72,73 emphasised that treatments must be carefully studied to design an
evidence-based approach to guide treatment strategies in NOAF patients in an ICU.
Walkey et al.70 recommend beta-blockers as a reasonable first choice of initial AF therapy, given
the limited and indirect evidence. The authors also commented on managing the risks of stroke,
and concluded that evidence is currently lacking on risks of bleeding and estimates of stroke risk
reduction associated with use of anticoagulation in critically ill patients. Therefore, the authors did
not recommend using anticoagulation in NOAF patients with elevated bleeding risk because it is not
currently known whether or not the benefits outweigh the risks.70
Vieillard-Baron and Boyd71 suggest a non-anti-arrhythmic-based approach to reduce NOAF by
optimising electrolytes and fluid status, limiting sympathetic activation and controlling the central
venous catheter position before considering any anti-arrhythmic drugs. It must be noted that this
treatment strategy was developed by the authors, and was based on the pathophysiology of AF
and its risk factors present in patients with sepsis. No high-quality evidence is available to support
this treatment approach.
Definitions used for new-onset atrial fibrillation
Studies varied in how they reported and defined NOAF. Four studies38,43,47,49 required NOAF to have a
heart rate of > 100 b.p.m. and two studies31,36 required NOAF to have a heart rate of > 120 b.p.m.
Nineteen studies8,27–30,32–35,37,39–42,44–46,48,50 did not provide a heart rate threshold for NOAF. Studies also
reported different time periods for which NOAF must be sustained, ranging from 30 seconds to 24
hours.27,30,31,41,43,47,49 Eighteen studies8,28,29,32–40,42,44–46,48,50 did not define the time period for which NOAF
must be sustained. Six studies8,28,29,38,39,50 clarified in which instances AF would be considered as new
onset; for example, when a patient had no prior history of AF,38 when a patient had no previous history
of atrial tachyarrhythmias and anti-arrhythmic drug use,39 when AF occurred during an ICU stay,39,50
and when AF was absent on admission.28,29 Ten studies32–35,37,40,44–46,48 did not provide any definition
for NOAF.
Recommendations for and barriers to future research
Most researchers concluded that further prospective research accounting for confounding factors is
required to determine the success and clinical implications of prophylactic and rhythm and rate control
strategies in critically ill patients with NOAF.8,27,28,30,32,36,37,39,41,44,45,48,53–58,61,62,70 Moreover, it has been
emphasised that the optimal regimens and the best dosing strategies for treatments are yet to be
established.38,42,49 Eight primary studies31,33–35,40,43,46,47 and four review articles59,60,63,64 did not provide
any recommendations for future research.
Kanji et al.56 recognised that there are very few prospective studies conducted to evaluate the treatment
strategies for NOAF in the critically ill population, given the prevalence of NOAF in this population and the
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associated morbidity and mortality. Kanji et al.56 argue that the lack of prospective trials is because of the
nature of this population. NOAF is considered an emergency, and enrolling these patients into prospective
trials is logistically difficult because rapid treatment is often needed. Moreover, the lack of standardised
outcome measures, such as the definition of successful cardioversion, was identified as a major limitation.
Kanji et al.56 also suggested that grouping AF together with other types of supraventricular tachycardias
might be inappropriate because the physiology and their treatment response might be different.
Two primary studies29,40 and three review articles61,62,64 that discussed anticoagulation strategies
in critically ill patients with NOAF did not provide any recommendations for the future research in
this population.
Expert panel review
We convened an expert panel (see Appendix 8) to review the findings of the scoping review to inform
definitions, treatments and confounders to be used in the ICU database analysis (see Chapter 4). The
scoping review highlighted that definitions of NOAF in patients in an ICU and definitions of treatment
success varied. In the absence of any consensus definition of NOAF, we adopted the agreed definition
of AF in patients outside an ICU: any AF lasting ≥ 30 seconds. We defined time to cardioversion as
the time to first reversion of sinus rhythm, and the time to rate control was defined as the time to a
heart rate of < 110 b.p.m. Two studies27,41 defined AF as lasting for longer than 30 seconds. No studies
provided a definition for time to cardioversion. Where studies defined a heart rate threshold for AF,
it was either > 100 b.p.m.38,43,47,49 or > 120 b.p.m.31,36 A list of the interventions used in the studies
identified in the scoping review was created and reviewed, but was not altered by the expert panel.
We then screened our databases for presence of data pertaining to identified interventions. A list
of identified and available interventions is shown in Appendix 8, Treatments to be included in the analysis
and identified but unavailable interventions in Appendix 8, Treatments of interest, but not possible with
our data. A list of confounding variables was created from those identified in studies in our scoping
review. This list was then supplemented though two rounds of individual review by expert panel
members, resulting in a final list of confounders that was ratified by the panel. We then screened
our databases for the presence of data pertaining to identified confounders. The final list is shown
in Appendix 8, Confounding/matching variables.
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Chapter 3 Database analysis part 1:
RISK-II database
Database analysis part 1: methods
Data sources
We analysed patient records from the RISK-II database, which includes anonymised, linked, routinely
collected data from (1) the Case Mix Programme (CMP) national clinical audit of adult intensive care,74
(2) Hospital Episode Statistics (HES) for England and (3) the Office for National Statistics (ONS)
mortality database.
Case Mix Programme data are collected for the purpose of service evaluation and quality improvement
in critical care.75 The CMP includes records for each admission to a participating adult high-dependency
unit or ICU in England, Wales and Northern Ireland. Not all ICUs participated during the period for
which data were extracted; coverage of adult general ICUs increased over the study period, reaching
100% in the final year of extracted data. Some, but not all, specialist ICUs participated (cardiothoracic
ICUs were excluded from the analysis; see Inclusion and exclusion criteria). The CMP was used to
identify the study sample, provide dates for the start and end of hospital admission and critical care,
and to identify patient demographics.
The HES database is collected for the purpose of reimbursing NHS trusts for the provision of hospital
services. The RISK-II database includes records from the admitted patient care section of HES, which
contains one record for each ‘episode of care’ under one consultant during a hospital admission. One
hospital admission may contain multiple episodes of care, one of which would generally correspond to
the period in critical care, but there are differences between trusts in the way that these data are
recorded; therefore, HES and CMP records do not align consistently. Each HES record includes up to
20 International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), diagnosis
codes and up to 24 Office of Population Censuses and Surveys Classification of Surgical Operations and
Procedures (OPCS-4) codes that were used to identify NOAF, comorbidities and diagnosis-specific rates
of subsequent hospitalisation (see Identification of new-onset atrial fibrillation).
The ONS mortality database contains information about all of the deaths registered in the UK, and was
used to derive indicators of mortality.
The anonymised RISK-II database is maintained by the Intensive Care National Audit and Research
Centre (ICNARC) (London, UK) and was linked by NHS Digital (Leeds, UK) using a standard deterministic
algorithm involving the NHS number (a unique patient identifier), date of birth, postcode and sex.
The RISK-II database includes CMP records from 1 April 2009 to 31 March 2016, HES records from
1 April 2004 to 31 March 2016 and ONS records from 1 April 2009 to 31 October 2018.
Inclusion and exclusion criteria
We included the records of patients admitted to an ICU between 1 April 2009 and 31 March 2016
(5 financial years). Contiguous ICU admissions, representing transfers between ICUs and readmissions to
an ICU within 1 calendar day, were combined into single records.We excluded admissions to cardiothoracic
units, admissions lasting < 4 hours and patients aged < 16 years at the time of ICU admission.
Identification of new-onset atrial fibrillation
The codes used for identifying health conditions are summarised in Table 9. We defined patients as
having NOAF during an ICU admission by identifying a CMP record that overlapped with a linked HES
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record that was the first HES record containing an ICD-10 code for AF for that patient anywhere in
the database. Adopting a cautious approach to defining NOAF, we excluded patients with a linked HES
record relating to the same hospital admission and contained an OPCS-4 procedure code for atrial
ablation, pacemaker insertion or DCC during the same hospital admission from this group, because AF
may have developed prior to ICU admission.
There are many possible ways that CMP records and HES records can overlap: the HES record may
commence on the same day or on an earlier/later date than the CMP record, and similarly may finish
on the same day or on an earlier/later date. Many of these scenarios result in uncertainty about
whether the AF developed prior to ICU admission, in an ICU or after discharge from an ICU. We,
therefore, implemented the following rules for classifying NOAF (Table 10):
l If the HES record commenced on the same day as the CMP record, then it was considered NOAF
only if there was also a prior HES record from the same hospital admission (i.e. if the patient was
admitted straight to an ICU from an emergency room and, therefore, had no prior HES record from
that hospital admission then we assumed that the AF developed prior to ICU admission).
l If the HES record commenced on an earlier date than the CMP record, then the AF was assumed to
have developed prior to ICU admission and not to represent NOAF.
l If the HES record commenced after the CMP record commenced and finished before the CMP
record finished, then the admission was considered to represent NOAF.
If the HES record continued beyond the CMP record, then it was considered NOAF only if the
discrepancy was only 1 day (to allow for minor discrepancies in data entry between the systems),
otherwise it was assumed that the AF developed after discharge from the ICU. As a sensitivity analysis,
TABLE 9 The ICD-10 diagnosis codes and OPCS-4 procedure codes
Condition ICD-10 or OPCS-4 code
Atrial fibrillation
Diagnosis I48
Atrial ablation/maze procedurea K572, K575, K578, K622 and K623
Pacemaker insertiona K601–19, K731–9, K741–3, K748–9, U311 and U318–9




Prior thromboembolism I63–4, I74








a Used only to differentiate NOAF from prior AF.
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we allowed for any amount of discrepancy in end date provided that other rules were met. This resulted in
two possible definitions of NOAF: one for use in the primary analysis and an alternative approach described
above for use in the sensitivity analysis. Both, however, reflect a cautious approach to identification of
NOAF and exclude many scenarios for which we cannot distinguish NOAF from prior or subsequent AF.
This has implications for the interpretation of results that will be highlighted below.
Identification of comorbidities and outcomes
Comorbidities were identified from any previously linked HES record that contained an ICD-10
diagnosis code for diabetes mellitus, hypertension, thromboembolism, valvular heart disease, dilating
cardiomyopathy, pulmonary hypertension or heart failure (see Table 9). The date and cause of death
were obtained from the linked ONS records. Subsequent hospital admissions were identified by linked
HES records and classified as involving AF, stroke or heart failure.
Selection of matched comparators
Observational research using routine data has a fixed ‘observation window’ within which the data
are collected (and within the RISK-II database, this window varies across the contributing data sets,
as described in Data sources). Patients admitted to an ICU at different points in time are, therefore,
followed up for different amounts of time. It is also common for the quality of routine data to vary
over time and between contributors to a data set (e.g. between hospitals). To ensure that follow-up
and data quality are comparable between patients with NOAF and any comparison group, we selected
a cohort of comparators matched on hospital and month/year of admission to ICU.
Comparator patients were selected from all available admissions that were classified as neither NOAF
nor prior AF (but including admissions for patients who subsequently developed AF). To ensure that
patients with multiple admissions were not over-represented among comparators, one admission was
selected at random from each patient’s set of candidate comparator admissions for consideration in the
TABLE 10 Classification of AF in the RISK-II database
Overlap between HES and CMP records
Classification of AFHES record start date HES record end date
Admitted to hospital on
same day as the ICU?
Before CMP record start Any No (by definition) Pre-existing AF
Same as CMP record start Any Yes Pre-existing AF
Same as CMP record start Same as or before CMP
record end
No NOAF
Same as CMP record start After CMP record end
(up to 1 day)
No NOAF
Same as CMP record start After CMP record end
(> 1 day)
No Subsequent AFa
After CMP record start and same as or
before CMP record end
Same as or before CMP
record end
Either NOAF
After CMP record start and same as or
before CMP record end
After CMP record end
(up to 1 day)
Either NOAF
After CMP record start and same as or
before CMP record end
After CMP record end
(> 1 day)
Either Subsequent AFa
After CMP record end After CMP record end
(by definition)
Either Subsequent AF
a Classified as NOAF in the sensitivity analysis.
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matching process. Matching was then performed with the largest ratio that could be supported while 
ensuring that at least 99% of patients with NOAF were included in comparisons.
Statistical analysis
Patient characteristics and comorbidities are reported as median with interquartile range (IQR) or as 
counts and percentages. To account for varying duration of follow-up of patients admitted at different 
points in time, outcomes were estimated using time-to-event methods with censoring of patients at the 
end of the relevant data set’s observation window (31 October 2020 for mortality or 30 March 2020 
for hospitalisation). Mortality was estimated using the Kaplan–Meier cumulative incidence function 
from the date of ICU admission and, separately, from the date of hospital discharge among hospital 
survivors. The cumulative incidences of subsequent hospitalisation with AF, stroke and heart failure 
were estimated using non-parametric methods to account for the competing risk of death.76,77 Mortality 
was assessed at hospital discharge, and at 90 days, 1 year, 3 years and 5 years after hospital discharge, 
among hospital survivors. The cumulative incidences of hospitalisation with AF, stroke and heart failure 
were assessed at 1, 3 and 5 years after hospital discharge, among hospital survivors.
We estimated the associations between NOAF and outcomes before and after adjustment for patient 
characteristics and comorbidities using multivariable regression models adjusting for age, sex and 
comorbidities. Odds ratios (ORs) for hospital mortality were estimated using logistic regression. Hazard 
ratios (HRs) for mortality after hospital discharge were estimated using Cox proportional hazard 
regression. For subsequent hospitalisation with AF, stroke and heart failure, we estimated unadjusted 
and adjusted cause-specific hazard ratios (CHRs),78,79 censoring patients at death or the limit of follow-up. 
The proportional hazard assumption was tested by visual inspection of Schoenfeld residual plots.
All covariates were modelled using dummy variables except for age, which was modelled continuously 
using a restricted cubic spline. Knot positions for the restricted cubic spline were selected in in accordance 
with the recommendations of Harrell.80
Finally, results for the primary analysis were compared with a sensitivity analysis that employed an 
alternative operational definition for NOAF, as detailed in Identification of new-onset atrial fibrillation.
Database analysis part 1: results
Data linkage and matching
The selection of records is summarised in Figure 2. Between 1 April 2009 and 31 March 2016, there 
were 965,576 admissions to 248 ICUs participating in the CMP, with links available to HES and ONS. 
After combining multiple records representing transfers and readmissions, a total of 919,801 distinct 
ICU admissions were extracted. Of these, 841,005 ICU admissions met the inclusion criteria. Of 8203 
records identified as NOAF or possible NOAF, 8145 were matched to 48,870 comparators. A total of 
4615 (56.7%) patients with NOAF and 27,690 matched comparators were included in the primary analysis.
How common is new-onset atrial fibrillation in critical care?
Of the 841,005 critical care admissions examined, 4615 (0.6%) admissions had a linked HES record 
indicating likely NOAF. A further 3548 (0.4%) admissions had a linked HES record indicating possible 
NOAF but where the HES record continued for > 1 day beyond the CMP record (the latter were 
included in the sensitivity analysis). Although the prevalence of NOAF using either definition appeared 
stable over time, the prevalence of prior AF (n = 165,150, 19.6%) increased over the first 5 years of 
the observation window (Figure 3). A reduction in prior AF in the final year of the data partly reflects 
the unavailability of procedure codes for identifying atrial ablation and pacemaker insertion in that 
year (a structural limitation of the database, which did not appear to affect the identification of NOAF).
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FIGURE 3 Prevalence of AF in the RISK-II database.
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What are the typical characteristics of patients with new-onset atrial fibrillation in critical
care and how to do these compare with other patients in critical care?
Patient characteristics and comorbidities are summarised in Table 11. Patients with NOAF tended to be
older and have higher levels of comorbidity, especially hypertension, heart failure and valvular heart
disease, than comparator patients without NOAF.
What are the outcomes for patients with new-onset atrial fibrillation in critical care and
how do these compare with those for other patients in critical care?
The outcomes are summarised in Table 12 and are illustrated in Figures 4 and 5. Patients with NOAF
were more likely to die, both during their hospital admission and after discharge, than comparator
patients without NOAF. They were also more likely to be subsequently admitted to hospital with AF,
stroke or heart failure.
How much of the difference in outcomes is explained by differences in patient
characteristics and comorbidities?
Adjusted outcomes are summarised in Table 13, with model coefficients provided in Appendix 5, Tables 20
and 21. The excess risk of hospital mortality reduced by about half when controlling for differences in
patient characteristics and comorbidities (OR 3.22, 95% CI 3.02 to 3.44, before adjustment, reducing to
OR 2.32, 95% CI 2.16 to 2.48, after adjustment).
TABLE 11 Patient characteristics and comorbidities
Characteristic NOAF patients (N= 4615) Comparator patients (N= 27,690)
Demographics
Age (years), mean (SD) 71.5 (11.3) 59.1 (17.8)
Sex (male), n (%) 2646 (57.3) 15,008 (54.2)
Ethnicity, n (%)
White 4332 (93.9) 25,157 (90.9)
Mixed 7 (0.2) 113 (0.4)
Asian 86 (1.9) 854 (3.1)
Black 48 (1.0) 564 (2.0)
Other 35 (0.8) 294 (1.1)
Not stated 107 (2.3) 708 (2.6)
Comorbidities, n (%)
Hypertension 3050 (66.1) 13,056 (47.2)
Heart failure 1146 (24.8) 2791 (10.1)
Diabetes mellitus 1085 (23.5) 5691 (20.6)
Valvular heart disease 578 (12.5) 1720 (6.2)
Prior thromboembolism 418 (9.1) 1715 (6.2)
Pulmonary hypertension 121 (2.6) 322 (1.2)
Dilated cardiomyopathy 30 (0.7) 141 (0.5)
SD, standard deviation.
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TABLE 12 Outcomes for patients with NOAF in critical care
Outcome
Cumulative incidence of event (95% CI) (%)
NOAF patients (N= 4615) Comparator patients (N= 27,690)
Mortality
During hospital admission, n (%) 2000 (43.9) 5367 (19.5)
Time after hospital discharge
90 days 8.4 (7.4 to 9.5) 4.1 (3.9 to 4.4)
1 year 17.4 (15.9 to 18.8) 10.6 (10.6 to 11.4)
3 years 31.8 (30.0 to 33.7) 22.2 (21.7 to 22.8)
5 years 44.0 (42.0 to 46.2) 30.0 (29.3 to 30.6)
Subsequent hospital admission for
Atrial fibrillation
1 yeara 25.9 (24.1 to 27.7) 2.3 (2.1 to 2.6)
3 yearsa 36.8 (34.6 to 38.9) 4.9 (4.6 to 5.3)
5 yearsa 42.7 (40.2 to 45.2) 7.0 (6.6 to 7.5)
Stroke
1 yeara 1.5 (1.1 to 2.1) 0.6 (0.5 to 0.7)
3 yearsa 2.7 (2.0 to 3.5) 1.3 (1.2 to 1.6)
5 yearsa 4.2 (3.2 to 5.6) 1.9 (1.7 to 2.2)
Heart failure
1 yeara 10.6 (9.4 to 11.9) 4.1 (3.8 to 4.4)
3 yearsa 16.5 (14.9 to 18.2) 7.2 (6.8 to 7.6)
5 yearsa 20.1 (18.8 to 23.0) 9.3 (8.9 to 9.8)


































FIGURE 4 Cumulative incidence of mortality from ICU admission, estimated using the Kaplan–Meier method.
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FIGURE 5 Cumulative incidence of mortality and hospitalisation after hospital discharge. (a) Mortality after discharge;
(b) hospitalisation with AF; (c) hospitalisation with stroke; (d) hospitalisation with heart failure. Cumulative incidence of
mortality estimated using the Kaplan–Meier approach. The cumulative incidences of hospital admission with AF, stroke
and heart failure estimated using non-parametric methods to account for competing risk of death. (continued )
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FIGURE 5 Cumulative incidence of mortality and hospitalisation after hospital discharge. (a) Mortality after discharge;
(b) hospitalisation with AF; (c) hospitalisation with stroke; (d) hospitalisation with heart failure. Cumulative incidence of
mortality estimated using the Kaplan–Meier approach. The cumulative incidences of hospital admission with AF, stroke
and heart failure estimated using non-parametric methods to account for competing risk of death.
TABLE 13 Regression models: main results
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Outcome




















213 609 907 5400 2.11 (1.83 to 2.44) 1.46 (1.26 to 1.70)
Death 91 days
to 1 year after
hospital discharge
227 2250 1512 20,688 1.38 (1.20 to 1.59) 0.99 (0.86 to 1.15)
Death > 1 year after
hospital discharge






















855 4231 1017 53,458 9.77 (8.91 to 10.70) 5.86 (5.33 to 6.44)
Subsequent hospital
admission for stroke




395 5087 1462 52,907 2.68 (2.39 to 2.99) 1.28 (1.14 to 1.44)
Odds ratios estimated using logistic regression± adjustment for age (using a restricted cubic spline with knots at positions
25, 54, 68 and 84 years), sex, diabetes mellitus, hypertension, prior thromboembolism, valvular heart disease, pulmonary
hypertension and heart failure. HRs estimated using Cox proportional hazards regression± adjustment for the same factors.
CHRs were estimated using Cox proportional hazards regression with censoring at death± adjustment for the same factors.
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For outcomes post discharge from hospital, an examination of the Schoenfeld residuals indicated that
the proportion hazards assumption was unlikely to be met for mortality or subsequent hospitalisation
with AF, but was met for subsequent hospitalisation with stroke and with heart failure. In response to
this, for mortality we partitioned follow-up into three time periods: 1–90 days, 90 days to 1 year and > 1
year. We then fitted separate Cox regression models for each time period (see Table 12). Results
suggested that a similar proportion of the excess risk of death in the first 90 days after hospital
discharge was explained by differences in patient characteristics and comorbidities as for death in
hospital. After 90 days, adjustment for these factors explained all of the excess risk of death associated
with NOAF (CHR ≈ 1.00, after adjustment).
The analysis of subsequent hospitalisations was complicated by the need to account for both the
proportion hazards assumption and the competing risk of death. Because subsequent hospitalisation
with AF exhibited the largest between-group difference, we elected to ignore the possible violation
of the proportional hazards assumption and present analysis of the entire follow-up period, in keeping
with the hospitalisation with stroke and heart failure. The results for hospitalisation with AF should,
therefore, be interpreted as an average over the follow-up period that should not be assumed to be
constant. Adjustment for patient characteristics and comorbidities indicated that about half of the
excess risk of subsequent hospitalisation with each of AF, stroke and heart failure was explained by
these factors.
Sensitivity analysis
For the sensitivity analysis, patients who had less-certain evidence indicating possible NOAF and their
corresponding comparators were included in the analysis (n = 8145 patients with NOAF or possible
NOAF and n = 48,870 comparators). Patient characteristics and comorbidities were similar between
the primary and the sensitivity analysis (see Appendix 5, Table 22). However, hospital mortality fell from
43.9% among patients with NOAF in the primary analysis to 34.5% among patients using the expanded
definition of NOAF in the sensitivity analysis (mortality among comparators was equivalent between
the analyses) (see Appendix 5, Table 23). The results from regression models (see Appendix 5, Table 24)
were consistent with the primary analysis in terms of the proportion explained by patient characteristics
and comorbidities. There remained a small but statistically significant impact of NOAF on mortality
> 1 year after hospital discharge; however, the CI overlapped with the equivalent interval from the
primary analysis. Sensitivity analysis outcomes are illustrated in Appendix 5, Figures 11 and 12.
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Chapter 4 Database analysis part 2:
intensive care unit databases
Parts of this chapter are adapted with permission from Bedford et al.
81 This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial
use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The text below includes minor additions and formatting changes to the original text.
The analysis of the RISK-II database shows that patients who develop NOAF during an ICU admission
are at a significantly increased risk of mortality and hospital readmission with AF, heart failure and
stroke. This highlights the importance of optimal management of this common problem.
Our scoping review has shown that the existing evidence for the best management of NOAF acquired
in an ICU is limited. Common concerns included small sample sizes and inadequate adjustment for
differences between treatment groups.
We, therefore, aimed to compare the clinical effectiveness of different NOAF treatments by analysing
two large ICU databases after performing comprehensive adjustments for measured confounding.
Database analysis part 2: methods
Study design
We carried out a retrospective observational study of two large ICU databases from the UK
(PICRAM82) and the USA [Medical Information Mart for Intensive Care III (MIMIC-III) v1.483].
The PICRAM database comprises data relating to > 12,000 patients who were treated in three general
ICUs in the UK from 2008 to 2015. MIMIC-III comprises data relating to > 40,000 patients who were
admitted to critical care units at a tertiary care hospital in the USA between 2001 and 2012.
All analyses were performed on each database individually given the potential for differences in
case mix and interventions. Combined analyses were performed for each outcome to confirm
findings. We adhered to the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines.84
Study population
We included all adult (aged ≥ 16 years) patients. For patients who were admitted more than once to an
ICU, we used their first admission. We excluded patients:
l cared for by a coronary care or cardiac surgery team
l with missing hospital outcome data
l with an ICU length of stay of < 24 hours85
l with significant arrhythmia in the first 3 hours of arrival to an ICU
l with pre-existing arrhythmias.
We defined patients as having a pre-existing arrhythmia if an arrhythmia or a medication prescribed
with an indication of heart rhythm management were identified in the patient’s medical history.
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Exposure and outcomes
For all ICUs that were included in the databases, routine practice was to display three lead
electrocardiograms continuously, with heart rhythm recorded by the bedside nurse at regular
intervals. We defined NOAF as the documentation of AF or atrial flutter lasting for ≥ 30 seconds.30
A documented heart rhythm was assumed to persist until the next identifiable rhythm was recorded.
The availability of data relating to the interventions of interest was assessed in theMIMIC-III and PICRAM
databases.TheMIMIC-III database allowed four interventions to be compared: i.v. amiodarone, i.v. beta-blockers,
i.v. calcium channel blockers and electrical cardioversion.The PICRAMdatabase allowed three interventions to
be compared: i.v. amiodarone, i.v. beta-blockers and i.v. digoxin.We analysed each intervention in an intention-
to-treat fashion, in which treatment groups were determined by first treatment after NOAF onset.86
Primary outcomes
The primary end points of this study were ICU mortality, hospital mortality, rate control and rhythm
control, which were analysed as time-to-event outcomes. We censored rate and rhythm control at
24 hours and censored mortality at 30 days. In the absence of a consensus definition of treatment
success for ICU-acquired NOAF, we defined time to cardioversion with our expert panel as the time
to first reversion of sinus rhythm42 and we defined time to rate control as the time to a heart rate of
< 110 b.p.m. in the subset of patients with a heart rate of ≥ 110 b.p.m.87
Secondary outcomes
We analysed the association of NOAF with hospital mortality. We calculated the CHR to estimate the
aetiological association between NOAF and hospital outcomes, considering hospital discharge as a
competing risk to mortality. We adjusted for the Oxford Acute Severity of Illness Score (OASIS),88
which was limited to the first 3 hours of ICU admission to avoid confounding post-NOAF onset.
The use of early scores has been shown to remain predictive of outcome.89
We explored the haemodynamic changes (heart rate, blood pressure and vasoactive medication dose)
that are associated with NOAF. We calculated the proportion of patients receiving vasoactive
medications in our cohort before and after NOAF onset. We calculated the vasoactive-inotropic score90
to quantify the change in composite dose of vasoactive medications for patients already receiving
vasoactive medications prior to AF onset.
Focusing on the period 6 hours pre and post NOAF, we used smooth additive quantile regression
models91 to fit the 75%, 50% and 25% quantiles of the distribution of each haemodynamic variable.
We excluded the haemodynamic data recorded after each patient’s first treatment for NOAF to
establish a natural history. All models included a binary covariate to indicate the onset of NOAF and
allowed for changes in smoothing spline post-AF onset.
We used multilevel linear models to test whether or not there were significant changes in heart rate,
blood pressure and vasoactive medication dose associated with NOAF. Each model included fixed linear
segmented regression terms, with a random effect per patient to account for repeated measurements.
Adjustment for confounding
We carried out a propensity score-weighted time-to-event analysis to adjust for measured confounding
in the selection of patients between treatment groups. All statistical analyses were performed using
R Core v4.0.2. We generated propensity score weights that were optimised to balance the covariate
distributions of the treatment groups92 using the WeightIt package.93 The confounding variables
included admission variables, laboratory variables and physiological variables adjacent to NOAF onset.
The list of confounding variables was generated based on the studies identified in our scoping review.
This list was then reviewed and supplemented by members of the study oversight panel. The admission
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variables included age; sex; the OASIS88 within the first 3 hours of ICU admission; use of preadmission
beta-blocker, antipsychotic or thyroid medication; severe congestive cardiac failure; chronic obstructive
pulmonary disease (COPD); liver disease; and thyroid disease. The laboratory variables at NOAF onset
included the most recent (to NOAF onset) plasma sodium, potassium, magnesium, creatinine and urea
concentrations; white cell count; platelet count; haemoglobin concentration; and prothrombin time. The
physiological/intervention variables at NOAF onset included systolic and mean blood pressure, heart
rate, body temperature, presence and dose of vasoactive agent, presence of bronchodilator therapy,
mechanical ventilation, renal replacement therapy and presence of central venous access.
We assessed the balance of covariates across weighted groups by tabulating group means pre and post
weighting. We calculated standardised mean differences (SMDs)94 and the maximum SMD of all
pairwise treatment group comparisons for each covariate.
We carried out a weighted Cox survival analysis to determine the average treatment effect of NOAF
treatments on our outcomes of interest. Missing laboratory values were handled by using multiple
imputation. We generated 20 imputed data sets. To account for the uncertainty in the generated
propensity scores and to allow for the estimation of 95% CIs around effect estimates, we performed
resampling with replacement (bootstrapping) with recalculation of propensity score weights and effect
estimates with each bootstrap sample. We obtained 1000 bootstrap samples from each imputed data
set.95 The effect estimates and CIs from each imputed data set were combined using Rubin’s rules.96
Critical Care Health Informatics Collaborative database analysis
We also analysed the Critical Care Health Informatics Collaborative (CCHIC) database.97 This database
was created with retrospectively collected detailed data from the ICU clinical information systems
from four general ICUs in London and Cambridge, in the UK, from 2014 to 2018.
Of our drugs of interest, the CCHIC database contains beta-blocker data only. We, therefore, decided
to use this database to analyse only the epidemiology and characteristics of NOAF to compare with
our main analyses.
We used the eligibility criteria stated in Study population. However, we were unable to exclude patients
with documented pre-existing arrhythmias because these data were not available in the CCHIC database.
Pre-existing arrhythmia was, therefore, determined only by the presence of arrhythmia during the first
3 hours of ICU admission. Full methods are outlined in Appendix 7.
Database analysis part 2: results
Study population
The MIMIC-III database contains data from 22,684 adult index ICU admissions. Of these patients,
220 had an ICU length of stay of < 24 hours. We identified 3905 of the remaining 22,464 patients
as having pre-existing AF or AF documented within the first 3 hours of their ICU admission. Of the
18,559 patients who fulfilled our inclusion criteria, 1065 (5.7%) developed NOAF during their ICU stay.
Of these patients, 742 went on to receive one of the interventions of interest. Only two patients
received digoxin as their initial treatment and were, therefore, excluded, leaving 740 patients for the
comparative analysis. This process is displayed in Figure 6.
The PICRAM database contains data from 12,270 adult index ICU admissions. Of these patients, 3004
had an ICU length of stay of < 24 hours. We identified 899 of the remaining 9266 patients as having
pre-existing AF or AF documented within the first 3 hours of ICU admission. Of the 8367 patients who
fulfilled our inclusion criteria, 952 (11.4%) developed NOAF during their ICU stay. Of these patients,
471 went on to receive one of the interventions of interest. Five patients had missing outcome data
and were, therefore, excluded from the analysis. Of those 466 patients with outcome data, only six patients
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received DCC or calcium channel blockers and were, therefore, excluded, leaving 460 patients for the
comparative analysis. This process is displayed in Figure 6. In both databases, patients who developed
NOAF were older, with a similar age difference as was identified in the RISK-II database analysis.
Patients who developed NOAF also had longer ICU and hospital length of stay, and higher ICU and
hospital mortality (see Appendix 6, Tables 25 and 26), than those who did not develop NOAF. The
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FIGURE 6 Study CONSORT flow diagrams. (a) MIMIC-III database; (b) PICRAM database. Reproduced with permission
from Bedford et al.81 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial
use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure. (continued )
DATABASE ANALYSIS PART 2: INTENSIVE CARE UNIT DATABASES






















Too few patients per

















FIGURE 6 Study CONSORT flow diagrams. (a) MIMIC-III database; (b) PICRAM database. Reproduced with permission
from Bedford et al.81 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial
use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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(N= 460) Overall (N= 1200)
Age (years), median (IQR) 74 (64–82) 70 (63–77) 72 (64–80)
Sex, n (%)
Female 372 (50) 186 (40) 558 (46)
Male 368 (50) 274 (60) 642 (54)
COPD, n (%) 53 (7.2) 63 (14) 116 (9.7)
Dialysis-dependent renal failure, n (%) 1 (0.1) 7 (1.5) 8 (0.7)
NYHA class III/IV heart failure, n (%) 0 (0) 2 (0.4) 2 (0.2)
Chronic liver disease, n (%) 11 (1.5) 20 (4.3) 31 (2.6)
Thyroid disorder, n (%) 33 (4.5) 28 (6.1) 61 (5.1)
Beta-blocker therapy prior to admission, n (%) 281 (42) 63 (14) 344 (30)
Antipsychotic therapy prior to admission, n (%) 27 (4.0) 7 (1.5) 34 (3.0)
Highest OASIS at 3 hours, median (IQR) 36 (31–41) 34 (26–39) 35 (29–40)
Mechanical ventilation at time of NOAF, n (%) 343 (46) 243 (53) 586 (49)
Renal replacement therapy during or < 12 hours
prior to NOAF, n (%)
47 (6.4) 65 (14) 112 (9.3)
i.v. vasoactive medication at time of NOAF, n (%) 101 (14) 124 (27) 225 (19)
Therapeutic anticoagulation at time of NOAF,
n (%)
36 (4.9) 48 (10) 84 (7.0)
Central venous catheter at time of NOAF, n (%) 429 (58) 326 (71) 755 (63)
Bronchodilator therapy on day of, or day
preceding, NOAF, n (%)
258 (35) 75 (16) 333 (28)
Plasma concentration, median (IQR)
Sodium (mmol/l) 139.0 (136.0–143.0) 137.0 (134.0–141.0) 139.0 (136.0–142.0)
Potassium (mmol/l) 4.00 (3.70–4.40) 4.20 (3.90–4.50) 4.00 (3.80–4.40)
Magnesium (mmol/l) 0.82 (0.78–0.95) 0.96 (0.84–1.12) 0.86 (0.78–1.00)
Urea (mmol/l) 9 (6–16) 14 (9–20) 11 (7–18)
Creatinine (µmol/l) 97 (62–159) 125 (78–214) 104 (69–186)
White cell count (× 109/l), median (IQR) 12 (8–16) 11 (8–16) 12 (8–16)
Haemoglobin concentration (g/l), median (IQR) 102 (92–115) 98 (88–113) 101 (90–114)
Platelet count (× 109/l), median (IQR) 190 (123–283) 166 (109–234) 181 (117–265)
Prothrombin time (seconds), median (IQR) 2.65 (2.57–2.80) 2.78 (2.71–2.94) 2.71 (2.61–2.89)
Systolic blood pressure prior to AF onset
(mmHg), median (IQR)
123 (106–141) 116 (101–133) 120 (104–138)
Mean blood pressure prior to AF onset (mmHg),
median (IQR)
80 (69–91) 77 (68–88) 78 (69–90)
Heart rate prior to AF onset (b.p.m.),
median (IQR)
96 (84–112) 115 (96–140) 102 (87–124)
DATABASE ANALYSIS PART 2: INTENSIVE CARE UNIT DATABASES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
The CCHIC database included data that were related to 33,451 adult first admissions to an ICU. Of
these patients, 7889 had an ICU length of stay of < 24 hours. We identified 2713 patients being paced
or with another significant arrhythmia during the first 3 hours of ICU admission. Of the remaining
22,849 patients, 1003 had missing hospital mortality data. Of the remaining 21,846 eligible patients,
2618 (12%) developed NOAF (see Appendix 7, Figure 23). The characteristics of patients with and
without NOAF are shown in Appendix 7, Table 34.
Characteristics of new-onset atrial fibrillation in treated patients
The time from ICU admission to the onset of NOAF in treated patients was similar between the
MIMIC-III and the PICRAM databases [median 40.5 hours (IQR 21–79 hours) vs. 40.3 hours (IQR
41–75 hours), respectively]. Patients with data reported in the MIMIC-III database had, on average,
shorter total durations of AF [median 11.6 hours (IQR 4–37 hours) vs. 18.1 hours (IQR 6–44 hours),
respectively]. The timing of onset and AF duration data are displayed in Figures 7 and 8, respectively.





(N= 460) Overall (N= 1200)
Treatment group (by first treatment), n (%)
Amiodarone 94 (13) 344 (75) 438 (36)
Beta-blocker 473 (64) 47 (10) 520 (43)
Calcium channel blocker 144 (19) 0 (0) 144 (12)
Digoxin 0 (0) 69 (15) 69 (5.8)
Electrical cardioversion 29 (3.9) 0 (0) 29 (2.4)
NYHA, New York Heart Association.
Reproduced with permission from Bedford et al.81 This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.
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FIGURE 7 Time from ICU admission to AF onset in treated patients. (a) MIMIC-III database; (b) PICRAM database.
Data from 93 patients with time to AF onset > 168 hours (7 days) not shown.
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Association of new-onset atrial fibrillation with hospital mortality
In the unadjusted analysis, NOAF was associated with an almost identical increased risk of hospital
mortality in the MIMIC-III and PICRAM databases [CHR 1.89 (95% CI 1.69 to 2.13) and CHR 1.89
(95% CI 1.68 to 2.13) respectively]. After adjustment for illness severity at ICU admission, this association
remained evident [CHR 1.47 (95% CI 1.31 to 1.65) and CHR 1.73 (95% CI 1.54 to 1.96) respectively].
New-onset atrial fibrillation treatments
Of the patients who were identified in the MIMIC-III database, 94 received amiodarone, 473 received
beta-blockers, 144 received calcium channel blockers and 29 received electrical cardioversion as their
initial NOAF treatment. In the PICRAM database, 344 patients received amiodarone, 47 received
beta-blockers and 69 received digoxin as their initial NOAF treatment. The characteristics of patients
by treatment group are displayed in Appendix 6, Tables 27 and 28, for the MIMIC-III and PICRAM
databases, respectively.
Adjustment for confounding
After propensity score weighting, covariates were well matched across all treatment groups in each
database. Across 30 variables, only the mean urea concentration in the MIMIC-III database had the
maximum pairwise SMD of > 0.2. Unweighted and weighted means for each treatment group can be
found in Appendix 6, Tables 29 and 30.
Rate control
The MIMIC-III database
The time at which 50% of patients had achieved rate control was 60 minutes, 60 minutes, 80 minutes
and 10 minutes in the amiodarone, beta-blocker, calcium channel blocker and electrical cardioversion
groups, respectively. The cumulative incidence curves of rate control for each treatment group are





























Total duration of AF per treated patient (hours)
120
FIGURE 8 Total duration of AF per treated patient. (a) MIMIC-III database; (b) PICRAM database. Data from 89 patients
with AF duration > 120 hours (5 days) not shown.
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In the unadjusted analysis, no differences were observed between any intervention and amiodarone in
the time to achieving rate control (see Appendix 6, Table 31).
After propensity score weighting, beta-blockers, calcium channel blockers and cardioversion were
not associated with any significant difference in rate of achieving rate control when compared with
amiodarone (HR 1.09, 95% CI 0.78 to 1.51; HR 0.81, 95% CI 0.55 to 1.19; and HR 1.59, 95% CI 0.44 to
5.75; respectively) (Figure 9; see Appendix 6, Table 31).
After initial rate control, reversion to a heart rate of ≥ 110 b.p.m. was common. Of those patients
achieving rate control, 65%, 62%, 80% and 68% of patients in the amiodarone, beta-blocker, calcium
channel blocker and electrical cardioversion groups, respectively, had at least one episode of a heart
rate of ≥ 110 b.p.m. within the 24 hours after initial rate control (see Appendix 6, Figure 14).
The PICRAM database
The time at which 50% of patients had achieved rate control was 96 minutes, 115 minutes and
241 minutes in the amiodarone, beta-blocker and digoxin groups, respectively. The unadjusted cumulative
incidence curves of rate control for each treatment group are displayed in Appendix 6, Figure 15.
In the unadjusted analysis, there was no evidence of a difference in achieving rate control between
beta-blocker therapy and amiodarone (HR 0.85, 95% CI 0.57 to 1.27); however, digoxin appeared
inferior to amiodarone in achieving rate control (HR 0.64, 95% CI 0.45 to 0.92).
After propensity score weighting, beta-blocker therapy was not associated with any significant
difference in the rate of achieving rate control [adjusted hazard ratio (aHR) 0.82, 95% CI 0.48 to 1.42]
compared with amiodarone. The reduced rate of achieving rate control with digoxin therapy remained
evident (aHR 0.56, 95% CI 0.34 to 0.92) (see Figure 9 and Appendix 6, Table 32).
After initial rate control, reversion to a heart rate of > 110 b.p.m. was common. Of those achieving
rate control, 66%, 59% and 76% of patients in the amiodarone, beta-blocker and digoxin groups,
respectively, had at least one episode of a heart rate of ≥ 110 b.p.m. within the 24 hours after initial
rate control. These findings are displayed in Appendix 6, Figure 16. These differences were not
significant in the unadjusted or adjusted analysis.
Combined database analysis
In the unadjusted combined analysis, beta-blocker therapy was associated with a higher rate of
achieving rate control (HR 1.26, 95% CI 1.10 to 1.43) and digoxin was associated with a lower rate of
achieving rate control (HR 0.69, 95% CI 0.52 to 0.91) than amiodarone. After adjustment, we found no
evidence of a difference between beta-blocker therapy and amiodarone in the rate of achieving rate
control (aHR 1.14, 95% CI 0.91 to 1.44). Consistent with the PICRAM database analysis, we found that
digoxin therapy was associated with a lower rate of achieving rate control than amiodarone (aHR 0.52,
95% CI 0.32 to 0.86) (see Appendix 6, Table 33).
In the unadjusted combined analysis, calcium channel blockers were associated with an increased
rate of reversion to a heart rate of ≥ 110 b.p.m. in those patients who initially achieved rate control




The time at which 50% of patients had achieved rhythm control was 159 minutes, 144 minutes,
285 minutes and 40 minutes in the amiodarone, beta-blocker, calcium channel blocker and electrical
cardioversion groups, respectively (see Appendix 6, Figure 17).
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FIGURE 9 Unadjusted and adjusted HRs for rate and rhythm control. (a) MIMIC-III unadjusted; (b) PICRAM unadjusted;
(c) MIMIC-III adjusted; (d) PICRAM adjusted. Adapted with permission from Bedford et al.81 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting changes to the
original figure.
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In the unadjusted analysis, there was no evidence of a difference in achieving rhythm control between
beta-blockers or cardioversion and amiodarone. Calcium channel blocker therapy was associated with a
reduced rate of achieving rhythm control (HR 0.65, 95% CI 0.50 to 0.84).
After propensity score weighting, there remained no evidence of a difference in achieving rhythm
control between beta-blockers (HR 0.91, 95% CI 0.61 to 1.35) or cardioversion (HR 2.00, 95% CI
0.86 to 4.65) and amiodarone. Calcium channel blockers remained associated with a lower rate of
achieving rhythm control (HR 0.59, 95% CI 0.37 to 0.92) than amiodarone (see Figure 9 and Appendix 6,
Table 31).
After initial rhythm control, reversion to AF was common. Of those patients achieving rhythm control,
36%, 39%, 47% and 46% of patients in the amiodarone, beta-blocker, calcium channel blocker and
electrical cardioversion groups, respectively, had at least one episode of AF within the 24 hours after
initial cardioversion (see Appendix 6, Figure 18). The differences in reversion rates were not significant
in the unadjusted or adjusted analysis (see Appendix 6, Table 31).
The PICRAM database
The time at which 50% of patients had achieved rhythm control was 80 minutes, 37 minutes and
255 minutes in the amiodarone, beta-blocker and digoxin groups, respectively. Cumulative incidence
curves of rhythm control for each treatment group are shown in Appendix 6, Figure 19.
In the unadjusted analysis, there was no evidence of a difference in achieving rhythm control between
beta-blocker therapy and amiodarone (HR 0.95, 95% CI 0.64 to 1.40); however, digoxin appeared to be
inferior to amiodarone (HR 0.57, 95% CI 0.41 to 0.81).
After propensity score weighting, beta-blocker therapy was not associated with any significant
difference in the rate of achieving rhythm control (HR 0.99, 95% CI 0.57 to 1.72). Digoxin was no longer
significantly associated with a lower rate of achieving rhythm control (HR 0.67, 95% CI 0.41 to 1.09)
(see Figure 9 and Appendix 6, Table 32).
After initial rhythm control, reversion to AF was common. Of those patients achieving rhythm control,
54%, 51% and 70% of patients in the amiodarone, beta-blocker and digoxin groups, respectively, had
at least one episode of AF within the 24 hours after initial cardioversion (see Appendix 6, Figure 20).
Differences in reversion rates were not significant in the unadjusted or adjusted analysis (see Appendix 6,
Table 32).
Combined analysis
Consistent with the individual database analyses, the unadjusted combined analysis suggested that
calcium channel blockers (HR 0.58, 95% CI 0.47 to 0.71) and digoxin (HR 0.58, 95% CI 0.41 to 0.83)
were associated with a reduced rate of achieving rhythm control compared with amiodarone.
Furthermore, beta-blocker therapy was also associated with a lower rate of achieving rhythm control
than amiodarone (HR 0.81, 95% CI 0.71 to 0.93).
After adjustment, we found no evidence of differences between beta-blockers (aHR 0.86, 95% CI 0.67
to 1.11), digoxin (aHR 0.64, 95% CI 0.35 to 1.17) or electrical cardioversion (aHR 1.58, 95% CI 0.71 to
3.51) and amiodarone in the rate of achieving rhythm control. We found that calcium channel blocker
therapy was associated with a lower rate of achieving rhythm control than amiodarone (aHR 0.56,
95% CI 0.39 to 0.79), which was consistent with our MIMIC-III database analysis (see Appendix 6, Table 33).
Consistent with the individual database analyses, there was no evidence of a difference in the rates of
reversion to AF between treatments in the unadjusted or the adjusted analyses.
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In the unadjusted analysis, beta-blocker therapy was associated with a reduced hospital mortality rate
(HR 0.64, 95% CI 0.44 to 0.93). Unadjusted survival curves for each treatment group in the MIMIC-III
database are displayed in Appendix 6, Figure 21.
After propensity score weighting, we found no evidence of a difference between beta-blockers (aHR 1.03,
95% CI 0.53 to 2.03), calcium channel blockers (aHR 1.30, 95% CI 0.61 to 2.76) or electrical cardioversion
(HR 0.96, 95% CI 0.31 to 3.01) and amiodarone in hospital mortality (see Appendix 6, Table 31).
The PICRAM database
We found no differences in hospital survival in the unadjusted analyses. Unadjusted survival curves for
each treatment group in the PICRAM database are displayed in Appendix 6, Figure 22.
After propensity score weighting, there remained no differences between beta-blockers (aHR 0.75,
95% CI 0.30 to 1.84) or digoxin (aHR 1.37, 95% CI 0.75 to 2.50) and amiodarone in hospital mortality
(see Appendix 6, Table 32).
Combined analysis
Consistent with our MIMIC-III database analysis, the combined unadjusted analysis suggested that
beta-blockers were associated with a reduced hospital mortality rate (HR 0.78, 0.62 to 0.99).
Cardioversion appeared to be associated with a significantly increased hospital mortality rate
(HR 1.92, 95% CI 1.16 to 3.17). After propensity score weighting, we found no significant difference
between beta-blockers (aHR 0.97, 95% CI 0.56 to 1.68), calcium channel blockers (aHR 1.21, 95% CI
0.62 to 2.39), digoxin (aHR 1.77, 95% CI 0.77 to 4.06) or cardioversion (aHR 0.87, 95% CI 0.25 to 3.00)
and amiodarone in hospital mortality (see Appendix 6, Table 33).
Haemodynamic changes associated with atrial fibrillation onset
Multilevel linear modelling revealed that NOAF was associated with a significant heart rate increase of
22 b.p.m. (p < 0.001) and 19 b.p.m. (p < 0.001) in the MIMIC-III and PICRAM databases, respectively.
The average heart rate after AF onset was 122 b.p.m. and 127 b.p.m., respectively.
New-onset atrial fibrillation was associated with a significant reduction in systolic blood pressure in
the MIMIC-III and the PICRAM databases of 7 mmHg and 4 mmHg, respectively (p < 0.001). This was
despite significant increases in the doses of vasoactive medication after NOAF onset in those receiving
vasoactive medications prior to NOAF onset [vasoactive-inotropic score increase of 2.5 (p < 0.001)
and 1.8 (p = 0.001), respectively]. New hypotension (systolic blood pressure of < 90 mmHg or mean
blood pressure of < 65 mmHg) occurred after NOAF in 28% and 21% of patients with a systolic blood
pressure of ≥ 90 mmHg or a mean blood pressure of ≥ 65 mmHg prior to AF onset, respectively.
There was a non-significant increase in the proportion of patients receiving vasoactive medications
after NOAF onset in the MIMIC-III database (17.6% to 20.2%; p = 0.29). This proportion was unchanged
after NOAF onset in the PICRAM database (29%).
The change in heart rate, blood pressure and vasoactive medication use over time, before and after AF
onset, is displayed in Figure 10.
Summary
This study demonstrated that NOAF during an ICU stay is common and is associated with significant
increases in heart rate, reductions in blood pressure and increases in vasoactive medication requirements.
NOAF was associated with an increased rate of hospital mortality despite adjusting for variables in a
validated mortality prediction model.
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FIGURE 10 Haemodynamic changes associated with AF onset. (a) Heart rate, MIMIC-III database; (b) heart rate PICRAM
database; (c) systolic blood pressure, MIMIC-III database; (d) systolic blood pressure, PICRAM database; (e) vasoactive-
inotropic score, MIMIC-III database; (f) vasoactive-inotropic score, PICRAM database; (g) proportion of patients on
vasoactive medications, MIMIC-III database; (h) proportion of patients on vasoactive medications, PICRAM database.
Vasoactive-inotropic score shown for those patients receiving vasoactive medications prior to AF onset. VIS= dopamine
dose (µg/kg/minute)+ dobutamine dose (µg/kg/minute)+ 100 × adrenaline dose (µg/kg/minute)+ 10 × milrinone dose
(µg/kg/minute)+ 10,000 ± vasopressin dose (units/kg/minute)+ 100 × noradrenaline dose (µg/kg/minute). Reproduced
with permission from Bedford et al.81 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original figure. (continued )
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FIGURE 10 Haemodynamic changes associated with AF onset. (a) Heart rate, MIMIC-III database; (b) heart rate PICRAM
database; (c) systolic blood pressure, MIMIC-III database; (d) systolic blood pressure, PICRAM database; (e) vasoactive-
inotropic score, MIMIC-III database; (f) vasoactive-inotropic score, PICRAM database; (g) proportion of patients on
vasoactive medications, MIMIC-III database; (h) proportion of patients on vasoactive medications, PICRAM database.
Vasoactive-inotropic score shown for those patients receiving vasoactive medications prior to AF onset. VIS= dopamine
dose (µg/kg/minute)+ dobutamine dose (µg/kg/minute)+ 100 × adrenaline dose (µg/kg/minute)+ 10 × milrinone dose
(µg/kg/minute)+ 10,000 ± vasopressin dose (units/kg/minute)+ 100 × noradrenaline dose (µg/kg/minute). Reproduced
with permission from Bedford et al.81 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original figure.
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Beta-blocker therapy was not associated with any difference in achieving rate or rhythm control, or
with any difference in hospital survival when compared with amiodarone. The hospital mortality benefit
with beta-blocker therapy that was identified in the unadjusted analysis of the MIMIC-III database was
no longer apparent after adjustment. This suggests that differences in survival were only because of
differences in patient characteristics between treatment groups.
Digoxin therapy was associated with a lower rate of achieving rate control than amiodarone. Calcium
channel blocker therapy was associated with a lower rate of achieving rhythm control than amiodarone.
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Chapter 5 Expert panel
To highlight our findings, identify uncertainties and formulate research recommendations weconvened an expert panel. We followed the National Institute for Health and Care Excellence
Research Recommendations Process and Methods Guide.98 Panel members are listed in Appendix 7,
Table 35.
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Statement of principal findings
The evidence base available for NOAF management in critically ill patients identified by our scoping
review was very limited. Many studies lacked a comparator group and many of those that had a
comparator group did not control for confounding factors. Only two randomised trials were identified,
both of which were small and inconclusive. We identified significant heterogeneity in the definitions of
both NOAF and successful treatment, making a synthesis of results difficult.
The limited evidence from our scoping review suggested that beta-blockers might be more effective
than amiodarone for the conversion to sinus rhythm and mortality outcomes; however, residual bias in
previous studies may explain these assertions. Whether or not and when to use anticoagulation is
unknown. No conclusive findings were reported owing to the low quality of the reviewed evidence.
Only one clinician survey was found, with a very low response rate.16
Our analysis of the RISK-II database demonstrated that patients who developed NOAF in an ICU were
older and had higher levels of comorbidity than those who did not. Even after controlling for these
differences, patients with NOAF still had substantially higher mortality in hospital and during the first
90 days after discharge. Patients who developed NOAF in an ICU also had higher rates of subsequent
hospitalisation with AF, stroke and heart failure than those who did not.
Our analysis of the detailed within-ICU MIMIC-III and PICRAM databases showed that NOAF is a
common problem that occurs in 6–11% of eligible ICU patients, depending on the data source. In an
ICU, NOAF is associated with a significant increase in heart rate and a significant decrease in blood
pressure, despite an increase in vasoactive medication doses. Supporting our RISK-II findings, we
identified a significantly increased hospital mortality rate associated with NOAF, even after adjusting
for other factors that are predictive of mortality.
These findings highlight the importance of identifying optimal treatment strategies for NOAF in
patients in an ICU. We found that the treatment of NOAF with digoxin or calcium channel blockers
as first-line therapy is associated with poorer rate control and rhythm control, respectively. Prior
to adjustment for confounding variables, we found that beta-blocker therapy was associated with
improved hospital survival. We also demonstrated that patients who received beta-blockers were
less unwell at admission and more stable after AF onset than those who received amiodarone. After
comprehensive adjustment of these factors, there were no identifiable differences in any outcome
between beta-blocker therapy and amiodarone.
Scoping review
The evidence base available for NOAF management in critically ill patients was very limited. A key
problem with the studies identified in this scoping review was that many (n = 12) were single-group
studies (i.e. lacking a comparator group). Of the 25 primary studies included in the review, only two
were RCTs30,31 and only three of the non-randomised comparative studies27–29 attempted to control for
confounding factors, which may have affected outcomes. For all of these studies, which used more
robust approaches, there were still serious concerns about how bias (arising from their designs and/or
analyses) might affect their results. Although the two RCTs30,31 did not find statistically significant
differences in conversion rates between the treatments studied, each contained < 60 patients.
Many studies27–30 concluded that more research is needed.
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Heterogeneity in the treatment dose (e.g. total doses ranging from < 1 g to 8 g for amiodarone8,31,32,34,35,42,43)
and administration (e.g. bolus or continuous infusion), and varying time points to assess conversion to sinus
rhythm (e.g. within 2 hours,30 4 hours,31 12 hours30 and 24 hours8,32,35,36) were observed across studies.
Comparing studies was, therefore, challenging. There is a need to establish optimal treatment dosing and
administration regimens, as well as validated definitions of treatment success. Six studies33,34,36,37,40,48 (14%)
were available only as conference abstracts. Only limited data could be extracted for these studies, making
their results more difficult to interpret.
Studies varied in how they reported and defined NOAF. Different heart rate thresholds for NOAF were
used.31,36,38,43,47,49 Studies also reported different time periods for which NOAFmust be sustained27,30,41,43,47,49
and for which instances AF would be considered NOAF.8,28,29,38,39,50 Ten studies32–35,37,40,44–46,48 did not provide
any definition for NOAF.
The evidence from this review34–36 suggests that beta-blockers might be more effective than
amiodarone for the conversion back to normal sinus rhythm, with better outcomes for mortality
reported in those who received beta-blockers than in those who received amiodarone.28,35 A recent
UK-wide survey16 found that amiodarone is the most commonly used pharmacological treatment for
NOAF in UK ICUs, which suggests that these studies are not changing current practice. Calcium
channel blockers appeared to be less effective than beta-blockers and amiodarone for conversion to
sinus rhythm.30,31,36 Two studies27,48 reported that hydrocortisone might be effective as a prophylactic
treatment. However, a larger comparative study27 reported slightly higher (but not statistically
significant) mortality associated with the use of hydrocortisone. All of the studies reporting effects of
hydrocortisone had significant methodological limitations.
The evidence base for NOAF treatment strategies was reported as very limited in two systematic
reviews, which agrees with our findings.53,56 Both systematic reviews were not able to report any
conclusive findings, citing the low quality of the reviewed evidence53 and methodological differences
between the included studies.56 In agreement with our findings, the review by Kanji et al.56 concluded
that a standardised outcome measure of success is needed as varying time points used to assess
conversion to sinus rhythm limits recommendations on treatment efficacy.56 Both systematic reviews
emphasised the urgent need for further research studies.53,56
The current literature29,62 suggests that it is unclear if the benefits of administering anticoagulants in
critically ill patients with NOAF for stroke prevention outweigh the increased risk of bleeding. Two
review articles61,64 proposed a patient-centred approach to administer anticoagulants only in patients
with high risk of arterial thromboembolic events. Outside the ICU, withholding anticoagulation for a
short time in the perioperative period in patients with AF undergoing elective surgery was not
associated with an increased risk of arterial thromboembolism and decreased the risk of major
bleeding.99 It is, however, not known how these findings translate to critically ill patients in ICUs.
The risk assessment scores for subsequent thromboembolism following the development of NOAF
have generally not been developed or validated in the ICU population. The CHA2DS2-VASc score100 has,
however, once been shown to be predictive of thromboembolic event risk in the ICU setting, although
with poor sensitivity and predictive value.101 Bleeding risk scores to guide anticoagulation decisions in
NOAF have been developed using population-based cohorts of patients with AF in the community.
Common risk factors used in these scores include older age, renal dysfunction, hypertension and a
history of bleeding. Comparative studies of these tools report varying results depending on the patient
population.102–105 Patients who develop NOAF during sepsis are at a higher risk of in-hospital and post-
discharge stroke and death than those who do not, despite adjusting for confounders.14,106 Those with
NOAF are at a higher risk of thromboembolic complications than patients with pre-existing AF.106
However, the individual risk of stroke and thromboembolic events in patients who develop NOAF
during an ICU admission remains poorly understood.
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Although community-based bleeding risk scores are chiefly composed of chronic comorbidities, the
bleeding risk in patients in an ICU is likely to be more related to acute factors, such as illness severity,
systemic inflammation, type and location of surgery, nutritional status, invasive devices, and acute
coagulopathy and thrombocytopenia.70,107–109 Bleeding risk in critically ill patients with NOAF is higher
than patients in the community, with one study demonstrating that 9% of patients who received
systemic anticoagulation had significant bleeding warranting cessation of anticoagulation and at least
one blood transfusion.8
A recent UK-wide survey suggested that around one-third of clinicians initiate anticoagulation in
patients with NOAF during an ICU admission.16 Once in stable AF in the community, anticoagulation
can be recommended for almost all patients with AF. However, the balance of risks in patients either in
an ICU or in whom AF was demonstrated only during the ICU admission is likely to be more complex
and dynamic. Modified risk scores that incorporate such complexities are, therefore, required for
critically ill patients with NOAF.
The RISK-II database analysis
This analysis of the RISK-II database provides clear evidence of a patient group developing NOAF in
critical care with substantially worse short- and long-term outcomes than patients without any record
of AF during or prior to ICU admission. We adopted a restrictive approach to ensure that patients’
CMP and HES records provided sufficient confidence in discriminating NOAF in the ICU from prior
and subsequent AF. In our sensitivity analysis, we adopted a slightly broader, yet still conservative,
definition of NOAF. The outcomes, although somewhat less severe, remained consistent with the
primary analysis. Outcomes were substantially worse for patients with AF than for patients with no AF,
even after controlling for patient characteristics and past medical history. Patients developing NOAF
during an ICU admission were less likely to survive and more likely to be readmitted with AF, stroke
or heart failure than those who did not develop NOAF. Comparison with other data sources suggests
that our methodology identified a subset of all patients who develop NOAF in critical care. Given the
inconsistent nature with which diagnoses are recorded in HES,110 the group identified as developing
NOAF in this analysis might best be interpreted as representing patients for whom their AF was of
sufficient clinical importance to be documented in their clinical notes (which are then used to code
diagnoses in HES records).
The evidence provided by multivariable regression indicates that the impact of NOAF on mortality
is not constant over time, but rather focused on the period in and immediately after discharge from
hospital. Patients who developed NOAF in an ICU had increased mortality up to the limit of follow-up.
However, from 90 days after hospital discharge, the increased mortality appeared to be entirely
explained by their older age, sex and comorbidities. During hospital admission and the first 90 days
after discharge, roughly half of the increased mortality appeared attributable to either NOAF or
unobserved clinical factors that are associated with it. These findings emphasise the importance of
developing strategies for both the treatment and the anticoagulation management of NOAF in the
period of critical illness and its immediate aftermath, for which current evidence is lacking.
We did not break down multivariable models for subsequent hospitalisation into similar time periods,
given the complexity of interpreting proportional hazards regressions with both non-proportional
hazards (effects that vary over time) and competing risks. However, given that hospitalisation is closely
related to mortality, it may be reasonable to assume that a similar pattern of varying effects over time
would be observed.
The MIMIC-III and PICRAM database analysis
To the best of our knowledge, this is the first study to quantify the haemodynamic changes associated
with NOAF onset in ICU patients accounting for patients’ pre-AF parameters at scale. We found that
NOAF during an ICU admission is associated with a significant increase in heart rate and a significant
decrease in blood pressure, despite an increase in vasoactive medication doses. Organised atrial
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activity contributes to ventricular filling, cardiac output and the closure of the atrioventricular valves.6
New-onset atrial fibrillation precludes these mechanisms and the effects of the loss of atrial contraction
on ventricular filling may be compounded by the diastolic dysfunction commonly seen during critical
illness.111 These mechanisms may explain why NOAF is temporally associated with a reduction in cardiac
index in non-ICU patients with chronic heart failure.7 Our findings are consistent with one previous study
that found that haemodynamic instability developed in 37% of post-surgical ICU patients after NOAF.8
Atrial contractile dysfunction occurs after brief episodes of AF112 and can last for several weeks after
achieving rhythm control.113 Any AF may, therefore, have considerable impact in any critically ill patient
with minimal physiological reserve. Indeed, episodes of NOAF lasting for ≥ 30 minutes in the ICU
are independently associated with increased hospital mortality.11 We found that NOAF is associated
with hospital mortality after adjustment for confounding variables, regardless of whether NOAF is
diagnosed based on continuous monitoring (ICU databases analysis) or from hospital diagnosis
codes (RISK-II database analysis). In both cases, some, but not all, of this association is explained by
confounding variables. The associated mortality risk was higher in our RISK-II analysis than in our
in-ICU analysis. This may be explained by the differing definitions, with NOAF in the RISK-II data
probably representing AF significant enough to result in a HES code versus any AF in the in-ICU data.
Together, our findings highlight the importance of optimal treatment and follow-up of patients who
develop NOAF during an ICU stay. We found that the use of digoxin is associated with lower rates of
achieving heart rate control than the use of amiodarone. Digoxin may be selected to reduce heart
rates without inducing hypotension; however, digoxin may be less effective during states of increased
sympathetic drive,114 including critical illness. One small study of patients in the ICU with AF with rapid
ventricular response (not exclusive to NOAF) demonstrated that digoxin was less effective at rate
control in patients receiving catecholaminergic medication.115
We found that the use of calcium channel blockers was associated with lower rates of achieving
rhythm control than amiodarone. These findings are supported by a small, randomised study of
paroxysmal AF outside the ICU,116 which reported a cardioversion proportion of 0% in patients who
received verapamil compared with 77% in patients who received amiodarone. Our findings contrast
with one RCT identified in our scoping review, which compared amiodarone with calcium channel
blockers31 and found no difference in achieving rhythm control. However, this study included only
20 patients per treatment group, making it difficult to draw any conclusions. We did not identify
any significant difference in hospital survival between any of the treatments when compared
with amiodarone.
In the MIMIC-III database, the unadjusted analysis demonstrated an apparent mortality benefit in the
beta-blocker treatment group. However, patients in the beta-blocker group were younger and less
unwell at presentation than those in the amiodarone group. After developing NOAF, patients in the
beta-blocker group had higher blood pressures, were less likely to be on vasoactive medications and
had lower inflammatory markers. After our comprehensive adjustment, the difference in mortality was
no longer evident. Our adjusted results conflict with one large study,28 which suggested a survival
benefit with beta-blockers over amiodarone therapy in patients with sepsis. However, this study was
unable to adjust for features around NOAF onset. Our study demonstrates that important differences
exist between treatment groups after the onset of AF, which may influence treatment choice. Failure
to adjust for these factors is likely to result in residual confounding.
Strengths and limitations
The scoping review was performed using systematic, transparent and robust methods. The bibliographic
database searches were comprehensive, which allowed maximal identification of relevant studies while
also minimising the possibility of publication or language biases affecting the review. We carried out the
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screening and data extraction processes in duplicate to reduce the risk of reviewer errors or biases
affecting the review. The main limitation of the scoping review was the methodological shortcomings of
the studies identified.
Our RISK-II database analysis allowed us to include > 4000 patients who developed NOAF and 27,000
matched comparators from ICUs across England, with long-term follow-up using routinely collected
data. However, the analysis is limited by the sensitivity of diagnostic records. Along with the limitations
in defining patients with NOAF, some outcomes also need careful interpretation. For example,
‘hospitalisation with stroke’ may miss both extremes of severity, in which mild strokes and transient
ischaemic events may not result in hospital admission and catastrophic strokes may result in death
without admission.
Our analysis of two within-ICU databases has several strengths. First, we carried out comprehensive
adjustment that included variables around the onset of AF. We show significant differences in these
peri-AF variables that have not been adjusted for in previous studies. Second, our analysis of granular
health-care data allowed a detailed analysis of the haemodynamic changes associated with NOAF.
Third, our analysis of routinely collected data over many years provided a sample size large enough to
demonstrate differential efficacy in NOAF treatments. This analysis also has limitations. The study was
retrospective in nature and the development of NOAF was not independently verified. Documentation
of AF in the MIMIC-III database has, however, been shown to be accurate for determining AF onset to
within 1 hour after independent review of a sample of electrocardiographic waveforms.89 Documentation
of comorbidities in the MIMIC-III database relied on hospital billing codes, which may not have identified
all cases. Furthermore, although good balance of numerous confounding covariates was achieved prior
to assessing treatment efficacy, we are unable to exclude bias introduced by residual unmeasured
confounding. Unmeasured variables, such as echocardiographic parameters, may have contributed to the
association between NOAF in ICU and outcome, and would not be represented in the propensity weights.
Finally, we acknowledge the difference in case mixes between UK and USA data. Overall, patients in the
MIMIC-III database were younger and had lower mortality than those in the PICRAM database, which
may explain part of the difference in NOAF incidence. Identifying patients who developed NOAF reduced
these differences by identifying sufficiently unwell patients in both databases. Owing to the underlying
differences, we primarily analysed each database in isolation, using the combined analysis to support
these primary findings.
Uncertainties
Either amiodarone or beta-blockers are commonly used in critically ill patients to control AF, but there
is little evidence to support whether or not one is superior. Purported beneficial effects of beta-blocker
therapy may be because of residual confounding in some studies.
In patients who develop NOAF while in an ICU, it is not clear in whom anticoagulation following
hospital discharge might be beneficial.
The incidence of AF and/or left ventricular dysfunction at hospital discharge and at 3 months following
the development of NOAF while in an ICU is unknown. However, readmission with heart failure and
thromboembolism is increased over the 5 years following an episode of NOAF while in an ICU,
particularly in the first year.
It remains unclear to what extent NOAF in patients in an ICU is causally related to worse outcomes.
Evidence for causality may be supported by future randomised prevention trials, in which a reduction
in AF burden is associated with better outcomes, or through the application of robust causal inference
methods in observational studies.
DOI: 10.3310/hta25710 Health Technology Assessment 2021 Vol. 25 No. 71
Copyright © 2021 Bedford et al. This work was produced by Bedford et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.




Implications for service provision
There are insufficient data available to make firm recommendations for service provision in the
management of NOAF identified during an ICU admission.
Suggested research priorities
Research priorities were suggested by the expert panel following data review (following the National
Institute for Health and Care Excellence Research Recommendations Process and Methods Guide;98
see Appendix 8). NOAF during an ICU stay is associated with substantially increased mortality, after
correction for associated risk factors. Both amiodarone and beta-blockers are commonly used, but
have significant side effects. Whether or not one is superior to the other has not been demonstrated.
A RCT of amiodarone compared with beta-blockers for the management of NOAF in critically ill patients
should be undertaken (see Appendix 8, Table 36).
The evidence for or against anticoagulation for patients who develop NOAF in an ICU is very scarce.
The risk of thromboembolism is increased in those who develop NOAF compared with those who do
not develop NOAF, even when corrected for known risk factors. However, current risk stratification
tools have not been validated in the ‘NOAF during ICU population’ and do not take into account
whether or not ICU treatments may affect future outcome. Whether or not there are subgroups of
patients who develop NOAF while in an ICU who may benefit from long-term anticoagulation is
unknown. Studies should be undertaken to create risk stratification tools or to investigate whether or
not current tools are applicable to the ‘NOAF during ICU population’ to identify patients sufficiently at
risk of future thromboembolism to merit consideration of anticoagulation (see Appendix 8, Table 37).
Readmissions with heart failure and thromboembolism increase over the 5 years following an episode
of NOAF while in an ICU, particularly in the first year. Whether these events are driven by persistent
left ventricular dysfunction and/or AF is unknown. A prospective cohort study to demonstrate the
incidence of AF and/or left ventricular dysfunction at hospital discharge and at 3 months following
development of NOAF should be undertaken (see Appendix 8, Table 38).
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Appendix 1 Search strategy
MEDLINE (via Ovid)
Date range searched: 1946 to present.






4. (“atrial fibrillation*” or AF).ab,ti.
5. “atrial flutter* “.ab,ti.
6. “atrial arrhythmia* “.ab,ti.
7. (“supraventricular tachycardia*” or SVT).ab,ti.
8. “NOAF*”.ab,ti.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8





15. “critical care unit* “.ab,ti.
16. “intensive therapy unit* “.ab,ti.
17. “high dependenc* “.ab,ti.
18. (ICU* or ITU* or HDU* or CCU*).ab,ti.
19. “critically unwell”.ab,ti.
20. “critically ill”.ab,ti.
21. (sepsis or “septic shock”).ab,ti.
22. 10 or 11 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
23. 9 and 22
24. limit 23 to animals
25. limit 23 to (“newborn infant (birth to 1 month)” or “infant (1 to 23 months)” or “preschool child
(2 to 5 years)” or “child (6 to 12 years)”)
26. “case report* “.ti.
27. 24 or 25 or 26
28. 23 not 27
29. “atrial fibrillation* “.ab,ti.
30. (cardiac or cardiothoracic or “cardio thoracic” or cardiopulmonary or “cardio pulmonary”).ab,ti.
31. “surg*”.ab,ti.
32. “coronary care unit* “.ab,ti.
33. 29 and 30 and 31
34. 29 and 32
35. 33 or 34
36. 28 not 35.
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EMBASE (via Ovid)
Date range searched: inception to 4 March 2019.






4. (“atrial fibrillation*” or AF).ab,ti.
5. “atrial flutter* “.ab,ti.
6. “atrial arrhythmia* “.ab,ti.
7. (“supraventricular tachycardia*” or SVT).ab,ti.
8. “NOAF*”.ab,ti.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8





15. “critical care unit* “.ab,ti.
16. “intensive therapy unit* “.ab,ti.
17. “high dependenc* “.ab,ti.
18. (ICU* or ITU* or HDU* or CCU*).ab,ti.
19. “critically unwell”.ab,ti.
20. “critically ill”.ab,ti.
21. (sepsis or “septic shock”).ab,ti.
22. 10 or 11 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
23. 9 and 22
24. limit 23 to animal studies
25. limit 23 to (infant <to one year> or preschool child <1 to 6 years> or school child <7 to
12 years>)
26. “case report* “.ti.
27. 24 or 25 or 26
28. 23 not 27
29. “atrial fibrillation* “.ab,ti.
30. (cardiac or cardiothoracic or “cardio thoracic” or cardiopulmonary or “cardio pulmonary”).ab,ti.
31. “surg*”.ab,ti.
32. “coronary care unit* “.ab,ti.
33. 29 and 30 and 31
34. 29 and 32
35. 33 or 34
36. 28 not 35
37. limit 36 to conference abstracts
38. 36 not 37.
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Cumulative Index to Nursing and Allied Health Literature
Date range searched: inception to 11 March 2019.
Date searched: 11 March 2019.
Records retrieved: 441.
Search strategy
1. ATRIAL FIBRILLATION/ (20,100)
2. ATRIAL FLUTTER/ (1521)
3. TACHYCARDIA, SUPRAVENTRICULAR/ (2593)
4. (“atrial fibrillation*” OR AF).ti,ab (24,117)
5. (“atrial flutter*”).ti,ab (1541)
6. (“atrial arrhythmia*”).ti,ab (867)
7. (“supraventricular tachycardia*” OR SVT).ti,ab (1683)
8. (NOAF*).ti,ab (9)
9. (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8) (32,813)
10. INTENSIVE CARE UNITS/ (32,253)
11. CRITICAL CARE/ (19,423)
12. SHOCK, SEPTIC/ (4198)
13. (“intensive care”).ti,ab (50,295)
14. (“critical care unit*”).ti,ab (1967)
15. (“intensive therapy unit*”).ti,ab (254)
16. (“high dependenc*”).ti,ab (627)
17. (ICU* OR ITU* OR HDU* OR CCU*).ti,ab (24,659)
18. (“critically unwell”).ti,ab (17)
19. (“critically ill”).ti,ab (17,286)
20. (10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19) (92,933)
21. (9 AND 20) (480)
22. (“atrial fibrillation*”).ti,ab (21,936)
23. (cardiac OR cardiothoracic OR “cardio thoracic” OR cardiopulmonary OR “cardio pulmonary”).ti,ab
(114,324)
24. (surg*).ti,ab (319,271)
25. (“coronary care unit*”).ti,ab (859)
26. (“case report*”).ti (44,822)
27. (22 AND 23 AND 24) (894)
28. (22 AND 25) (20)
29. (26 OR 27 OR 28) (45,731)
30. 21 NOT 29 (361)
31. 30 [Human age groups Infant∼Newborn: birth-1 month OR Infant: 1-23 months OR
Child∼Preschool: 2-5 years OR Child: 6-12 years] (37)
32. ANIMAL STUDIES/ (98,956)
33. (30 AND 32) (1)
34. (31 OR 33) (38)
35. 30 NOT 34 (323).
DOI: 10.3310/hta25710 Health Technology Assessment 2021 Vol. 25 No. 71
Copyright © 2021 Bedford et al. This work was produced by Bedford et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
87
Web of Science
Includes Conference Proceedings Citation Index –Science, Science Citation Index Expanded, Social
Sciences Citation Index, Arts & Humanities Citation Index, Conference Proceedings Citation Index-
Science, Conference Proceedings Citation Index- Social Science & Humanities, The Book Citation
Index-Science, The Book Citation Index – Social Science & Humanities, Emerging Sources Citation Index,
Current chemical reactions-expanded and Index Chemicus.
Date ranged searched: 1949 to 2019.
Date searched: 6 March 2019.
Records retrieved: 1772.
Records retrieved after filtering by title: 137.
Search strategy
“TOPIC: (atrial AND fibrillat*).
Refined by: TOPIC: ((intensive OR critical) AND (care OR therapy)).
Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC”.
Cochrane Library
Includes Cochrane Reviews, Cochrane Protocols and Trials.
Date range searched: inception to 11 March 2019.
Date searched: 11 March 2019.
Records retrieved in Cochrane Reviews: 0.
Records retrieved in Cochrane Protocols: 0.
Records retrieved in Trials: 96.
Search strategy
“atrial fibrillation” AND (“intensive care” OR “critical care” OR “intensive therapy”).
Database of Abstracts of Reviews of Effects
Date range searched: inception to 11 March 2019.
Date searched: 11 March 2019.
Records retrieved: 4.
Search strategy
(“atrial fibrillation” AND (“critical care” OR “intensive care”).
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OpenGrey
Date range searched: inception to 11 March 2019.
Date searched: 11 March 2019.
Records retrieved: 2.
Search strategy
“Atrial fibrillation” AND (“Intensive Care” OR “Critical Care” OR “Intensive Therapy”).
Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov
URL: https://clinicaltrials.gov/.
Date range searched: inception to 11 March 2019.
Date searched: 11 March 2019.
Records retrieved: 264.
Search strategy
“Atrial fibrillation” in CONDITION field OR “Atrial flutter” in OTHER TERMS field.
International Standard Randomised Controlled Trial Number
Date range searched: inception to 11 March 2019.
Date searched: 11 March 2019.
Records retrieved: 292.
Search strategy
ATRIAL FIBRILLATION” in TEXT field.
EU clinical trials register
Date range searched: inception to 11 March 2019.
Date searched: 11 March 2019.
Records retrieved: 12.
Search strategy
“atrial fibrillation” AND (“critical care” OR “intensive care” OR “intensive therapy”).
World Health Organization International Clinical Trials Registry Platform
Date range searched: inception to 11 March 2019.
Date searched: 11 March 2019.
Records retrieved: 12.
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Search strategy
“atrial fibrillation” AND (“critical care” OR “intensive care” OR “intensive therapy”).
National Institute for Health Research UK Clinical Trials Gateway
Date range searched: inception to 11 March 2019.
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Appendix 2 Risk-of-bias assessment
Reproduced with permission from Sterne et al.
25 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits others
to copy and distribute this work, for non-commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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Revised Cochrane risk-of-bias tool for randomized trials (RoB 2)
TEMPLATE FOR COMPLETION
Edited by Julian PT Higgins, Jelena Savović, Matthew J Page, Jonathan AC Sterne
on behalf of the RoB2 Development Group
Version of 22 August 2019
The development of the RoB 2 tool was supported by the MRC Network of Hubs for Trials Methodology Research (MR/L004933/2- N61), with the support of the host MRC 
ConDuCT-II Hub (Collaboration and innovation for Difficult and Complex randomised controlled Trials In Invasive procedures - MR/K025643/1), by MRC research grant 
MR/M025209/1, and by a grant from The Cochrane Collaboration.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Study details 
Reference
Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, et al. Amiodarone versus diltiazem for rate control in
critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149-53. http://dx.doi.org/10.1097/00003246-200106000-00011 
Study design
X Individually-randomized parallel-group trial 
Cluster-randomized parallel-group trial 
Individually randomized cross-over (or other matched) trial 






































Experimental: Amiodarone Comparator: Diltiazem 
 
Specify which outcome is being assessed for risk of bias Rate control 
 
Specify the numerical result being assessed. In case of multiple alternative analyses 
being presented, specify the numeric result (e.g. RR = 1.52 (95% CI 0.83 to 2.77) 




Is the review team’s aim for this result…? 
X to assess the effect of assignment to intervention (the ‘intention-to-treat’ effect) 
 to assess the effect of adhering to intervention (the ‘per-protocol’ effect) 
 
If the aim is to assess the effect of adhering to intervention, select the deviations from intended intervention that should be addressed (at least one must be checked):  
 occurrence of non-protocol interventions 
 failures in implementing the intervention that could have affected the outcome 
 non-adherence to their assigned intervention by trial participants 
 
Which of the following sources were obtained to help inform the risk-of-bias assessment? (tick as many as apply) 
X Journal article(s) with results of the trial 
 Trial protocol 
 Statistical analysis plan (SAP) 
 Non-commercial trial registry record (e.g. ClinicalTrials.gov record) 
 Company-owned trial registry record (e.g. GSK Clinical Study Register record) 
  “Grey literature” (e.g. unpublished thesis) 
 Conference abstract(s) about the trial 
 Regulatory document (e.g. Clinical Study Report, Drug Approval Package) 
 Research ethics application 
 Grant database summary (e.g. NIH RePORTER or Research Councils UK Gateway to Research) 
 Personal communication with trialist 

















































































Risk of bias assessment  
Responses underlined in green are potential markers for low risk of bias, and responses in red are potential markers for a risk of bias. Where questions relate only to sign 
posts to other questions, no formatting is used. 
 
Domain 1: Risk of bias arising from the randomization process  
  
Signalling questions Comments Response options 
1.1 Was the allocation sequence random? Patients were "randomly assigned" to treatments NI 
1.2 Was the allocation sequence concealed until 
participants were enrolled and assigned to 
interventions? 
NI 
1.3 Did baseline differences between 
intervention groups suggest a problem with the 
randomization process?  
Important baseline differences in sex and age (though could also be due to the play of 
chance). 
PY  
Risk-of-bias judgement  High  
Optional: What is the predicted direction of bias 
arising from the randomization process? 
 NA / Favours experimental / Favours 
comparator / Towards null /Away 






































Domain 2: Risk of bias due to deviations from the intended interventions (effect of assignment to 
intervention) 
  
Signalling questions Comments Response options 
2.1. Were participants aware of their assigned 
intervention during the trial? 
Participants in intensive care. No blinding of interventions given. PN  
2.2. Were carers and people delivering the 
interventions aware of participants' assigned 
intervention during the trial? 
Y  
2.3. If Y/PY/NI to 2.1 or 2.2: Were there 
deviations from the intended intervention that 
arose because of the trial context? 
 NI 
2.4 If Y/PY to 2.3: Were these deviations likely 
to have affected the outcome? 
 NA  
2.5. If Y/PY/NI to 2.4: Were these deviations 
from intended intervention balanced between 
groups? 
 NA  
2.6 Was an appropriate analysis used to 
estimate the effect of assignment to 
intervention? 
Full ITT analysis Y  
2.7 If N/PN/NI to 2.6: Was there potential for a 
substantial impact (on the result) of the failure 
to analyse participants in the group to which 
they were randomized? 
 NA  
Risk-of-bias judgement  Some concerns 
Optional: What is the predicted direction of bias 
due to deviations from intended interventions? 
 NA / Favours experimental / 
Favours comparator / Towards 
















































































Domain 2: Risk of bias due to deviations from the intended interventions (effect of adhering to 
intervention) 
  
Signalling questions Comments Response options 
2.1. Were participants aware of their assigned 
intervention during the trial? 
 Y / PY / PN / N / NI 
2.2. Were carers and people delivering the 
interventions aware of participants' assigned 
intervention during the trial? 
Y / PY / PN / N / NI 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: 
Were important non-protocol interventions 
balanced across intervention groups? 
 NA / Y / PY / PN / N / NI 
2.4. [If applicable:] Were there failures in 
implementing the intervention that could have 
affected the outcome? 
 NA / Y / PY / PN / N / NI 
2.5. [If applicable:] Was there non-adherence 
to the assigned intervention regimen that could 
have affected participants’ outcomes? 
 NA / Y / PY / PN / N / NI 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: 
Was an appropriate analysis used to estimate 
the effect of adhering to the intervention? 
 NA / Y / PY / PN / N / NI 
Risk-of-bias judgement  Low / High / Some concerns 
Optional: What is the predicted direction of bias 
due to deviations from intended interventions? 
 NA / Favours experimental / 
Favours comparator / Towards 







































Domain 3: Missing outcome data 
 
  
Signalling questions Comments Response options 
3.1 Were data for this outcome available for 
all, or nearly all, participants randomized? 
  PY  
3.2 If N/PN/NI to 3.1: Is there evidence that the 
result was not biased by missing outcome 
data? 
 NA  
3.3 If N/PN to 3.2: Could missingness in the 
outcome depend on its true value? 
 NA  
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome depended on its 
true value? 
NA  
Risk-of-bias judgement  Low  
Optional: What is the predicted direction of bias 
due to missing outcome data? 
 NA / Favours experimental / 
Favours comparator / Towards 
















































































Domain 4: Risk of bias in measurement of the outcome 
 
  
Signalling questions Comments Response options 
4.1 Was the method of measuring the outcome 
inappropriate? 
 N  
4.2 Could measurement or ascertainment of 
the outcome have differed between 
intervention groups? 
 PN  
4.3 If N/PN/NI to 4.1 and 4.2: Were outcome 
assessors aware of the intervention received by 
study participants? 
 PY  
4.4 If Y/PY/NI to 4.3: Could assessment of the 
outcome have been influenced by knowledge of 
intervention received? 
Sustained rate reduction of 30% is an objective outcome PN  
4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was influenced by 
knowledge of intervention received? 
NA  
Risk-of-bias judgement  Low  
Optional: What is the predicted direction of bias 
in measurement of the outcome? 
 NA / Favours experimental / 
Favours comparator / Towards 







































Domain 5: Risk of bias in selection of the reported result  
 
  
Signalling questions Comments Response options 
5.1 Were the data that produced this result 
analysed in accordance with a pre-specified 
analysis plan that was finalized before 
unblinded outcome data were available for 
analysis? 
 NI 
Is the numerical result being assessed likely to 
have been selected, on the basis of the results, 
from... 
  
5.2. ... multiple eligible outcome 
measurements (e.g. scales, definitions, time 
points) within the outcome domain? 
 NI 
5.3 ... multiple eligible analyses of the data?  NI 
Risk-of-bias judgement  Some concerns 
Optional: What is the predicted direction of bias 
due to selection of the reported result? 
 NA / Favours experimental / 
Favours comparator / Towards 






















































































Risk-of-bias judgement  High  
Optional: What is the overall predicted direction 
of bias for this outcome? 
 NA / Favours experimental / 
Favours comparator / 
Towards null /Away from 









































Balser JR, Martinez EA, Winters BD, Perdue PW, Clarke AW, Huang W, et al. Beta-adrenergic blockade accelerates conversion of postoperative 
supraventricular tachyarrhythmias. Anesthesiology 1998;89:1052-9. http://dx.doi.org/10.1097/00000542-199811000-00004  
 
Study design 
X Individually-randomized parallel-group trial 
 Cluster-randomized parallel-group trial 
 Individually randomized cross-over (or other matched) trial 
 
For the purposes of this assessment, the interventions being compared are defined as 
Experimental: Diltiazem Comparator: Esmolol 
 
Specify which outcome is being assessed for risk of bias Rhythm control 
 
Specify the numerical result being assessed. In case of multiple alternative analyses 
being presented, specify the numeric result (e.g. RR = 1.52 (95% CI 0.83 to 2.77) 
and/or a reference (e.g. to a table, figure or paragraph) that uniquely defines the result 
being assessed. 
2hr conversion subgroup of AFib patients 
 
Is the review team’s aim for this result…? 
X to assess the effect of assignment to intervention (the ‘intention-to-treat’ effect) 
 to assess the effect of adhering to intervention (the ‘per-protocol’ effect) 
 
If the aim is to assess the effect of adhering to intervention, select the deviations from intended intervention that should be addressed (at least one must be checked):  
 occurrence of non-protocol interventions 
 failures in implementing the intervention that could have affected the outcome 
 non-adherence to their assigned intervention by trial participants 
 
Which of the following sources were obtained to help inform the risk-of-bias assessment? (tick as many as apply) 
X Journal article(s) with results of the trial 
















































































 Statistical analysis plan (SAP) 
 Non-commercial trial registry record (e.g. ClinicalTrials.gov record) 
 Company-owned trial registry record (e.g. GSK Clinical Study Register record) 
  “Grey literature” (e.g. unpublished thesis) 
 Conference abstract(s) about the trial 
 Regulatory document (e.g. Clinical Study Report, Drug Approval Package) 
 Research ethics application 
 Grant database summary (e.g. NIH RePORTER or Research Councils UK Gateway to Research) 
 Personal communication with trialist 









































Risk of bias assessment  
Responses underlined in green are potential markers for low risk of bias, and responses in red are potential markers for a risk of bias. Where questions relate only to sign 
posts to other questions, no formatting is used. 
Domain 1: Risk of bias arising from the randomization process  
  
Signalling questions Comments Response options 
1.1 Was the allocation sequence random? Patients "were randomized" NI 
1.2 Was the allocation sequence concealed until 
participants were enrolled and assigned to 
interventions? 
NI 
1.3 Did baseline differences between 
intervention groups suggest a problem with the 
randomization process?  
 PN  
Risk-of-bias judgement  Some concerns 
Optional: What is the predicted direction of bias 
arising from the randomization process? 
 NA / Favours experimental / Favours 
comparator / Towards null /Away 
















































































Domain 2: Risk of bias due to deviations from the intended interventions (effect of assignment to 
intervention) 
  
Signalling questions Comments Response options 
2.1. Were participants aware of their assigned 
intervention during the trial? 
Patients were in an ICU. Abstract says study was "unblinded" PN  
2.2. Were carers and people delivering the 
interventions aware of participants' assigned 
intervention during the trial? 
Y  
2.3. If Y/PY/NI to 2.1 or 2.2: Were there 
deviations from the intended intervention that 
arose because of the trial context? 
Similar proportions of post-randomisation use of digoxin but no reporting on the use of 
"DC cardioversion implemented at the discretion of physician staff" 
NI 
2.4 If Y/PY to 2.3: Were these deviations likely 
to have affected the outcome? 
 NA  
2.5. If Y/PY/NI to 2.4: Were these deviations 
from intended intervention balanced between 
groups? 
 NA  
2.6 Was an appropriate analysis used to 
estimate the effect of assignment to 
intervention? 
 Y  
2.7 If N/PN/NI to 2.6: Was there potential for a 
substantial impact (on the result) of the failure 
to analyse participants in the group to which 
they were randomized? 
 NA  
Risk-of-bias judgement  Some concerns 
Optional: What is the predicted direction of bias 
due to deviations from intended interventions? 
 NA / Favours experimental / 
Favours comparator / Towards 








































Domain 2: Risk of bias due to deviations from the intended interventions (effect of adhering to 
intervention) 
  
Signalling questions Comments Response options 
2.1. Were participants aware of their assigned 
intervention during the trial? 
 Y / PY / PN / N / NI 
2.2. Were carers and people delivering the 
interventions aware of participants' assigned 
intervention during the trial? 
Y / PY / PN / N / NI 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: 
Were important non-protocol interventions 
balanced across intervention groups? 
 NA / Y / PY / PN / N / NI 
2.4. [If applicable:] Were there failures in 
implementing the intervention that could have 
affected the outcome? 
 NA / Y / PY / PN / N / NI 
2.5. [If applicable:] Was there non-adherence 
to the assigned intervention regimen that could 
have affected participants’ outcomes? 
 NA / Y / PY / PN / N / NI 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: 
Was an appropriate analysis used to estimate 
the effect of adhering to the intervention? 
 NA / Y / PY / PN / N / NI 
Risk-of-bias judgement  Low / High / Some concerns 
Optional: What is the predicted direction of bias 
due to deviations from intended interventions? 
 NA / Favours experimental / 
Favours comparator / Towards 

















































































Domain 3: Missing outcome data 
 
  
Signalling questions Comments Response options 
3.1 Were data for this outcome available for 
all, or nearly all, participants randomized? 
  Data for all 44 patients with atrial fibrillation were reported Y  
3.2 If N/PN/NI to 3.1: Is there evidence that the 
result was not biased by missing outcome 
data? 
 NA  
3.3 If N/PN to 3.2: Could missingness in the 
outcome depend on its true value? 
 NA  
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome depended on its 
true value? 
NA  
Risk-of-bias judgement  Low  
Optional: What is the predicted direction of bias 
due to missing outcome data? 
 NA / Favours experimental / 
Favours comparator / Towards 








































Domain 4: Risk of bias in measurement of the outcome 
 
  
Signalling questions Comments Response options 
4.1 Was the method of measuring the outcome 
inappropriate? 
 N  
4.2 Could measurement or ascertainment of 
the outcome have differed between 
intervention groups? 
 N  
4.3 If N/PN/NI to 4.1 and 4.2: Were outcome 
assessors aware of the intervention received by 
study participants? 
Electrocardiograms and rhythm strips reviewed by a cardiologist who was blinded to 
treatment 
N  
4.4 If Y/PY/NI to 4.3: Could assessment of the 
outcome have been influenced by knowledge of 
intervention received? 
 NA  
4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was influenced by 
knowledge of intervention received? 
NA  
Risk-of-bias judgement  Low  
Optional: What is the predicted direction of bias 
in measurement of the outcome? 
 NA / Favours experimental / 
Favours comparator / Towards 

















































































Domain 5: Risk of bias in selection of the reported result  
 
  
Signalling questions Comments Response options 
5.1 Were the data that produced this result 
analysed in accordance with a pre-specified 
analysis plan that was finalized before 
unblinded outcome data were available for 
analysis? 
 NI 
Is the numerical result being assessed likely to 
have been selected, on the basis of the results, 
from... 
  
5.2. ... multiple eligible outcome 
measurements (e.g. scales, definitions, time 
points) within the outcome domain? 
Likely that there is only one way in which the outcome can be measured PN  
5.3 ... multiple eligible analyses of the data? Outcome likely to be analysable in only one way PN  
Risk-of-bias judgement  Some concerns 
Optional: What is the predicted direction of bias 
due to selection of the reported result? 
 NA / Favours experimental / 
Favours comparator / Towards 
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Risk-of-bias judgement  Some concerns 
Optional: What is the overall predicted direction 
of bias for this outcome? 
 NA / Favours experimental / 
Favours comparator / 
Towards null /Away from 

















































































Appendix 3 Data extraction tables for
single-group studies
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TABLE 15 Methods and characteristics of prospective single-group studies
Study details Population characteristics Intervention
First author and year: Delle Karth
200547
Setting: cardiologic ICU
Note: medical patients included in
the study
Country: Austria
Sample size: n= 17 (data extracted
for medical patients only; the study
also includes cardiac-surgical
patients)
NOAF patients: n = 15 (88.2%)
Primary diagnosis: perspiratory failure (17.6%), heart failure (35%),
sepsis (17.6%) and cardiopulmonary resuscitation (11.7%)
Median (range) age reported: 63 (56.5–73) years
Male: n = 11 (64.7%)
Severity of illness: median (range) SAPS II reported 53 (44.5–63)
Patients on vasopressors: n = 15 (88.2%)
Patients with CVD: n = 6 (35%) (heart failure)
Patients with acute renal failure: n = 3 (17.6%)
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: n= 13 (76.5%)
Serum potassium: NR
Definition of NOAF: ‘recent-onset (< 1 hour) tachycardic (> 100 beats per
minute) sustained (> 10 minutes) atrial fibrillation’
Ibutilide: patients received up to two 10-minute i.v.
infusions of 1.0 mg of ibutilide, with an interval of
10 minutes. If AF did not terminate during or within
10 minutes after the end of the first infusion, the second
infusion was administered. If AF persisted at minute 60,
ibutilide treatment was considered unsuccessful and
further treatment (beyond minute 60) was started at the
discretion of the treating physician
Line of NOAF treatment: not specified
First author and year: Hennersdorf
200246
Setting: university hospital ICU
Country: Germany
Sample size: n= 26
NOAF patients: n = 7 (27%)
Primary diagnosis: hypertension (31%), hypertrophic obstructive
cardiomyopathy (8%), dilative cardiomyopathy (12%), cor pulmonale (15%),
coronary artery disease (19%), sepsis with cardiac involvement (15%) and
reduced left ventricular ejection fraction (15%)
Mean age: 68± 11 years
Male: n = 21 (80.7%)
Severity of illness: APACHE II score, median (range) 8 (5–24)
Ibutilide was administered as an infusion over a period of
10 minutes. The dose of ibutilide was 1 mg i.v.; in the case
of persisting arrhythmia and body weight of > 70 kg, a
second infusion of 1 mg of ibutilide was administered after
30 minutes. Before the ibutilide infusion was started, all
patients were given magnesium (1 g, i.v.) and potassium
(if the potassium serum level was < 4.5 mmol/l). Magnesium
and potassium were administered to prevent proarrhythmic
effects (torsade de pointes tachycardia)







































Study details Population characteristics Intervention
Note: results reported separately for
NOAF group
Patients on vasopressors: NR
Patients with CVD: hypertrophic obstructive cardiomyopathy (8%), dilative
cardiomyopathy (12%), cor pulmonale (15%), coronary artery disease (19%)
and reduced left ventricular ejection fraction (15%)
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: n= 19 (73%) (not specified if at
the onset)
Serum potassium: NR
Definition of NOAF: NR
Line of NOAF treatment: second line
All patients received amiodarone (150 mg, i.v.) as the
first-line drug. If patients failed to convert back to
sinus rhythm, ibutilide was given i.v. 2 hours after the
administration of amiodarone
First author and year: Mayr 200349
Setting: Surgical ICU
Country: Austria
Sample size: n= 37
NOAF patients: n = 31 (84%)
Surgery type: abdominal (35.1%), cardiac (35.1%), vascular (2.7%),
trauma (10.81%), orthopaedic (8.1%) and thoracic (5.4%)
Pneumonia after surgery: 2.7%
Median age (range): all patients, 72 years (34–94 years); primary responders,
67 years (34–82 years); non-responders, 73.5 years (51–94 years)
Male: all patients, n = 16/37 (43.2%); primary responders, n = 7/13 (53.8%);
non-responders, n = 9/24 (37.5%)
Severity of illness: median (range) SAPS reported – all patients, 13 (5–29);
primary responders, 14 (5–29); non-responders, 13 (9–26)
Patients on vasopressors: all patients, n = 29/37 (78.37%); primary responders,














































































































































































































































































































































































































TABLE 15 Methods and characteristics of prospective single-group studies (continued )





(N= 37), n (%)
Primary
responders
(N= 13), n (%)
Non-responders
(N= 24), n (%)
Coronary artery
disease
22 (59.45) 7 (53.8) 15 (62.5)
Heart failure 13 (35) 4 (30.76) 9 (37.5)
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium (mmol/l): all patients, 4.2 (IQR 3.5–5); primary responders,
4.2 (IQR 3.5–5); non-responders, 4.2 (IQR 3.6–4.7)
Definition of NOAF: ‘SVT were defined as narrow-complex, non-sinus
tachycardias with heart rate > 100 beats/min for at least 15 mins’
Electrical cardioversion: if required, patients were sedated
with etomidate. A maximum of four consecutive shocks
were administered. In patients not responding to electrical
cardioversion or in recurrent arrhythmia, i.v. anti-arrhythmic
therapy was started
Line of NOAF treatment: not specified
First author and year: Nakamura
201645
Setting: medical/surgical ICU for
in-hospital patients and emergency
ICU for emergency outpatients
Country: Japan
Sample size: n= 16
NOAF patients: 100%
Primary diagnosis: sepsis (50%) and heart failure (56.2%)
Mean age: 75.0 ± 13.1 years
Male: n = 7 (43.75%)
Severity of illness: mean APACHE II score reported, 24.3 ± 6.0; mean SOFA
score reported, 8.6± 3.1
Patients on vasopressors: in 62.5% of patients, noradrenaline had been given
with landiolol
Switching therapy from landiolol to a bisoprolol patch:
switching occurred where a continuous landiolol infusion
was used for AF-related tachycardia, and its administration
duration reached 6 days, or where long-term therapy was
expected before day 6. A 4mg/24 hour bisoprolol patch
was attached and the landiolol infusion was stopped after
6 hours. Median landiolol administration time before
bisoprolol patch use: 88.1 hours. Median landiolol dosage on
bisoprolol patch use: 3.1 µg/kg/minute. Median noradrenaline
dosage on bisoprolol patch use: 0.20 µg/kg/minute







































Study details Population characteristics Intervention
Patients with CVD: n = 9 (56.2%) (heart failure)
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium: NR
Definition of NOAF: NR










Severity of illness: NR
Patients on vasopressors: NR
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium: NR
Definition of NOAF: NR
For NOAF rate control and conversion: i.v. amiodarone
used in 74.5% of episodes
For stroke prophylaxis: i.v. heparin used in 36.4% of
episodes














































































































































































































































































































































































































TABLE 15 Methods and characteristics of prospective single-group studies (continued )
Study details Population characteristics Intervention
First author and year: Sleeswijk
200839
Setting: tertiary ICU, 12 bed
Country: the Netherlands
Sample size: n= 29
NOAF patients: 100%
Primary diagnosis: NR
Medical patients: magnesium responders, n= 11; magnesium non-responders,
n= 9
Surgery patients: magnesium responders, n = 5; magnesium non-responders,
n= 4
Mean age: magnesium responders, 64± 16 years; magnesium non-responders
69± 17 years
Male: n = 14 (48%) (magnesium responders, n = 7; magnesium non-responders,
n= 7)
Severity of illness: mean APACHE II score reported – all patients, 19 ± 7
(magnesium responders, 18 ± 7; magnesium non-responders, 21± 7)
Patients on vasopressors: n = 17 (59%) (all patients) (magnesium responders,
n= 8, 50%; magnesium non-responders, n = 9, 69%)
Patients with CVD: n = 14 (48%) (all patients) (magnesium responders, n = 5,
31%; magnesium non-responders, n= 9, 69%)
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium: NR
Definition of NOAF: ‘New-onset AF was defined as newly developed AF
during the ICU stay in patients without a previous history of atrial
tachyarrhythmias and anti-arrhythmic drug use. Diagnosis was confirmed
by a 12-lead electrocardiogram (ECG)’
Magnesium infusion: patients received MgSO4 bolus
followed by continuous infusion. The infusion rate was
reduced to half when plasma (Mg2+) was > 2.0 mmol/l and
stopped when plasma (Mg2+) was > 3.0 mmol/l. Where
sinus rhythm was achieved, the infusion was stopped at
the discretion of the treating clinician
Line of NOAF treatment: first line. Where no rhythm or
rate control (< 110 b.p.m.) was achieved after 1 hour of
starting the MgSO4 infusion, an infusion of amiodarone
(loading dose of 300 mg followed by an infusion of
1200mg/24 hours) was started. Where sinus rhythm was
achieved, the amiodarone infusion was stopped at the
discretion of the treating clinician
Line of NOAF treatment: second line
APACHE, Acute Physiology and Chronic Health Evaluation; CVD, cardiovascular disease; NR, not reported; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure







































TABLE 16 Results of prospective single-group studies
Study Results Adverse effects
Recommendations for/barriers
to the future research
Delle Karth
200547
l The authors reported that
82.4% of patients converted
back to sinus rhythm. The
median (range) ICU length
of stay was reported as
35 (13–44) days
l The mean time to termination
of the arrhythmia was
17.7 ± 12.5 minutes (range
4 to 45 minutes) after start
of the first infusion. The total
administered dose to those
who were successfully
converted with ibutilide
ranged from 0.5 mg to 2mg
(mean 1.20 ± 47mg)
l Sustained polymorphic
ventricular tachycardia
reported in one patient and
this required emergency
DCC. Repetitive ventricular
salvos was reported in
two patients and ibutilide
therapy had to be
discontinued. Increased
ventricular premature
complexes were reported in
12 patients but ibutilide
infusion did not have to be
stopped. One patient
experienced a ventricular
pause of 3 seconds before




l Conversion to sinus rhythm
was achieved in 71% (n= 5)
of patients with recent-onset




Torsade de pointes (n= 3/26,
11.5%)
NR
Mayr 200349 l A total of 13 patients
(35%, 95% CI 20% to 53%)
primarily responded to DCC
with restoration of sinus
rhythm, of whom eight
patients remained in sinus
rhythm (24%, 95% CI 12%
to 41%) at 1 hour. At 24
and 48 hours, six (16%,
95% CI 6% to 32%) and
five (13.5%, 95% CI 5% to
29%) patients remained in
sinus rhythm, respectively
l Eight patients converted
back to sinus rhythm in
response to the first DCC
shock and four patients to
the second DCC shock. One
out of 22 patients returned
to sinus rhythm after three
DCC shocks, whereas no
patient responded to a
fourth DCC shock
NR The optimal therapeutic
regimen for effective and rapid
termination of new-onset SVT
in surgical ICU patients still
remains to be established
Nakamura
201645
l Survival was achieved in
81.3% of the patients for
whom switching therapy was
administered. The authors
reported that three patients
(18.75%) died of primary
diseases after > 3 days from
switching therapy. In all
patients who survived,
bisoprolol patch therapy was
continued on the ward
l The authors reported that
there were no obvious
adverse events in any
patient and switching
therapy was successfully
completed in all the patients
It would be worth to conduct
the further study investigating
the efficacy of this switching
therapy in the future
continued
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TABLE 16 Results of prospective single-group studies (continued )
Study Results Adverse effects
Recommendations for/barriers
to the future research
Slavik 200340
(abstract)
l Authors reported that
optimal rate control and
conversion was achieved in
47% of NOAF episodes
l Authors reported that
optimal stroke prophylaxis
was achieved in 91% of
NOAF episodes
l Note: appropriateness of
therapy assessed as optimal,
appropriate and inappropriate;
however, definitions not
reported in the abstract
l i.v. amiodarone:
hypotension (35.6%)





l Seven patients converted to
sinus rhythm within 1 hour
after the start of the MgSO4
infusion, whereas nine
patients had a decrease
in ventricular rate of
< 110 b.p.m. All patients
achieved cardioversion after
the start of the MgSO4
infusion without any
additional therapy. Mean
(SD) and median (range)
time until conversion in the
magnesium responders was
7 (± 11) hours and 2 (1–45)
hours, respectively. The
addition of amiodarone
after 1 hour of the MgSO4
infusion was required for
13 patients (magnesium
non-responders). Of these
13 patients, 11 achieved
cardioversion within
24 hours. Mean (SD) and
median (range) conversion
time in magnesium non-
responders was 13 (± 21)
hours and 4 (2–78) hours,
respectively. The total mean
(SD) and median (range)
conversion time was 9.3
(± 16.3) hours and 3 (1–78)
hours, respectively. The
24-hour conversion rate in




l Authors reported that no
serious events that would
cause the discontinuation
of the treatment were
observed during the study
A randomized controlled trial
is needed to investigate
whether this strategy is
superior to other
treatment regimes
NR, not reported; SD, standard deviation; SVT, supraventricular tachycardia.
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TABLE 17 Methods and characteristics of retrospective single-group studies
Study details Population characteristics Intervention
First author and year: Burris 201044
Setting: surgical ICU
Country: USA
Sample size: n= 30
Note: data extracted only for
patients with atrial arrhythmias
(total study n = 120: this includes
controls that did not develop
arrhythmias)
NOAF patients: NR
Primary diagnosis: general surgery (60%), vascular surgery (33%),
orthopaedics (3.3%) and neurosurgery (3.3%)
Mean age: 66.2 ± 7.3 years
Male: NR
Severity of illness: NR
Patients on vasopressors: n = 14 (46.6%) (intraoperative)
Patients with CVD: coronary artery disease, 40%; chronic heart failure 16.7%
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium: 3.9± 66 mmol/l (preoperative)
Definition of NOAF: NR
Amiodarone (63%), metoprolol (26%), esmolol (13.3%),
diltiazem (6.7%), digoxin (3.3%), multiple drug regimens
(10%). Electrical cardioversion (only in combination with
pharmacological treatment), n= 4 (13.3%)
Line of NOAF treatment: not specified for each treatment
First author and year: Kanji 20128
Setting: three academic mixed
medical/surgical ICUs
Country: Canada
Sample size: n= 139
NOAF patients: 100%
Primary diagnosis: admission diagnosis reported – sepsis (18%), respiratory
failure/pneumonia (19%), cardiogenic shock/cardiac arrest (4%),
cerebrovascular accident (1%), rapid AF (4%), postoperative care (48%) and
other (6%)
Mean age: 71.6 ± 12.5 years
Male: n = 83 (60%)
Severity of illness: mean APACHE II score reported: 22.6 ± 9.0
Patients on vasopressors: NR
Patients with CVD: coronary artery disease (29%), valvular heart disease (1%),
congestive heart failure (6%) and cardiomyopathy (dilated, hypertrophic) (2%)
Rhythm control attempted (n = 105) by administering
i.v. amiodarone. Rate control attempted (n= 28) by
administering beta-blockers, calcium channel blockers or
digoxin, alone or in combination















































































































































































































































































































































































































TABLE 17 Methods and characteristics of retrospective single-group studies (continued )
Study details Population characteristics Intervention
Patients with acute renal failure: NR
Patients with acute respiratory failure: n = 27 (19%)
Mechanical ventilation at NOAF onset: NR
Serum potassium: < 3.5 mmol/l, n= 15 (11%)
Definition of NOAF: ‘Definition for NOAF cases reported as “defined as those
with no previous documented history of any atrial arrhythmia documented in
the physical or electronic medical record”’
First author and year: Kyo 201950
Setting: two mixed ICUs (emergency
and medicosurgical ICU)
Country: Japan














(N= 44), n (%)
Cardiovascular 33 (38) 14 (34) 19 (43)
Pulmonary 26 (31) 15 (37) 11 (25)
Gastrointestinal 10 (12) 4 (10) 6 (14)
Neurology 4 (5) 1 (2) 3 (7)
Trauma 3 (4) 3 (7) –
Skin and soft tissue 5 (6) 2 (5) 3 (7)
Other 4 (5) 2 (5) 2 (5)
Median age (range): all patients, 71 (64–78) years, successful electrical
cardioversion, 71 (64–79) years; unsuccessful electrical cardioversion,
71 (62–77) years
Male: all patients, n = 58 (68%) (successful electrical cardioversion,
n= 30,73%; unsuccessful electrical cardioversion, n = 28, 64%)
Electrical cardioversion: the 85 electrical cardioversion
sessions included 142 shocks, with a median of one
(IQR 1–2) shock per electrical cardioversion session. The
delivered electrical cardioversion energy was ≤ 100 J in 91%
of first shocks and 83% of second shocks in all patients







































Study details Population characteristics Intervention
Severity of illness: APACHE II score at ICU admission, median (range) –
all patients, 26 (17–34); successful electrical cardioversion, 26 (18–35);
unsuccessful electrical cardioversion, 26 (16–31)
SOFA score at the onset of AF, median (range): all patients 8 (5–11);













(N= 44), n (%)
Noradrenaline 24 (28) 12 (29) 12 (27)
Dopamine 21 (25) 10 (24) 11 (25)
Dobutamine 25 (29) 14 (34) 11 (25)
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: not specified whether at the time of
onset – all patients, n= 71 (84%); successful electrical cardioversion, n= 37
(90%); unsuccessful electrical cardioversion, n= 34 (77%)
Serum potassium (mmol/l), median (range): all patients, 4.0 (3.7–4.6);
successful electrical cardioversion, 4.2 (3.9–4.8); unsuccessful electrical
cardioversion, 3.9 (3.6–4.3)
Definition of NOAF: ‘New-onset AF was defined as the first AF rhythm on














































































































































































































































































































































































































TABLE 17 Methods and characteristics of retrospective single-group studies (continued )
Study details Population characteristics Intervention
First author and year: Liu 201641
Setting: medical ICU
Country: Taiwan (Province of China)










(N= 75), n (%)
Respiratory tract 112 (67.9) 48 (64)
Urinary tract 35 (21.2) 14 (18.7)
Gastrointestinal 9 (5.5) 5 (6.7)
Other 9 (5.5) 8 (10.7)
Mean age: NOAF to sinus rhythm, 77.8± 10.3 years; NOAF to AF,
76.2 ± 11.0 years
Male: NOAF to sinus rhythm, n= 90 (54.5%); NOAF to AF, n = 46 (61.3%)
Severity of illness: mean SOFA score reported – NOAF to sinus rhythm,
7.6± 3.0; NOAF to AF, 9.3 ± 3.2. Mean APACHE II score: NOAF to sinus
rhythm, 22.8± 5.8; NOAF to AF, 24.6± 6.1
Patients on vasopressors:
Vasopressor
NOAF to sinus rhythm
(N= 165), n (%)
NOAF to AF
(N= 75), n (%)
Dopamine 64 (38.8) 49 (65.3)







































Study details Population characteristics Intervention
Patients with CVD:
Cardiovascular disease
NOAF to sinus rhythm
(N= 165), n (%)
NOAF to AF
(N= 75), n (%)
Heart failure 35 (21.2) 15 (20)
Coronary artery disease 70 (42.4) 37 (49.3)
Patients with acute renal failure: NOAF to sinus rhythm, n= 65 (39.4%);
NOAF to AF, n = 39 (52.0%)
Patients with acute respiratory failure: NOAF to sinus rhythm n = 150
(90.9%); NOAF to AF, n = 71 (94.7%)
Mechanical ventilation at NOAF onset: NOAF to sinus rhythm, n = 143
(86.7%); NOAF to AF, n = 69 (92.0%)
Serum potassium (mmol/l): NOAF to AF, 4.2 ± 1.0; NOAF to sinus rhythm,
4.1± 0.9
Definition of NOAF: ‘The absence of P waves and irregular ventricular activity
lasting for more than 30 seconds’. NOAF to AF defined as ‘persistent or
recurrent AF 7 days after the onset of NOAF’
Amiodarone (n= 80, 33.3%), beta-blockers (n = 88, 36.7%),
non-dihydropyridine calcium channel blockers (n = 66,
27.5%), digoxin glycosides (n = 27, 11.3%), electrical
cardioversion (n = 8, 3.3%)
Line of NOAF treatment: not specified for each treatment
First author and year: Mayr 200443
Setting: 12-bed general and surgical
ICU in a university teaching hospital
Country: Austria
Sample size: n= 131
NOAF patients: 93%
Primary diagnosis: type of surgery
Type of surgery
All patients
(N= 131), n (%)
Responders
(N= 98), n (%)
Non-responders
(N= 33), n (%)
Cardiac 61 (46.56) 46 (46.9) 15 (45.45)
General 53 (40.45) 41 (41.8) 12 (36.36)
Vascular 7 (5.3) 5 (5.1) 2 (6.2)
Trauma 5 (3.8) 2 (2) 3 (9.1)
Orthopaedic 5 (3.8) 4 (4.1) 1 (3)
Amiodarone infusion: amiodarone was infused via
central venous catheter at 90 mg/hour for a maximum
of 12 hours, followed by a weaning regimen (initially
40–60mg/hour for a maximum of 3 days, then 20mg/hour
for another 5–7 days). Amiodarone was continued orally
(200mg TDS) in some patients. The amiodarone infusion
was stopped when the heart rate dropped below 60 b.p.m.















































































































































































































































































































































































































TABLE 17 Methods and characteristics of retrospective single-group studies (continued )
Study details Population characteristics Intervention
Sepsis: all patients, 23.9%; responders, 24%; non-responders, 23.6%
Mean age: all patients, 68± 12 years (responders, 68 ± 12 years;
non-responders, 67± 14 years)
Male: all patients, n = 82 (62.6%) (responders, n = 58, 59.2%; non-responders,
n= 24, 72.7%)
Severity of illness: mean MODS reported: all patients, 7.5 ± 3.4 (responders,
7.4± 3.4; non-responders, 7.9 ± 3.5)
Patients on vasopressors: NR
Patients with CVD: NR
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium: NR
Definition of NOAF: ‘New-onset supraventricular tachyarrhythmias were
defined as “narrow-complex non-sinus tachyarrhythmias with heart rates
≥ 100 bpm lasting for longer than 30 minutes”’
First author and year: Mitrić 201642
Setting: medical-surgical trauma ICU
Country: Australia
Sample size: n= 177 (no recurrence




Mean age, median (range): all patients, 69 (60–75) years [no recurrence of AF,
65 (57–75) years; recurrence of AF, 71 (61–76)]
Male: all patients, n = 113 (64%) (no recurrence of AF, n = 53, 61%; recurrence
of AF, n= 60, 66%)
Severity of illness, median (range): APACHE II score reported – all patients,
22 (17–28) [no recurrence of AF, 21 (17–26); recurrence of AF, 23 (17–29)].
SAPS II reported: all patients, 41 (31–53) [no recurrence of AF, 39 (30–49);
recurrence of AF, 44 (31–58)]. Charlson Comorbidity Index Score reported:
all patients, 2 (1–4) [no recurrence of AF, 2 (1–4); recurrence of AF, 3 (2–5)]
Amiodarone: a bolus dose was defined as a fixed dose of
> 150mg given over 20 minutes to an hour, a continuous
infusion was a fixed dose of amiodarone delivered hourly
by a syringe pump for > 2 hours and delay to an infusion
was a gap of 1 hour in the fluid administration record for







































Study details Population characteristics Intervention





(N= 177), n (%)
No recurrent AF
(N= 86), n (%)
Recurrent AF
(N= 91), n (%)
Myocardial infarction 43 (24) 17 (20) 26 (29)
Congestive cardiac
failure
22 (12) 6 (7) 16 (18)
Ischaemic heart
disease
58 (33) 23 (27) 35 (38)
Rheumatic heart
disease
2 (1) 2 (2) 0 (0)
Mitral valve disease 9 (5) 7 (8) 2 (2)
Patients with acute renal failure: NR
Patients with acute respiratory failure: NR
Mechanical ventilation at NOAF onset: NR
Serum potassium (mmol/l): reported as median (IQR) for the recurrent AF
group only
Parameter
On the day AF initially
reverted (n= 81)a On day AF recurred (n= 73)a
Kmin 4.2 (3.8–4.5) 4.2 (4.0–4.6)
Kmax 4.3 (4.1–4.7) 4.4 (4.1–4.7)
a Differing patient numbers owing to missing data.
Definition of NOAF: ‘a rhythm on the electrocardiogram (ECG) with
replacement of P waves with rapid oscillations or fibrillatory waves that vary
in size, shape and timing, associated with an irregular, frequently rapid,










No. of amiodarone boluses, n (%)
0 62 (35) 43 (42) 19 (25)
1 98 (55) 51 (50) 47 (61)
2 12 (7) 5 (5) 7 (9)
3 5 (3) 2 (2) 3 (4)
Amiodarone dosing, n (%)
Bolus only 23 (13) 3 (3) 20 (23)
Infusion only 62 (35) 43 (50) 19 (25)
Bolus and
infusion

















24 (16–40) 20 (12–28) 31 (20–58)
Line of NOAF treatment: first line
APACHE, Acute Physiology and Chronic Health Evaluation; CVD, cardiovascular disease; ECG, electrocardiography; MODS, Multiple Organ Dysfunction Score; NR, not reported;













































































































































































































































































































































































































TABLE 18 Results of retrospective single-group studies
Study Results Adverse effects
Recommendations for/barriers
to the future research
Burris 201044 l Authors reported that 33%
of patients treated with
amiodarone achieved successful
conversion to sinus rhythm
l In total, 10% of all patients did
not convert to sinus rhythm and
6.7% of those who converted
later reverted to arrhythmia
NR Randomized prospective studies
are required to determine the
success of alternative treatments
and should provide the evidence
needed to streamline management
of this problem
Kanji 20128 l Rhythm control alone was
attempted in 105 patients
(103 patients were administered
i.v. amiodarone and two patients
were administered sotalol).
Successful rhythm conversion
was achieved in 90 (87%)
patients at some time while
receiving amiodarone. In total,
38 (42%) out of 90 patients
reverted to AF during their ICU
stay after maintaining normal
sinus rhythm for at least
24 hours after cardioversion.
Authors reported that of the
patients with successful rhythm
conversion (n = 90), 51 (57%)
converted within 6 hours and
66 (73%) converted within
24 hours. Of the 74 patients in
this group who were discharged
from ICU, 13 (18%) left the
ICU in AF. Two patients treated
with sotalol converted to
sinus rhythm, but one patient
reverted to AF after being in
sinus rhythm for 24 hours. Both
patients (who received sotalol)
were discharged from the ICU
in normal sinus rhythm
l Twenty-eight (20%) patients were
treated with rate-controlling
agents alone (beta-blockers,
calcium channel blockers or
digoxin, alone or in combination).
Twenty-one (75%) patients
converted to sinus rhythm while
receiving rate-control therapy
alone, and five (19%) out of
27 ICU survivors were discharged
from the ICU in AF
NR In the general adult critically ill
population, more research is
required to determine (1) whether
or not attempting rhythm control
is more effective at restoring
sinus rhythm than attempting
rate control alone, (2) whether or
not attempting rhythm control
improves clinical outcomes,
and (3) what is the optimal
anticoagulation strategy in
patients who develop NOAF
Kyo 201950 l Electrical cardioversion was
successful in 41 (48%) patients.
Of these patients, 11 (13%)
maintained sinus rhythm until
ICU discharge and 30 (35%) had
recurrent AF. Among the 44
(52%) patients with unsuccessful
electrical cardioversion, seven
(8%) did not convert back to
sinus rhythm until after ICU
discharge, whereas 37 (44%)
converted to sinus rhythm
during their ICU stay
NR Further studies are needed to
investigate the potential factors
associated with the maintenance
of SR [sinus rhythm] to establish
a better understanding of new-
onset AF in critically ill patients
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TABLE 18 Results of retrospective single-group studies (continued )
Study Results Adverse effects
Recommendations for/barriers
to the future research
l Authors reported no difference
in median length of ICU stay
(days) between the patients
who had successful electrical
cardioversion and those who
had unsuccessful electrical
cardioversion [16 (11–17)
vs. 15 (7–23), respectively]
l No difference in the number
of ICU deaths was observed
between groups [n= 16 (39%)
in the successful electrical
cardioversion group vs. 14
(32%) in the unsuccessful
electrical cardioversion group]
l Similarly, no difference in
median length of hospital stay
(days) was found between the
patient groups [28 (16–62)
in the successful electrical
cardioversion group vs. 31
(19–60) in the unsuccessful
electrical cardioversion group]
l Authors also did not find
any difference in hospital
death between the patients
with successful electrical
cardioversion and the patients
with unsuccessful electrical
cardioversion [21 (51%)
vs. 17 (39%), respectively]
Liu 201641 l Fifty-two out of 80 patients
(65%) who received amiodarone
converted to sinus rhythm
l Sixty-seven out of 88 patients
(76.1%) who were treated with
beta-blockers converted back to
sinus rhythm
l Forty-seven out of 66 patients
(71.21%) who were treated with
non-dihydropyridine calcium
channel blockers converted to
sinus rhythm
l Fifteen out of 27 patients
(55.55%) treated with digoxin
glycosides converted back to
sinus rhythm
l Fifty per cent of patients who
were treated with electrical
cardioversion converted back to
sinus rhythm
NR A larger, prospective comparative
study is needed to elucidate the
clinical implications between a
rate control and a rhythm control
strategy in patients with sepsis
and NOAF
Mayr 200443 l Sinus rhythm was achieved in
54.2% of patients within the
first 12 hours, in 64% within
24 hours and in 74.8% within
48 hours. Heart rate decreased
significantly in all patients
(–37%) during the observation
period, but the decrease was
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TABLE 18 Results of retrospective single-group studies (continued )
Study Results Adverse effects
Recommendations for/barriers
to the future research
l The authors reported no
differences in the length of
surgical ICU stay between
responders and non-responders
(13 ± 10 days vs. 14 ± 11 days,
respectively). It was reported
that there was a trend of higher
surgical ICU mortality in non-
responders (39.4%) than in
responders (24.5%) (p = 0.1;
28.2% in all patients)
Mitrić 201642 l Eighty-six (49%) patients were
successfully treated with
amiodarone, without recurrence
of AF until discharge from ICU.
AF recurred in 91 patients
(51%) at least once during the
ICU stay, after initial successful
conversion to normal
sinus rhythm
l The median ICU length
of stay was reported as
7 (IQR 4–13) days in all
patients, 6 (IQR 3–12) days in
patients who had no recurrence
of AF and 8 (IQR 4–16) days in
patients who had recurrence
of AF
l The median hospital length
of stay was reported as
25 (IQR 13–58) days,
21 (IQR 12–46) days and
31 (IQR 18–70) days for all
patients, patients who had no
recurrence of AF and patients
who had recurrence of AF,
respectively
l In total, 23 (13%) patients
died in an ICU: 10 (12%)
who had no recurrence of AF
and 13 (14%) patients who did
l Forty-seven (17%) of all patients
died in the hospital: 22 (26%)
patients who had no recurrent
AF and 25 (27%) patients who
had recurrent AF
NR A clear dosing guide is not
available and further research
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Appendix 4 Excluded studies
TABLE 19 Excluded studies on full text with reason for exclusion
Study
Excluded based on
Population Study design Outcome Intervention
American Association of Critical Care Nurses (AACN).
Preventing new-onset atrial fibrillation in the ICU.
AACN Bold Voices 2018;10:20
✗
Agnihotri K, Patel P, Charilou P, Patel NJ, Badheka A,
Noseworthy P, et al. Impact of Atrial Fibrillation on Mortality,
Length of Stay and Cost in Patients with Sepsis. Proceedings
of the 38th Annual Scientific Sessions of the Heart Rhythm
Society, Heart Rhythm, 10–13 May 2017, Chicago, IL, USA
✗
Akella K, Akella S, Akella SL, Chendrasekhar A. Atrial
Fibrillation in Elderly (Age > 65 Years) Trauma Patients is
Associated with Increased Mortality and Morbidity. Paper
presented at the CHEST 2017 Annual Meeting, Canada,
2017. Cardiovasc Dis 2017;152:A66
✗
Akhtar MI, Ullah H, Hamid M. Magnesium, a drug of
diverse use. J Pak Med Assoc 2011;61:1220–5
✗
Al-Hashimi M, Thompson JP. Drugs acting on the heart:
anti-arrhythmics. Anaesth and Intensive Care Med
2012;13:374–7
✗
Al-Khafaji A, Cho Su M. Atrial fibrillation in critical care.
(Comment on: Intensive Care Med 2006 Mar;32:398–404)
2006;32:1099–100
✗
Ambrus DB, Benjamin EJ, Bajwa EK, Hibbert KA, Walkey AJ.
Risk factors and outcomes associated with new-onset
atrial fibrillation during acute respiratory distress
syndrome. J Crit Care 2015;30:994–7
✗
Anane C, Owusu IK, Attakorah J. Monitoring amiodarone
therapy in cardiac arrthythmias in the intensive care unit of
a teaching hospital in Ghana. Int J Cardiol 2011;10
✗
Ando G, Di Rosa S, Rizzo F, Carerj S, Bramanti O, Giannetto M,
et al. Ibutilide for cardioversion of atrial flutter: efficacy of a
single close in recent-onset arrhythmias.Minerva
Cardioangiologica 2004;52:37–42
✗
Arita Y, Segawa T, Yamamoto S, Hasegawa S. Landiolol
is effective for the treatment of tachycardia-induced
cardiogenic shock in patients during septic shock therapy.
BMJ Case Rep 2017;2017:bcr–2017–222268
✗
Arnautovic J, Mazhar A, Souther B, Mikhjian G, Huda N.
New-Onset Atrial Fibrillation in Patients with Septic Shock.
Proceedings of the 47th Society of Critical Care Medicine
Critical Care Congress (SCCM), 25–28 February 2018,
San Antonio, TX, USA, abstract number 184
✗
Arrigo M, Bettex D, Rudiger A. Management of atrial
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TABLE 19 Excluded studies on full text with reason for exclusion (continued )
Study
Excluded based on
Population Study design Outcome Intervention
Arrigo M, Bettex D, Rudiger A. [Treatment of atrial
fibrillation in intensive care units and emergency
departments.] Med Klin Intensivmed Notfmed
2015;110:614–20
✗
Arrigo M, Bettex D, Rudiger A. Response to: comment on
‘Management of Atrial Fibrillation in Critically Ill Patients’.
Crit Care Res Pract 2016;2016:9724504
✗
Arrigo M, Feliot E, Gayat E, Mebazaa A. Cardiovascular
events after ICU discharge in patients with new-onset
atrial fibrillation: a report from the FROG-ICU study.
Int J Cardiol 2018;270:203
✗
Arrigo M, Ishihara S, Feliot E, Rudiger A, Deye N, Cariou A,
et al. New-onset atrial fibrillation in critically ill patients
and its association with mortality: a report from the
FROG-ICU study. Int J Cardiol 2018;266:95–9
✗
Arsura EL, Solar M, Lefkin AS, Scher DL, Tessler S.
Metoprolol in the treatment of multifocal atrial
tachycardia. Crit Care Med 1987;15:591–4
✗
Aydogdu M, Hanazay C, Aldag Y, Baha A, Bilgin S, Gursel
G. Effects of atrial fibrillation on intensive care unit
outcomes in patients with respiratory failure. J Med Surg
Intensive Care Med 2017;8:32–8
✗
Badheka AO, Tuliani T, Rathod A, Shenoy M, Afonso L,
Jacob S. Role of lipid lowering therapy and renin
angiotensin blockade in outcomes of patients with atrial
fibrillation. Am J Cardiol 2012;109:1238
✗
Balik M. New-onset atrial fibrillation in critically ill patients –
implications for rhythm rather than rate control therapy?
Int J Cardiol 2018;266:147–8
✗
Balik M, Kolnikova I, Maly M,Waldauf P, Tavazzi G, Kristof J.
Antiarrhythmic Therapy for Supraventricular Arrhythmias in
Septic Shock. Proceedings of the 29th Annual Congress of
the European Society of Intensive Care Medicine (ESICM),
1–5 October 2016, Milan, Italy, abstract number A793
✗
Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy
of flecainide in patients with supraventricular arrhythmias
and respiratory insufficiency. Intensive Care Med
1994;20:42–4
✗
Bender JS. Supraventricular tachyarrhythmias in the
surgical intensive care unit: an under-recognized event.
Am Surg 1996;62:73–5
✗
Bernal E, Wolf S, Cripps M. New-onset, postoperative
tachyarrhythmias in critically ill surgical patients. Burns
2018;44:249–55
✗
Bernard EO, Schmid ER, Schmidlin D, Scharf C, Candinas R,
Germann R. Ibutilide versus amiodarone in atrial
fibrillation: a double-blinded, randomized study. Crit Care
Med 2003;31:1031–4
✗
Bowles HF, Thangathurai D, Morgan GE, Mikhail M.
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TABLE 19 Excluded studies on full text with reason for exclusion (continued )
Study
Excluded based on
Population Study design Outcome Intervention
Carrera P, Thongprayoon C, Cheungpasitporn W, Iyer VN,
Moua T. Epidemiology and outcome of new-onset atrial
fibrillation in the medical intensive care unit. J Crit Care
2016;36:102–6
✗
Champion S. Comment on ‘management of atrial fibrillation in
critically ill patients’. Crit Care Res Pract 2015;2015:732598
✗
Champion S. An overlook of new-onset atrial fibrillation in
the critically ill using automated detection: have we over
looked at it? Crit Care Med 2017;45:e1195
✗
Champion S, Gaüzère BA, Vandroux D, Lefort Y. [Is it worth
delivering Direct-Current Counter shock to critically ill
patients with supra-ventricular tachyarrhythmia?]
Ann Cardiol Angeiol 2018;67:260–3
✗
Chapman MJ, Moran JL, O’Fathartaigh MS, Peisach AR,
Cunningham DN. Management of atrial tachyarrhythmias in
the critically ill: a comparison of intravenous procainamide
and amiodarone. Intensive Care Med 1993;19:48–52
✗
Clayton B, Ball S, Read J, Waddy S. Risk of
thromboembolism in patients developing critical illness-
associated atrial fibrillation. Clin Med 2018;18:282–7
✗
Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA.
Intravenous amiodarone for acute heart rate control in the
critically ill patient with atrial tachyarrhythmias. Am J
Cardiol 1998;81:594–8
✗
Crawford TC, Oral H. Cardiac arrhythmias: management of
atrial fibrillation in the critically ill patient. Crit Care Clin
2007;23:855–72, vii
✗
Darwish OS, Strube S, Phan A, Tanios M. The Safety and
Efficacy of Anticoagulation for Atrial Fibrillation in Patients
with Severe Sepsis in the Medical Intensive Care Unit.
Proceedings of the American Heart Association Quality of
Care and Outcomes Research in Cardiovascular Disease
and Stroke 2010 Scientific Sessions, 19–21 May 2010,
Washington, DC, USA
✗
Darwish OS, Strube S, Nguyen HM, Tanios MA. Challenges
of anticoagulation for atrial fibrillation in patients with
severe sepsis. Ann Pharmacother 2013;47:1266–71
✗
Davies GE, Cudworth P, Lawler PG. Intravenous magnesium
therapy in critically ill patients. Anaesthesia 1992;47:1104
✗
Delle Karth G, Reinelt P, Buberl A, Geppert A, Huelsmann
M, Berger R, Heinz G. Circadian variation in ventricular
tachycardia and atrial fibrillation in a medical-cardiological
ICU. Intensive Care Med 2003;29:963–8
✗
Duarte PAD, Leichtweis GE, Andriolo L, Delevatti YA,
Jorge AC, Fumagalli AC, et al. Factors associated with the
incidence and severity of new-onset atrial fibrillation in
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TABLE 19 Excluded studies on full text with reason for exclusion (continued )
Study
Excluded based on
Population Study design Outcome Intervention
Duarte PAD, Leichtweis GE, Andriolo L, Delevatti YA,
Jorge AC, Fumagalli AC, et al. Corrigendum to ‘Factors
Associated with the Incidence and Severity of New-Onset
Atrial Fibrillation in Adult Critically Ill Patients’. Crit Care
Res Pract 2019;2019:5710734
✗
Duby JJ, Heintz SJ, Bajorek SA, Heintz BH, Durbin-Johnson
BP, Cocanour CS. Prevalence and course of atrial
fibrillation in critically ill trauma patients. J Intensive Care
Med 2017;32:140–5
✗
Eckardt L. Innovations to the therapy of atrial fibrillations
in intensive care medicine. Medizinische Klinik-
intensivmedizin Und Notfallmedizin 2014;109:564–5
✗
Edwards JD, Kishen R. Significance and management of
intractable supraventricular arrhythmias in critically ill
patients. Crit Care Med 1986;14:280–2
✗
Edwards JD, Wilkins RG. Atrial fibrillation precipitated by
acute hypovolaemia. BMJ (Clin Res Ed) 1987;294:283–4
✗
Faniel R, Schoenfeld P. Intravenous amiodarone: a
successful treatment for rapid atrial fibrillation in intensive
care patients. Eur Heart J 1981;2:115
✗
Flato Uri Adrian P, Buhatem T, Merluzzi T, Bianco Antonio
Carlos M. New anticoagulants in critical care settings. Rev
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Appendix 5 RISK-II supplementary material
TABLE 20 Regression model coefficients for mortality after hospital discharge
Independent variable
Coefficient (95% CI) in outcome model for mortality
1 to 90 days after
discharge
91 days to 1 year after
discharge > 1 year after discharge
NOAF 0.380 (0.231 to 0.529) –0.005 (–0.148 to 0.138) 0.037 (–0.043 to 0.116)
Age (years) (RCS)
Spline base variable 1 0.060 (0.039 to 0.081) 0.076 (0.058 to 0.093) 0.060 (0.050 to 0.070)
Spline base variable 2 –0.047 (–0.079 to –0.015) –0.068 (–0.094 to –0.042) –0.032 (–0.047 to –0.017)
Spline base variable 3 0.233 (0.069 to 0.397) 0.273 (0.138 to 0.409) 0.151 (0.072 to 0.229)
Male sex (vs. female) 0.080 (–0.035 to 0.196) 0.159 (0.063 to 0.255) 0.108 (0.053 to 0.163)
Hypertension –0.099 (–0.229 to 0.031) –0.091 (–0.198 to 0.015) 0.036 (–0.025 to 0.098)
Heart failure 0.303 (0.137 to 0.469) 0.498 (0.359 to 0.637) 0.350 (0.266 to 0.433)
Diabetes mellitus 0.190 (0.054 to 0.326) 0.064 (–0.052 to 0.180) 0.218 (0.154 to 0.283)
Prior thromboembolism 0.326 (0.127 to 0.525) 0.099 (–0.084 to 0.283) 0.219 (0.118 to 0.320)
Pulmonary hypertension 0.604 (0.231 to 0.977) 0.297 (–0.084 to 0.679) 0.458 (0.235 to 0.681)
Valvular heart disease 0.212 (0.017 to 0.407) –0.015 (–0.196 to 0.166) 0.075 (–0.027 to 0.178)
RCS, restricted cubic spline.
Coefficients estimated using Cox proportional hazards regression with dummy variables for all independent variables
except age, which was modelled continuously using a RCS with knots at 24, 54, 68 and 84 years.
TABLE 21 Regression model coefficients for subsequent hospitalisation
Independent variable
Coefficient (95% CI) in model for subsequent hospitalisation with:
Atrial fibrillation Stroke Heart failure
NOAF 1.767 (1.672 to 1.862) 0.384 (0.112 to 0.656) 0.247 (0.132 to 0.362)
Age (years) (RCS) 0.041 (0.037 to 0.044) 0.028 (0.020 to 0.036) 0.026 (0.022 to 0.030)
Male sex (vs. female) 0.227 (0.134 to 0.320) 0.063 (–0.149 to 0.276) 0.102 (0.010 to 0.194)
Hypertension 0.282 (0.174 to 0.390) 0.483 (0.228 to 0.738) 0.477 (0.360 to 0.594)
Heart failure 0.484 (0.365 to 0.602) 0.160 (–0.154 to 0.475) 2.005 (1.904 to 2.107)
Diabetes mellitus 0.142 (0.036 to 0.248) 0.151 (–0.093 to 0.395) 0.386 (0.287 to 0.485)
Prior thromboembolism 0.202 (0.042 to 0.362) 1.425 (1.173 to 1.677) 0.024 (–0.144 to 0.191)
Pulmonary hypertension 0.236 (–0.100 to 0.572) 0.705 (–0.011 to 1.421) 0.465 (0.214 to 0.716)
Valvular heart disease 0.346 (0.205 to 0.487) 0.255 (–0.104 to 0.613) 0.410 (0.285 to 0.536)
RCS, restricted cubic spline.
Coefficients estimated using Cox cause-specific proportional hazards regression with censoring on date of death and
dummy variables for all independent variables except age, which was modelled continuously using a restricted cubic
spline with knots at 24, 54, 68 and 84 years.
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TABLE 22 Sensitivity analysis: patient characteristics and comorbidities
Variable NOAF patients (sensitivity) (N= 8145) Comparator patients (N= 48,870)
Demographics
Age (years), mean (SD) 71.6 (11.5) 59.0 (17.9)
Sex (male), n (%) 4684 (57.5) 26,445 (54.1)
Ethnicity, n (%)
White 7634 (93.7) 44,365 (90.8)
Mixed 17 (0.2) 236 (0.5)
Asian 149 (1.8) 1573 (3.2)
Black 92 (1.1) 945 (1.9)
Other 57 (0.7) 534 (1.1)
Not stated 196 (2.4) 1217 (2.5)
Comorbidities, n (%)
Hypertension 5329 (65.4) 22,917 (46.9)
Heart failure 2049 (25.2) 4999 (10.2)
Diabetes mellitus 1946 (23.9) 9998 (20.5)
Valvular heart disease 1107 (13.6) 3011 (6.2)
Prior thromboembolism 722 (8.9) 3053 (6.2)
Pulmonary hypertension 213 (2.6) 574 (1.2)
Dilating cardiomyopathy 73 (0.9) 229 (0.5)
SD, standard deviation.
TABLE 23 Sensitivity analysis: outcomes
Outcome
Cumulative incidence of event (95% CI) (%)
NOAF patients (sensitivity) (N= 8145) Comparator patients (N= 48,870)
Mortality
During hospital admission, n (%) 2774 (34.5) 9595 (19.7)
Time after hospital discharge
90 days 8.8% (8.0 to 9.6) 4.2% (4.0 to 4.4)
1 year 18.6% (17.6 to 19.7) 11.1% (10.8 to 11.5)
3 years 34.1% (32.8 to 35.4) 22.4% (22.0 to 22.8)
5 years 46.3% (44.9 to 47.8) 30.1% (29.6 to 30.6)
Subsequent hospital admission fora
Atrial fibrillation
1 year 28.2 (26.8 to 29.4) 2.3 (2.2 to 2.5)
3 years 39.8 (38.3 to 41.3) 5.0 (4.7 to 5.3)
5 years 46.2 (44.4 to 47.9) 7.1 (6.7 to 7.5)
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TABLE 23 Sensitivity analysis: outcomes (continued )
Outcome
Cumulative incidence of event (95% CI) (%)
NOAF patients (sensitivity) (N= 8145) Comparator patients (N= 48,870)
Stroke
1 year 1.6 (1.3 to 2.0) 0.6 (0.6 to 0.7)
3 years 3.1 (2.6 to 3.8) 1.4 (1.2 to 1.5)
5 years 4.5 (3.8 to 5.4) 2.0 (1.8 to 2.2)
Heart failure
1 year 11.1 (10.2 to 12.0) 4.3 (4.0 to 4.5)
3 years 17.4 (16.3 to 18.6) 7.5 (7.2 to 7.8)
5 years 21.8 (20.3 to 23.3) 9.7 (9.3 to 10.0)
a Estimates of risk of hospital admission use a non-parametric method to additionally account for the competing risk





































































FIGURE 12 Sensitivity analysis: outcomes after hospital discharge. (a) Mortality after discharge; (b) hospitalisation with AF;
(c) hospitalisation with stroke; (d) hospitalisation with heart failure. (continued )
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FIGURE 12 Sensitivity analysis: outcomes after hospital discharge. (a) Mortality after discharge; (b) hospitalisation with AF;
(c) hospitalisation with stroke; (d) hospitalisation with heart failure.
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2774 9595 2.14 (2.03 to 2.25) 1.51 (1.43 to 1.59)
Outcome




















456 1247 1614 9497 2.26 (2.05 to 2.49) 1.54 (1.38 to 1.71)
Death 91 days to
1 year after
hospital discharge
514 4595 2716 36,352 1.50 (1.37 to 1.65) 1.04 (0.95 to 1.16)
Death > 1 year
after hospital
discharge
1582 19,351 8054 171,327 1.76 (1.67 to 1.86) 1.07 (1.01 to 1.13)
Outcome




















1926 8461 1865 96,570 10.67 (10.02 to 11.38) 6.41 (5.99 to 6.85)
Subsequent hospital
admission for stroke




857 10,517 2718 95,410 2.71 (2.51 to 2.92) 1.25 (1.15 to 1.35)
Odds ratios estimated using logistic regression ± adjustment for age (using a restricted cubic spline with knots at
positions 25, 54, 68 and 84 years), sex, diabetes mellitus, hypertension, prior thromboembolism, valvular heart disease,
pulmonary hypertension and heart failure. HRs estimated using Cox proportional hazards regression ± adjustment for
the same factors. Cause-specific hazard ratios estimated using Cox proportional hazards regression with censoring at
death± adjustment for the same factors.
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Appendix 6 Intensive care unit databases
supplementary material
Parts of this appendix are reproduced or adapted with permission from Bedford et al.
81 This
is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The appendix includes minor additions and formatting changes to the original appendix.
TABLE 25 Characteristics of patients with NOAF vs. those without: MIMIC-III database
Characteristic Never had AF (N= 17,494) NOAF (N= 1065)
Age (years), median (IQR) 59 (47–73) 75 (64–83)
Sex, n (%)
Female 8440 (48) 518 (49)
Male 9054 (52) 547 (51)
Weight (kg), median (IQR) 77 (64–91) 77 (65–92)
ICU length of stay (days), median (IQR) 1.8 (1.0–3.5) 5.8 (3.0–11.8)
ICU mortality, n (%) 1260 (7.2) 265 (25)
Hospital length of stay (days), median (IQR) 6 (4–12) 12 (7–21)
Hospital mortality, n (%) 1887 (11) 347 (33)
TABLE 26 Characteristics of patients with NOAF vs. those without: PICRAM database
Characteristic Never had AF (N= 7415) NOAF (N= 952)
Age (years), median (IQR) 61 (45–71) 71 (64–78)
Sex, n (%)
Female 3120 (42) 368 (39)
Male 4295 (58) 584 (61)
Weight (kg), median (IQR) 72 (62–83) 75 (65–85)
ICU length of stay (days), median (IQR) 2.4 (1.5–4.7) 6.1 (3.1–12.8)
ICU mortality, n (%) 628 (8.5) 193 (20)
Hospital length of stay (days),a median (IQR) 13 (7–25) 19 (10–40)
Hospital mortality, n (%) 1122 (16) 350 (37)
a Thirty-two patients for whom hospital length of stay was unknown are not included.
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TABLE 27 Characteristics of included patients by treatment group: MIMIC-III database
Characteristic
Treatment group
Overall (N= 740)Amiodarone (N= 94) Beta-blocker (N= 473)
Calcium channel
blocker (N= 144) DCC (N= 29)
Age (years), median (IQR) 76 (63–83) 73 (64–83) 73 (65–81) 77 (69–85) 74 (64–82)
Sex, n (%)
Female 51 (54) 234 (49) 77 (53) 10 (34) 372 (50)
Male 43 (46) 239 (51) 67 (47) 19 (66) 368 (50)
COPD, n (%) 3 (3.2) 28 (5.9) 19 (13) 3 (10) 53 (7.2)
NYHA class III/IV heart failure, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Dialysis-dependent renal failure, n (%) 0 (0) 1 (0.2) 0 (0) 0 (0) 1 (0.1)
Chronic liver disease, n (%) 2 (2.1) 7 (1.5) 2 (1.4) 0 (0) 11 (1.5)
Thyroid disorder, n (%) 2 (2.1) 27 (5.7) 3 (2.1) 1 (3.4) 33 (4.5)
Beta-blocker therapy prior to admission, n (%) 38 (46) 193 (45) 37 (28) 13 (52) 281 (42)
Antipsychotic medication prior to admission, n (%) 4 (4.8) 19 (4.4) 4 (3.1) 0 (0) 27 (4.0)
Highest OASIS at 3 hours, median (IQR) 38 (32–43) 36 (31–40) 36 (30–40) 40 (33–43) 36 (31–41)
Mechanical ventilation at time of NOAF, n (%) 60 (64) 206 (44) 55 (38) 22 (76) 343 (46)
Renal replacement therapy during or < 12 hours prior to NOAF, n (%) 5 (5.3) 38 (8.0) 1 (0.7) 3 (10) 47 (6.4)
i.v. vasoactive medication at time of NOAF, n (%) 34 (36) 45 (9.5) 9 (6.2) 13 (45) 101 (14)
Therapeutic anticoagulation at time of NOAF, n (%) 6 (6.4) 23 (4.9) 5 (3.5) 2 (6.9) 36 (4.9)
Central venous catheter at time of NOAF, n (%) 69 (73) 261 (55) 75 (52) 24 (83) 429 (58)









































Overall (N= 740)Amiodarone (N= 94) Beta-blocker (N= 473)
Calcium channel
blocker (N= 144) DCC (N= 29)
Plasma concentration, median (IQR)
Sodium (mmol/l) 138 (136–141) 140 (137–143) 140 (137–143) 138 (136–143) 139 (136–143)
Potassium (mmol/l) 4.0 (3.7–4.5) 3.9 (3.6–4.3) 4.0 (3.7–4.3) 4.1 (3.7–4.4) 4.0 (3.7–4.4)
Magnesium (mmol/l) 0.86 (0.78–0.95) 0.82 (0.78–0.95) 0.86 (0.78–0.95) 0.82 (0.78–0.91) 0.82 (0.78–0.95)
Urea (mmol/l) 10.0 (6.4–15.4) 8.9 (5.7–15.7) 8.9 (6.1–15.4) 19.8 (9.5–23.8) 9.3 (6.1–16.1)
Creatinine (µmol/l) 97 (71–168) 97 (62–159) 88 (62–139) 159 (86–270) 97 (62–159)
White cell count (× 109/l), median (IQR) 13.6 (8.8–19.7) 11.6 (8.8–15.5) 11.3 (7.5–16.3) 13.1 (10.5–16.3) 11.8 (8.5–16.1)
Haemoglobin concentration (g/l), median (IQR) 100 (88–113) 104 (92–115) 101 (93–116) 99 (91–111) 102 (92–115)
Platelet count (× 109/l), median (IQR) 179 (91–258) 190 (129–286) 205 (137–291) 161 (111–219) 190 (123–283)
Prothrombin time (seconds), median (IQR) 15.2 (13.7–17.8) 14.2 (13.1–16.3) 14.0 (12.9–15.6) 15.0 (13.6–17.5) 14.2 (13.1–16.4)
Systolic blood pressure after AF onset (mmHg), median (IQR) 103 (93–122) 119 (104–140) 115 (97–132) 93 (88–111) 116 (100–135)
Mean blood pressure after AF onset (mmHg), median (IQR) 72 (63–81) 80 (69–92) 76 (66–88) 67 (61–78) 78 (67–90)
Heart rate after AF onset (b.p.m.), median (IQR) 124 (110–139) 121 (102–136) 124 (110–141) 123 (98–147) 122 (104–137)
























































































































































































































































































































































































































Age (years), median (IQR) 69 (63–77) 70 (64–76) 75 (65–81) 70 (63–77)
Sex, n (%)
Female 141 (41) 20 (43) 25 (36) 186 (40)
Male 203 (59) 27 (57) 44 (64) 274 (60)
COPD, n (%) 51 (15) 1 (2.1) 11 (16) 63 (14)
NYHA class III/IV heart failure, n (%) 2 (0.6) 0 (0) 0 (0) 2 (0.4)
Dialysis-dependent renal failure, n (%) 6 (1.7) 0 (0) 1 (1.4) 7 (1.5)
Chronic liver disease, n (%) 14 (4.1) 1 (2.1) 5 (7.2) 20 (4.3)
Thyroid disorder, n (%) 21 (6.1) 3 (6.4) 4 (5.8) 28 (6.1)
Beta-blocker therapy prior to admission,
n (%)
44 (13) 10 (21) 9 (13) 63 (14)
Antipsychotic medication prior to
admission, n (%)
5 (1.5) 1 (2.1) 1 (1.4) 7 (1.5)
Highest OASIS at 3 hours, median (IQR) 34 (27–40) 34 (22–38) 30 (25–36) 34 (26–39)
Mechanical ventilation at time of NOAF,
n (%)
192 (56) 22 (47) 29 (42) 243 (53)
Renal replacement therapy during or
< 12 hours prior to NOAF, n (%)
52 (15) 5 (11) 8 (12) 65 (14)
i.v. vasoactive medication at time of
NOAF, n (%)
105 (31) 6 (13) 13 (19) 124 (27)
Therapeutic anticoagulation at time of
NOAF, n (%)
37 (11) 5 (11) 6 (8.7) 48 (10)
Central venous catheter at time of
NOAF, n (%)
262 (76) 32 (68) 32 (46) 326 (71)
Bronchodilator therapy on day of, or day
preceding, NOAF, n (%)
57 (17) 7 (15) 11 (16) 75 (16)
Plasma concentration, median (IQR)
Sodium (mmol/l) 137 (134–141) 139 (136–144) 138 (135–140) 137 (134–141)
Potassium (mmol/l) 4.2 (3.9–4.5) 4.1 (4.0–4.6) 4.2 (3.9–4.4) 4.2 (3.9–4.5)
Magnesium (mmol/l) 0.95 (0.84–1.14) 1.01 (0.92–1.16) 0.92 (0.82–1.08) 0.96 (0.84–1.12)
Urea (mmol/l) 13.8 (9.5–20.1) 12.1 (7.8–17.7) 13.2 (8.2–18.5) 13.6 (8.8–19.5)
Creatinine concentration (μmol/l) 134 (78–224) 108 (70–151) 112 (84–185) 125 (78–214)
White cell count (× 109/l), median (IQR) 11.1 (7.5–16.2) 10.6 (7.6–13.4) 12.0 (9.5–16.8) 11.1 (7.7–16.3)
Haemoglobin concentration (g/l),
median (IQR)
97 (87–111) 103 (94–112) 101 (90–116) 98 (88–113)
Platelet count (× 109/l), median (IQR) 163 (105–231) 192 (118–247) 180 (136–237) 166 (109–234)
Prothrombin time (seconds), median
(IQR)
16.2 (15.0–19.0) 15.5 (14.4–17.0) 16.6 (15.0–19.4) 16.1 (15.0–19.0)
Systolic blood pressure after AF onset
(mmHg), median (IQR)
112 (97–128) 128 (108–156) 119 (103–135) 116 (99–131)
Mean blood pressure after AF onset
(mmHg), median (IQR)
74 (67–85) 83 (73–94) 78 (70–88) 75 (67–86)
Heart rate after AF onset (b.p.m.),
median (IQR)
128 (107–149) 125 (110–146) 120 (98–140) 127 (107–147)
NYHA, New York Heart Association.
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TABLE 29 Unweighted and weighted covariate means by treatment group: MIMIC-III database
Variable
Unweighted means Weighted means Maximum pairwise SMD
Amiodarone Beta-blocker
Calcium channel
blocker DCC Amiodarone Beta-blocker
Calcium channel
blocker DCC Unweighted Weighted
Age (years) 71.84 71.98 72.56 74.14 72.90 72.56 72.74 72.72 0.17 0.03
Male sex 0.46 0.51 0.47 0.66 0.51 0.51 0.51 0.54 0.20 0.03
OASIS 3-hour score 36.80 35.21 35.22 38.93 35.87 35.89 35.94 36.71 0.48 0.11
Beta-blocker on
admission
0.40 0.45 0.31 0.52 0.44 0.44 0.41 0.49 0.21 0.08
Antipsychotic medication
on admission
0.05 0.06 0.03 0.00 0.04 0.04 0.04 0.00 0.06 0.04
Thyroid disorder 0.02 0.06 0.02 0.03 0.04 0.04 0.04 0.05 0.04 0.01
COPD 0.03 0.06 0.13 0.10 0.06 0.08 0.08 0.11 0.10 0.05
Liver disease 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.02 0.01
Dialysis-dependent renal
failure
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Plasma sodium
concentration (mmol/l)
138.10 139.63 140.04 139.28 139.32 139.48 139.46 139.47 0.35 0.03
Plasma potassium
concentration (mmol/l)
4.10 4.02 4.02 4.03 4.01 4.02 4.01 3.97 0.15 0.08
Plasma magnesium
concentration (mmol/l)
0.86 0.86 0.87 0.84 0.85 0.85 0.85 0.83 0.20 0.17
Plasma creatinine
concentration (mmol/l)
164.16 148.06 125.38 219.54 157.14 152.43 149.86 163.62 0.57 0.08
Plasma urea
concentration (µmol/l)
11.97 12.00 12.12 18.48 12.28 13.02 13.32 15.14 0.69 0.30
White cell count (× 109/l) 14.92 12.68 12.63 15.31 13.52 13.33 12.88 13.81 0.32 0.11
Haemoglobin
concentration (g/l)














































































































































































































































































































































































































TABLE 29 Unweighted and weighted covariate means by treatment group: MIMIC-III database (continued )
Variable
Unweighted means Weighted means Maximum pairwise SMD
Amiodarone Beta-blocker
Calcium channel
blocker DCC Amiodarone Beta-blocker
Calcium channel
blocker DCC Unweighted Weighted
Platelet count (× 10/l) 207 215 221 184 206 209 209 200 0.29 0.07
Therapeutic
anticoagulation at time of
NOAF
0.06 0.05 0.03 0.07 0.05 0.04 0.04 0.04 0.03 0.01
Log-prothrombin time 2.76 2.70 2.70 2.74 2.72 2.72 2.72 2.74 0.24 0.10
Systolic blood pressure
after AF onset (mmHg)
105.88 119.20 116.69 89.62 113.40 113.60 113.54 108.28 0.83 0.15
Mean blood pressure
after AF onset (mmHg)
67.26 74.67 74.45 58.11 71.23 71.37 71.92 67.57 0.76 0.20
Heart rate after AF onset
(b.p.m.)
123.68 120.74 123.56 122.14 123.32 122.87 123.09 125.32 0.11 0.09
Temperature (°C) 37.04 37.02 37.06 36.88 37.02 37.02 37.06 37.02 0.23 0.05
i.v. vasoactive medication
at time of NOAF
0.36 0.10 0.06 0.45 0.17 0.16 0.15 0.21 0.39 0.06
Noradrenaline dose
(µg/kg/minute)
0.12 0.02 0.01 0.08 0.03 0.03 0.02 0.04 0.66 0.09
Vasopressin dose
(µg/kg/minute)
0.17 0.05 0.02 0.29 0.07 0.07 0.05 0.10 0.48 0.08
Bronchodilator therapy
on day of, or day
preceding, NOAF
0.35 0.33 0.43 0.28 0.33 0.33 0.35 0.30 0.15 0.04
Mechanical ventilation at
time of NOAF
0.64 0.44 0.38 0.76 0.51 0.50 0.47 0.58 0.38 0.11
Central venous catheter
at time of NOAF
0.73 0.55 0.52 0.83 0.63 0.61 0.61 0.68 0.31 0.08
Renal replacement
therapy during or
< 12 hours prior to NOAF







































TABLE 30 Unweighted and weighted covariate means by treatment group: PICRAM database
Variable
Unweighted means Weighted means Maximum pairwise SMD
Amiodarone Beta-blocker Digoxin Amiodarone Beta-blocker Digoxin Unweighted Weighted
Age (years) 68.60 68.94 71.78 69.52 69.23 70.24 0.28 0.09
Male sex 0.59 0.57 0.64 0.60 0.59 0.62 0.06 0.02
OASIS 3-hour 33.77 31.17 29.83 32.75 32.62 31.91 0.43 0.09
Beta-blocker on admission 0.13 0.21 0.13 0.14 0.16 0.15 0.08 0.02
Antipsychotic medication on admission 0.01 0.02 0.01 0.02 0.02 0.01 0.01 0.01
Thyroid disorder 0.06 0.06 0.06 0.06 0.06 0.07 0.01 0.00
COPD 0.15 0.02 0.16 0.12 0.05 0.13 0.14 0.07
Liver disease 0.04 0.02 0.07 0.04 0.03 0.05 0.05 0.02
NYHA class III/IV heart failure 0.01 NA 0.00 0.00 NA 0.00 0.01 0.00
Dialysis-dependent renal failure 0.02 0.00 0.01 0.01 0.00 0.01 0.02 0.01
Plasma sodium concentration (mmol/l) 137.51 139.79 138.05 138.13 138.91 138.31 0.40 0.14
Plasma potassium concentration (mmol/l) 4.24 4.30 4.20 4.24 4.26 4.24 0.19 0.05
Plasma magnesium concentration (mmol/l) 0.99 1.02 0.96 0.99 1.00 0.99 0.29 0.08
Plasma creatinine concentration (mmol/l) 171.42 142.16 156.38 164.82 165.09 164.62 0.25 0.00
Plasma urea concentration (µmol/l) 16.01 13.68 13.88 15.03 14.56 14.27 0.27 0.09
White cell count (× 109/l) 12.60 11.24 12.88 12.48 11.94 12.52 0.25 0.09
Haemoglobin concentration (g/l) 100.55 104.40 105.42 101.74 102.35 101.98 0.27 0.03














































































































































































































































































































































































































TABLE 30 Unweighted and weighted covariate means by treatment group: PICRAM database (continued )
Variable
Unweighted means Weighted means Maximum pairwise SMD
Amiodarone Beta-blocker Digoxin Amiodarone Beta-blocker Digoxin Unweighted Weighted
Therapeutic anticoagulation at time of NOAF 0.11 0.11 0.09 0.11 0.13 0.11 0.02 0.02
Log-prothrombin time 2.86 2.80 2.92 2.86 2.82 2.88 0.41 0.18
Systolic blood pressure after AF onset (mmHg) 117.19 123.94 119.54 118.81 120.14 119.19 0.22 0.04
Mean blood pressure after AF onset (mmHg) 75.35 80.36 78.03 76.66 77.66 76.93 0.26 0.05
Heart rate after AF onset (b.p.m.) 125.48 129.06 117.77 124.50 125.74 124.48 0.41 0.05
Temperature (°C) 36.58 36.84 36.54 36.63 36.75 36.60 0.34 0.17
i.v. vasoactive medication at time of NOAF 0.31 0.13 0.19 0.26 0.22 0.24 0.18 0.04
Noradrenaline dose (µg/kg/minute) 0.06 0.04 0.04 0.06 0.05 0.06 0.23 0.05
Vasopressin dose (µg/kg/minute) 0.05 NA 0.00 0.02 NA 0.00 0.29 0.12
Bronchodilator therapy on day of, or day preceding, NOAF 0.17 0.15 0.16 0.17 0.18 0.16 0.02 0.02
Mechanical ventilation at time of NOAF 0.56 0.47 0.42 0.52 0.53 0.49 0.14 0.04
Central venous catheter at time of NOAF 0.76 0.68 0.46 0.69 0.71 0.64 0.30 0.07
Renal replacement therapy during or < 12 hours prior to NOAF 0.15 0.11 0.12 0.14 0.14 0.13 0.04 0.01







































TABLE 31 Unadjusted and adjusted HRs for each outcome and associated 95% CIs: MIMIC-III database
Treatment Unadjusted HR 95% CI Adjusted HR 95% CI
Rate control
Beta-blocker 1.03 0.81 to 1.30 1.09 0.78 to 1.51
Calcium channel blocker 0.83 0.62 to 1.12 0.81 0.55 to 1.19
Cardioversion 1.01 0.39 to 2.62 1.59 0.44 to 5.75
Rhythm control
Beta-blocker 0.91 0.73 to 1.12 0.91 0.61 to 1.35
Calcium channel blocker 0.65 0.50 to 0.84 0.59 0.37 to 0.92
Cardioversion 1.45 0.82 to 2.57 2.00 0.86 to 4.65
Reversion to AF
Beta-blocker 1.18 0.79 to 1.78 1.37 0.67 to 2.78
Calcium channel blocker 1.44 0.90 to 2.31 1.73 0.78 to 3.84
Cardioversion 1.80 0.83 to 3.90 1.01 0.28 to 3.71
Reversion to heart rate of ≥ 110 b.p.m.
Beta-blocker 1.08 0.80 to 1.46 0.95 0.59 to 1.52
Calcium channel blocker 1.44 1.00 to 2.07 1.61 0.93 to 2.79
Cardioversion 0.67 0.30 to 1.53 0.93 0.36 to 2.42
Hospital mortality
Beta-blocker 0.64 0.44 to 0.93 1.03 0.53 to 2.03
Calcium channel blocker 0.77 0.50 to 1.20 1.30 0.61 to 2.76
Cardioversion 1.56 0.86 to 2.83 0.96 0.31 to 3.01
TABLE 32 Unadjusted and adjusted HRs for each outcome and associated 95% CIs: PICRAM database
Treatment Unadjusted HR 95% CI Adjusted HR 95% CI
Rate control
Beta-blocker 0.85 0.57 to 1.27 0.82 0.48 to 1.42
Digoxin 0.64 0.45 to 0.92 0.56 0.34 to 0.92
Rhythm control
Beta-blocker 0.95 0.64 to 1.40 0.99 0.57 to 1.72
Digoxin 0.57 0.41 to 0.81 0.67 0.41 to 1.09
Reversion to AF
Beta-blocker 0.79 0.50 to 1.27 0.84 0.42 to 1.65
Digoxin 1.21 0.78 to 1.89 1.32 0.71 to 2.47
Reversion to heart rate of ≥ 110 b.p.m.
Beta-blocker 0.94 0.58 to 1.52 0.88 0.43 to 1.79
Digoxin 1.41 0.91 to 2.19 1.14 0.63 to 2.09
Hospital mortality
Beta-blocker 0.74 0.40 to 1.38 0.75 0.30 to 1.84
Digoxin 1.21 0.79 to 1.86 1.37 0.75 to 2.50
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TABLE 33 Unadjusted and adjusted HRs for each outcome and associated 95% CIs: combined databases
Treatment Unadjusted HR 95% CI Adjusted HR 95% CI
Rate control
Beta-blocker 1.26 1.10 to 1.43 1.14 0.91 to 1.44
Calcium channel blocker 1.06 0.86 to 1.29 0.88 0.63 to 1.23
Digoxin 0.69 0.52 to 0.91 0.52 0.32 to 0.86
Electrical cardioversion 1.74 0.90 to 3.36 2.30 0.87 to 6.06
Rhythm control
Beta-blocker 0.81 0.71 to 0.93 0.86 0.67 to 1.11
Calcium channel blocker 0.58 0.47 to 0.71 0.56 0.39 to 0.79
Digoxin 0.58 0.41 to 0.83 0.64 0.35 to 1.17
Electrical cardioversion 1.25 0.77 to 2.03 1.58 0.71 to 3.51
Reversion to AF
Beta-blocker 0.68 0.55 to 0.84 0.72 0.48 to 1.08
Calcium channel blocker 0.81 0.58 to 1.13 0.89 0.48 to 1.64
Digoxin 1.39 0.90 to 2.14 2.22 0.95 to 5.21
Electrical cardioversion 1.02 0.52 to 1.98 0.64 0.20 to 2.02
Reversion to heart rate of ≥ 110 b.p.m.
Beta-blocker 1.00 0.85 to 1.17 0.88 0.65 to 1.18
Calcium channel blocker 1.62 1.28 to 2.06 1.54 1.00 to 2.37
Digoxin 1.24 0.92 to 1.66 1.26 0.75 to 2.12
Electrical cardioversion 1.24 0.68 to 2.26 0.90 0.32 to 2.51
Hospital mortality
Beta-blocker 0.78 0.62 to 0.99 0.97 0.56 to 1.68
Calcium channel blocker 0.95 0.67 to 1.33 1.21 0.62 to 2.39
Digoxin 1.16 0.76 to 1.79 1.77 0.77 to 4.06
Electrical cardioversion 1.92 1.16 to 3.17 0.87 0.25 to 3.00
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Appendix 7 Critical Care Health Informatics
Collaborative database analysis
Aim
The aim of this brief report was to investigate the incidence and characteristics of NOAF in a
multicentre UK-based intensive care population. The CCHIC database was not included in the main
analysis because it lacks data pertaining to most anti-arrhythmic medications.
This analysis was performed to allow comparison with data extracted for the main analysis to assess
consistency and generalisability of our findings in the main report.
Methods
Study design
We carried out a retrospective analysis of patient data collected for the Health Informatics
Collaborative (CCHIC) database. The HIC database was created with retrospectively collected detailed
data from the ICU clinical information systems relating to patients treated on four general ICUs in
London and Cambridge, UK, from 2014 to 2018.
Study population
We included data relating to all adult patients during their first ICU admission. We used the eligibility
criteria stated in Chapter 4, Study population. However, we were unable to exclude patients with
documented pre-existing arrhythmias because these data were not available in the CCHIC database.
Pre-existing arrhythmia was, therefore, determined only by the presence of arrhythmia during the first
3 hours of ICU admission.
Results
Study population
The CCHIC database included data relating to 33,451 adult first admissions to an ICU. Of these
patients, 7889 had an ICU length of stay of < 24 hours. We identified 2713 patients being paced or
with another significant arrhythmia during the first 3 hours of ICU admission. Of the remaining 22,849
patients, 1003 had missing hospital mortality data. Of the remaining 21,846 eligible patients, 2618 (12%)
developed NOAF. This process is outlined in Figure 23. No data were missing in our cohort for baseline
demographic variables. Acute Physiology and Chronic Health Evaluation (APACHE) II scores were
missing for 3635 patients. Hospital length of stay was missing for 2008 patients. Patients who developed
NOAF appeared older and more unwell and more likely to be male and, interestingly, slightly more likely
to have had elective surgery than those who did not develop NOAF (Table 34).
Characteristics of new-onset atrial fibrillation
The median time from ICU admission to the first episode of NOAF was 43 hours (IQR 23.5–73 hours).
The median total duration of AF per patient who developed NOAF was 13.5 hours (IQR 4–37 hours).
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Adult f irst admissions
(n = 33,451)


















FIGURE 23 The CCHIC database analysis flow chart.
TABLE 34 The CCHIC database analysis patient characteristics
Characteristic Never AF (N= 19,228) NOAF (N= 2618)
Age (years), median (IQR) 60 (45–70) 70 (65–80)
Sex, n (%)
Female 8266 (43) 885 (34)
Male 10,962 (57) 1733 (66)
APACHE II score, median (IQR) 14 (11–18) 16 (13–21)
Missing, n 3237 398
Elective surgery, n (%) 6513 (34) 991 (38)
ICU length of stay (days), median (IQR) 2 (1–5) 5 (3–11)
ICU mortality, n (%) 845 (4.4) 250 (9.5)
Hospital length of stay (days), median (IQR) 13 (8–26) 18 (10–36)
Missing, n 1729 279
Hospital mortality, n (%) 1673 (8.7) 450 (17)
APACHE, Acute Physiology and Chronic Health Evaluation.
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Discussion
This analysis demonstrates that the incidence of NOAF and the time to NOAF onset among eligible
patients is similar across the PICRAM and CCHIC databases. The association between NOAF and
mortality was evident in the CCHIC database. The total duration of AF per patient appeared shorter in
the CCHIC database than in the PICRAM database. The CCHIC database analysis included treated and
untreated episodes of AF; therefore, the average duration may have been reduced by very brief
episodes in which treatment was not felt to be warranted.
Conclusion
The epidemiology of NOAF identified in the CCHIC database is like that observed in the PICRAM
database. Similar incidence and onset times suggest that the NOAF identified by bedside observations
is a comparable phenomenon across these databases.
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Appendix 8 Expert panel details
Parts of this appendix are reproduced or adapted with permission from Bedford et al.
81 This
is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The appendix includes minor additions and formatting changes to the original appendix.
Expert panel details and research recommendations
Treatments and confounding variables
The following lists were drawn initially from the scoping review and were then refined and ratified by
the expert panel, as outlined in Chapter 2, Expert panel review.
Treatments of interest











TABLE 35 Expert panel members and roles
Name Role Institution
Professor Peter Watkinson Associate professor of intensive care
medicine
University of Oxford, Oxford, UK
Dr Jonathan Bedford Clinical research fellow University of Oxford, Oxford, UK
Dr Andrew Walden Consultant in intensive care medicine Intensive care unit, Royal Berkshire
Hospital, Reading, UK
Professor Ben O’Brien Professor of perioperative medicine St Bartholomew’s Hospital & Barts Heart
Centre, London, UK
Dr Kim Rajappan Consultant in cardiology Oxford University Hospitals NHS
Foundation Trust, Oxford, UK
Dr Ian Taylor Lay representative NA
Mrs Cathy Taylor Lay representative NA
NA, not applicable.
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Treatments of interest but not possible with our data
Propafenone, ibutilide and landiolol were identified as candidate therapies in the scoping review;





l Congestive cardiac failure.
l Severe respiratory disease/pulmonary fibrosis.
l COPD (previous or current diagnosis).
l Chronic liver disease (previous or current diagnosis).
l Chronic renal failure.
l Thyroid disorders (previous or current diagnosis, or taking relevant medications).
l Preadmission beta-blockers.
l Preadmission antipsychotic medication.
Admission factors
l Illness severity in the first 3 hours (therefore, not influenced by NOAF, as we are excluding patients
in AF in the first 3 hours).




l Presence and type of vasopressor/inotrope.
l Dose of vasopressor/inotrope.
l White cell count.
l Plasma electrolyte (K, Mg, Na, Ca) concentrations.
l Plasma urea and creatinine concentrations.
l Platelet count.
l Prothrombin time.
l Presence of therapeutic dose anticoagulation.
l Presence of bronchodilator therapy.
l Mechanical ventilation.
l Haemofiltration (current or previous 12 hours).
l Presence of central venous access.
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TABLE 36 Research recommendation 1: amiodarone vs. beta-blockers
Domain Description
Step 2: prioritise
Uncertainty identified Either amiodarone or beta-blockers are commonly used in critically ill patients to
control AF, but there is little evidence to support whether or not one is superior
Reason uncertain (conflicting
or lack of evidence)?
Although cohort studies have suggested survival advantages to beta-blockers,
the evidence is conflicting and subject to bias
Step 3: two-component research recommendation
Structured statement A RCT of amiodarone vs. beta-blockers for management of NOAF in critically ill
patients should be undertaken
Structured rationale NOAF during ICU is associated with substantially increased mortality after
correction for associated risk factors. Both amiodarone and beta-blockers are
commonly used but have significant side effects. Whether or not one is superior to
the other has not been demonstrated




l mortality (30 and 90 days)
l length of stay (ICU and hospital)
l AF burden post commencing treatment
l rate control post commencing treatment
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Risk stratification tools for anticoagulation
TABLE 37 Research recommendation 2: risk stratification tools for anticoagulation
Domain Description
Step 2: prioritise
Uncertainty identified It is not clear in which patients who develop NOAF while in an ICU anticoagulation
following hospital discharge might be beneficial
Reason uncertain (conflicting
or lack of evidence)?
There is very little evidence to inform practice, but the risk of thromboembolism is
increased in comparison with those who do not develop NOAF even when corrected for
known risk factors
Step 3: two-component research recommendation
Structured statement Whether or not there are subgroups of patients who develop NOAF while in an ICU who
may benefit from long-term anticoagulation is unknown. Studies should be undertaken to
create risk stratification tools or investigate whether or not current tools are applicable
to the ‘NOAF during ICU population’ to identify patients sufficiently at risk of future
thromboembolism to merit consideration of anticoagulation
Structured rationale The risk of thromboembolism is increased compared with those who do not develop
NOAF, even when corrected for known risk factors. However, current risk stratification
tools have not been validated in the ‘NOAF during ICU population’ and do not take
account if ICU treatments that may affect future outcome
PICOS Patients: patients experiencing an episode of NOAF during an ICU admission
Intervention/control: none
Outcome: thromboembolism
Study type: cohort study with long-term follow-up
Incidence of atrial fibrillation and left ventricular dysfunction
TABLE 38 Research recommendation 3: incidence of AF and left ventricular dysfunction
Domain Description
Step 2: prioritise
Uncertainty identified The incidence of AF and/or left ventricular dysfunction at hospital discharge and at
3 months following development of NOAF while in an ICU is unknown. However,
readmission with heart failure and thromboembolism is increased over the 5 years
following an episode of NOAF while in an ICU, particularly in the first year
Reason uncertain (conflicting
or lack of evidence)?
Lack of evidence
Step 3: two-component research recommendation
Structured statement A prospective cohort study to demonstrate the incidence of AF and/or left ventricular
dysfunction at hospital discharge and at 3 months following development of NOAF
should be undertaken
Structured rationale Readmission with heart failure and thromboembolism is increased over the 5 years following
an episode of NOAF while in an ICU, particularly in the first year.Whether or not these
events are driven by persistent left ventricular dysfunction and/or AF is unknown
PICOS Patients: patients who experience NOAF while in an ICU
Intervention: AF detection and echocardiogram at/near hospital discharge and at 3 months
Control: NA
Outcomes: AF, left ventricular dysfunction, heart failure, thromboembolism,
CHA2DS2-VASc and anticoagulation
Study type: prospective cohort
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischaemic
attack, vascular disease, age 65 to 74 years, sex category; NA, not applicable.
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